NZ742345B2 - Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof - Google Patents
Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof Download PDFInfo
- Publication number
- NZ742345B2 NZ742345B2 NZ742345A NZ74234512A NZ742345B2 NZ 742345 B2 NZ742345 B2 NZ 742345B2 NZ 742345 A NZ742345 A NZ 742345A NZ 74234512 A NZ74234512 A NZ 74234512A NZ 742345 B2 NZ742345 B2 NZ 742345B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- composition
- topical
- active agent
- day
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 547
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 title claims description 97
- 230000000590 parasiticidal Effects 0.000 title abstract description 6
- -1 isoxazoline compound Chemical class 0.000 claims abstract description 279
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 222
- 230000000699 topical Effects 0.000 claims abstract description 145
- 239000003937 drug carrier Substances 0.000 claims abstract description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 26
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 26
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 13
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims abstract description 10
- 239000000969 carrier Substances 0.000 claims description 62
- 239000004544 spot-on Substances 0.000 claims description 61
- 239000004540 pour-on Substances 0.000 claims description 51
- 206010061217 Infestation Diseases 0.000 claims description 49
- 229910052736 halogen Inorganic materials 0.000 claims description 45
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 210000003491 Skin Anatomy 0.000 claims description 39
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 claims description 37
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 229940031578 diisopropyl adipate Drugs 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 claims description 28
- NHDHVHZZCFYRSB-UHFFFAOYSA-N Pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 claims description 25
- 239000005927 Pyriproxyfen Substances 0.000 claims description 25
- 150000002367 halogens Chemical class 0.000 claims description 25
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 24
- 125000001188 haloalkyl group Chemical group 0.000 claims description 22
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 125000004429 atoms Chemical group 0.000 claims description 20
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 17
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 17
- 241000238631 Hexapoda Species 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 239000005660 Abamectin Substances 0.000 claims description 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 13
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 12
- 125000006771 (C1-C6) haloalkylthio group Chemical group 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000004741 (C1-C6) haloalkylsulfonyl group Chemical group 0.000 claims description 11
- 239000003630 growth substance Substances 0.000 claims description 11
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 10
- 125000004749 (C1-C6) haloalkylsulfinyl group Chemical group 0.000 claims description 10
- 125000006828 (C2-C7) alkoxycarbonyl group Chemical group 0.000 claims description 10
- 125000006773 (C2-C7) alkylcarbonyl group Chemical group 0.000 claims description 10
- 208000006551 Parasitic Disease Diseases 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- ONKUXPIBXRRIDU-UHFFFAOYSA-N diethyl decanedioate Chemical compound CCOC(=O)CCCCCCCCC(=O)OCC ONKUXPIBXRRIDU-UHFFFAOYSA-N 0.000 claims description 10
- 125000005347 halocycloalkyl group Chemical group 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000005842 heteroatoms Chemical group 0.000 claims description 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 8
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 8
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- HBALWXLTPDKZCF-UHFFFAOYSA-N 1-thiophen-3-yl-3,4-dihydroisoquinoline Chemical compound N=1CCC2=CC=CC=C2C=1C=1C=CSC=1 HBALWXLTPDKZCF-UHFFFAOYSA-N 0.000 claims description 7
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 7
- 229940031569 diisopropyl sebacate Drugs 0.000 claims description 7
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 claims description 7
- AZSNMRSAGSSBNP-XPNPUAGNSA-N 22,23-dihydroavermectin B1a Chemical compound C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 AZSNMRSAGSSBNP-XPNPUAGNSA-N 0.000 claims description 6
- 229960002418 Ivermectin Drugs 0.000 claims description 6
- 229940035295 Ting Drugs 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- QOVTVIYTBRHADL-UHFFFAOYSA-N 4-amino-6-(1,2,2-trichloroethenyl)benzene-1,3-disulfonamide Chemical compound NC1=CC(C(Cl)=C(Cl)Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O QOVTVIYTBRHADL-UHFFFAOYSA-N 0.000 claims description 5
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 claims description 5
- WPNHOHPRXXCPRA-TVXIRPTOSA-N Eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 claims description 5
- 239000005912 Lufenuron Substances 0.000 claims description 5
- PWPJGUXAGUPAHP-UHFFFAOYSA-N Lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 claims description 5
- YZBLFMPOMVTDJY-LSGXYNIPSA-N Moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)/C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-LSGXYNIPSA-N 0.000 claims description 5
- 229960004816 Moxidectin Drugs 0.000 claims description 5
- 229960000275 clorsulon Drugs 0.000 claims description 5
- 229940100539 dibutyl adipate Drugs 0.000 claims description 5
- 229960002346 eprinomectin Drugs 0.000 claims description 5
- 229960000521 lufenuron Drugs 0.000 claims description 5
- FYQGBXGJFWXIPP-UHFFFAOYSA-N (2E,4E)-3,7,11-trimethyldodeca-2,4-dienoic acid, ethyl ester Chemical compound CCOC(=O)C=C(C)C=CCC(C)CCCC(C)C FYQGBXGJFWXIPP-UHFFFAOYSA-N 0.000 claims description 4
- NVEPPWDVLBMNMB-SNAWJCMRSA-N 1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine Chemical compound CN1CCCN=C1\C=C\C1=C(C)C=CS1 NVEPPWDVLBMNMB-SNAWJCMRSA-N 0.000 claims description 4
- 229950000775 CYROMAZINE Drugs 0.000 claims description 4
- 229950004178 Closantel Drugs 0.000 claims description 4
- 239000005891 Cyromazine Substances 0.000 claims description 4
- LVQDKIWDGQRHTE-UHFFFAOYSA-N Cyromazine Chemical compound NC1=NC(N)=NC(NC2CC2)=N1 LVQDKIWDGQRHTE-UHFFFAOYSA-N 0.000 claims description 4
- 229950006719 Fluazuron Drugs 0.000 claims description 4
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 4
- BWCRYQGQPDBOAU-WZBVPYLGSA-N Milbemycin D Chemical compound C1C[C@H](C)[C@@H](C(C)C)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 BWCRYQGQPDBOAU-WZBVPYLGSA-N 0.000 claims description 4
- 229960005121 Morantel Drugs 0.000 claims description 4
- JMPFSEBWVLAJKM-UHFFFAOYSA-N N-{5-chloro-4-[(4-chlorophenyl)(cyano)methyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide Chemical compound ClC=1C=C(NC(=O)C=2C(=C(I)C=C(I)C=2)O)C(C)=CC=1C(C#N)C1=CC=C(Cl)C=C1 JMPFSEBWVLAJKM-UHFFFAOYSA-N 0.000 claims description 4
- RAOCRURYZCVHMG-UHFFFAOYSA-N Oxibendazole Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 claims description 4
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 claims description 4
- 229960004546 Thiabendazole Drugs 0.000 claims description 4
- WJCNZQLZVWNLKY-UHFFFAOYSA-N Tiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims description 4
- 230000000507 anthelmentic Effects 0.000 claims description 4
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 4
- YOWNVPAUWYHLQX-UHFFFAOYSA-N fluazuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C(OC=2C(=CC(=CN=2)C(F)(F)F)Cl)=C1 YOWNVPAUWYHLQX-UHFFFAOYSA-N 0.000 claims description 4
- 229930000073 hydroprenes Natural products 0.000 claims description 4
- 229960001614 levamisole Drugs 0.000 claims description 4
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 claims description 4
- 229960002762 oxibendazole Drugs 0.000 claims description 4
- 229960005134 pyrantel Drugs 0.000 claims description 4
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 claims description 4
- 239000004308 thiabendazole Substances 0.000 claims description 4
- 235000010296 thiabendazole Nutrition 0.000 claims description 4
- 125000004761 (C2-C7) alkylaminocarbonyl group Chemical group 0.000 claims description 3
- 125000006829 (C2-C7) haloalkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000006808 (C2-C7) haloalkylaminocarbonyl group Chemical group 0.000 claims description 3
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002669 Albendazole Drugs 0.000 claims description 3
- DFNYGALUNNFWKJ-UHFFFAOYSA-N Aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 claims description 3
- IRHZVMHXVHSMKB-UHFFFAOYSA-N Fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 claims description 3
- 229960003439 Mebendazole Drugs 0.000 claims description 3
- BAXLBXFAUKGCDY-UHFFFAOYSA-N Mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims description 3
- 239000005918 Milbemectin Substances 0.000 claims description 3
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims description 3
- 229960005282 febantel Drugs 0.000 claims description 3
- 229960005473 fenbendazole Drugs 0.000 claims description 3
- HMCCXLBXIJMERM-UHFFFAOYSA-N methyl N-[[2-[(2-methoxyacetyl)amino]-4-phenylsulfanylanilino]-(methoxycarbonylamino)methylidene]carbamate Chemical compound C1=C(NC(NC(=O)OC)=NC(=O)OC)C(NC(=O)COC)=CC(SC=2C=CC=CC=2)=C1 HMCCXLBXIJMERM-UHFFFAOYSA-N 0.000 claims description 3
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 claims description 3
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 claims description 3
- 229960004454 oxfendazole Drugs 0.000 claims description 3
- 229960000323 triclabendazole Drugs 0.000 claims description 3
- 125000006774 (C2-C7) haloalkylcarbonyl group Chemical group 0.000 claims description 2
- CKVMAPHTVCTEMM-ALPQRHTBSA-N Milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 claims description 2
- 229960002245 Selamectin Drugs 0.000 claims description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940031954 dibutyl sebacate Drugs 0.000 claims description 2
- 229940099245 milbemycin oxime Drugs 0.000 claims description 2
- AFJYYKSVHJGXSN-XHKIUTQPSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N/O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-XHKIUTQPSA-N 0.000 claims description 2
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- 229940057847 POLYETHYLENE GLYCOL 600 Drugs 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 126
- 238000009472 formulation Methods 0.000 description 94
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 93
- 241000238876 Acari Species 0.000 description 85
- 239000002904 solvent Substances 0.000 description 66
- 241000282472 Canis lupus familiaris Species 0.000 description 65
- 241000282326 Felis catus Species 0.000 description 65
- 241000258242 Siphonaptera Species 0.000 description 65
- 150000002148 esters Chemical class 0.000 description 53
- 241001465754 Metazoa Species 0.000 description 47
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3S,3aR,6R,6aR)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 44
- 235000019441 ethanol Nutrition 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 41
- CFRPSFYHXJZSBI-DHZHZOJOSA-N Nitenpyram Chemical compound [O-][N+](=O)/C=C(\NC)N(CC)CC1=CC=C(Cl)N=C1 CFRPSFYHXJZSBI-DHZHZOJOSA-N 0.000 description 38
- 229940079888 nitenpyram Drugs 0.000 description 38
- 241000283690 Bos taurus Species 0.000 description 37
- 229930012896 (S)-methoprene Natural products 0.000 description 36
- NFGXHKASABOEEW-MRXNPFEDSA-N (S)-methoprene Chemical compound COC(C)(C)CCC[C@H](C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-MRXNPFEDSA-N 0.000 description 35
- 239000002253 acid Substances 0.000 description 33
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 33
- 150000002500 ions Chemical class 0.000 description 32
- 244000045947 parasites Species 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000004094 surface-active agent Substances 0.000 description 27
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 26
- 235000014113 dietary fatty acids Nutrition 0.000 description 26
- 239000000194 fatty acid Substances 0.000 description 26
- 238000003892 spreading Methods 0.000 description 26
- 150000001298 alcohols Chemical class 0.000 description 25
- 244000078703 ectoparasites Species 0.000 description 25
- 229940074076 glycerol formal Drugs 0.000 description 25
- 230000002045 lasting Effects 0.000 description 25
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 23
- 239000003981 vehicle Substances 0.000 description 23
- 229960004063 Propylene glycol Drugs 0.000 description 22
- 239000003085 diluting agent Substances 0.000 description 22
- 235000013772 propylene glycol Nutrition 0.000 description 22
- 229940083542 Sodium Drugs 0.000 description 20
- 230000037396 body weight Effects 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 229910052708 sodium Inorganic materials 0.000 description 20
- 235000015424 sodium Nutrition 0.000 description 20
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 150000004665 fatty acids Chemical class 0.000 description 19
- 238000002425 crystallisation Methods 0.000 description 18
- 230000005712 crystallization Effects 0.000 description 18
- 230000002708 enhancing Effects 0.000 description 18
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 18
- 239000012049 topical pharmaceutical composition Substances 0.000 description 18
- 241000258924 Ctenocephalides felis Species 0.000 description 17
- 125000000304 alkynyl group Chemical group 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 13
- 229960002622 Triacetin Drugs 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 13
- 235000013773 glyceryl triacetate Nutrition 0.000 description 13
- 239000001087 glyceryl triacetate Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 12
- 125000003282 alkyl amino group Chemical group 0.000 description 12
- 239000004530 micro-emulsion Substances 0.000 description 12
- 230000002265 prevention Effects 0.000 description 12
- 241000403354 Microplus Species 0.000 description 11
- 241000283898 Ovis Species 0.000 description 11
- 241001674048 Phthiraptera Species 0.000 description 11
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 11
- 230000003071 parasitic Effects 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 230000001839 systemic circulation Effects 0.000 description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 125000004432 carbon atoms Chemical group C* 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 229960005150 glycerol Drugs 0.000 description 10
- 239000003961 penetration enhancing agent Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 241000255925 Diptera Species 0.000 description 9
- 210000002832 Shoulder Anatomy 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 229960004217 benzyl alcohol Drugs 0.000 description 9
- 239000004359 castor oil Substances 0.000 description 9
- 235000019438 castor oil Nutrition 0.000 description 9
- 150000001991 dicarboxylic acids Chemical class 0.000 description 9
- 201000009910 diseases by infectious agent Diseases 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- 241000229754 Iva xanthiifolia Species 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- RUOJZAUFBMNUDX-UHFFFAOYSA-N Propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 8
- 241000238680 Rhipicephalus microplus Species 0.000 description 8
- SOFLHPFCJKLSJL-BUDFFRDRSA-N [(2S,3S,4R,5R)-2-(acetyloxymethyl)-4-hydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-3-yl] 2-methylpropanoate Chemical compound CC(C)C(=O)O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SOFLHPFCJKLSJL-BUDFFRDRSA-N 0.000 description 8
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 150000001735 carboxylic acids Chemical class 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000004440 haloalkylsulfinyl group Chemical group 0.000 description 8
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 8
- 229920001983 poloxamer Polymers 0.000 description 8
- 229940032159 propylene carbonate Drugs 0.000 description 8
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 8
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 8
- KQNPFQTWMSNSAP-UHFFFAOYSA-N Isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 7
- 241000790252 Otodectes cynotis Species 0.000 description 7
- 210000002381 Plasma Anatomy 0.000 description 7
- 235000019445 benzyl alcohol Nutrition 0.000 description 7
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 7
- XNWFRZJHXBZDAG-UHFFFAOYSA-N ethylene glycol monomethyl ether Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 7
- 125000004438 haloalkoxy group Chemical group 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000002480 mineral oil Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-Dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 6
- 241000271566 Aves Species 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 6
- 241000238678 Boophilus Species 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 229950003442 Methoprene Drugs 0.000 description 6
- 241001481696 Rhipicephalus sanguineus Species 0.000 description 6
- 240000003516 Rumex sanguineus Species 0.000 description 6
- 210000003625 Skull Anatomy 0.000 description 6
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 6
- 230000000111 anti-oxidant Effects 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 244000079386 endoparasites Species 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 239000010408 film Substances 0.000 description 6
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 description 6
- 239000002917 insecticide Substances 0.000 description 6
- 244000144972 livestock Species 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 229930002897 methoprenes Natural products 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 230000002335 preservative Effects 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 230000002194 synthesizing Effects 0.000 description 6
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 5
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 5
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-Ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 5
- QCAHUFWKIQLBNB-UHFFFAOYSA-N 3-(3-methoxypropoxy)propan-1-ol Chemical compound COCCCOCCCO QCAHUFWKIQLBNB-UHFFFAOYSA-N 0.000 description 5
- 240000009176 Dahlia pinnata Species 0.000 description 5
- 241000257232 Haematobia irritans Species 0.000 description 5
- FSVJFNAIGNNGKK-UHFFFAOYSA-N Praziquantel Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 5
- 241000509427 Sarcoptes scabiei Species 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000003096 antiparasitic agent Substances 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 150000001733 carboxylic acid esters Chemical class 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 229940093476 ethylene glycol Drugs 0.000 description 5
- 150000002334 glycols Chemical class 0.000 description 5
- 125000004995 haloalkylthio group Chemical group 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 230000000749 insecticidal Effects 0.000 description 5
- 230000000670 limiting Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 230000003389 potentiating Effects 0.000 description 5
- 229960002957 praziquantel Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 4
- CUVLMZNMSPJDON-UHFFFAOYSA-N 1-(1-butoxypropan-2-yloxy)propan-2-ol Chemical compound CCCCOCC(C)OCC(C)O CUVLMZNMSPJDON-UHFFFAOYSA-N 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 4
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 4
- URZHQOCYXDNFGN-UHFFFAOYSA-N 2,4,6-trimethyl-2,4,6-tris(3,3,3-trifluoropropyl)-1,3,5,2,4,6-trioxatrisilinane Chemical compound FC(F)(F)CC[Si]1(C)O[Si](C)(CCC(F)(F)F)O[Si](C)(CCC(F)(F)F)O1 URZHQOCYXDNFGN-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241001480824 Dermacentor Species 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- XUGNVMKQXJXZCD-UHFFFAOYSA-N Isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 4
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 4
- 229960002479 Isosorbide Drugs 0.000 description 4
- 229940067606 Lecithin Drugs 0.000 description 4
- 241001113970 Linognathus Species 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 241000920471 Lucilia caesar Species 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- YLYBTZIQSIBWLI-UHFFFAOYSA-N Octyl acetate Chemical compound CCCCCCCCOC(C)=O YLYBTZIQSIBWLI-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- 229940026235 PROPYLENE GLYCOL MONOLAURATE Drugs 0.000 description 4
- 241001481703 Rhipicephalus <genus> Species 0.000 description 4
- 210000001732 Sebaceous Glands Anatomy 0.000 description 4
- 241001494115 Stomoxys calcitrans Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000607479 Yersinia pestis Species 0.000 description 4
- 230000001058 adult Effects 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 229940075495 isopropyl palmitate Drugs 0.000 description 4
- 239000002949 juvenile hormone Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000001630 malic acid Substances 0.000 description 4
- 229940099690 malic acid Drugs 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- HWGXPHSUTYGITL-GFCCVEGCSA-N methyl 4-[(2R)-6-methyl-4-oxoheptan-2-yl]benzoate Chemical compound COC(=O)C1=CC=C([C@H](C)CC(=O)CC(C)C)C=C1 HWGXPHSUTYGITL-GFCCVEGCSA-N 0.000 description 4
- 230000003278 mimic Effects 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 4
- 150000002923 oximes Chemical class 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 4
- 229940116351 sebacate Drugs 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229910052718 tin Inorganic materials 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
- RWKSBJVOQGKDFZ-UHFFFAOYSA-N 16-methylheptadecyl 2-hydroxypropanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)C(C)O RWKSBJVOQGKDFZ-UHFFFAOYSA-N 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- 239000005996 Blood meal Substances 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 241000258922 Ctenocephalides Species 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 241000282324 Felis Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N Glycol stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000005906 Imidacloprid Substances 0.000 description 3
- YWTYJOPNNQFBPC-UHFFFAOYSA-N Imidacloprid Chemical compound [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 description 3
- 241000238681 Ixodes Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000257226 Muscidae Species 0.000 description 3
- 208000006123 Myiasis Diseases 0.000 description 3
- 229940068968 Polysorbate 80 Drugs 0.000 description 3
- 241000509416 Sarcoptes Species 0.000 description 3
- 229940091252 Sodium supplements Drugs 0.000 description 3
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 241000244031 Toxocara Species 0.000 description 3
- 241000243774 Trichinella Species 0.000 description 3
- 241001259047 Trichodectes Species 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 229940046009 Vitamin E Drugs 0.000 description 3
- 230000000895 acaricidal Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 230000002141 anti-parasite Effects 0.000 description 3
- 230000003078 antioxidant Effects 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 201000008680 babesiosis Diseases 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002194 fatty esters Chemical class 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 235000011087 fumaric acid Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 150000002314 glycerols Chemical class 0.000 description 3
- 125000000262 haloalkenyl group Chemical group 0.000 description 3
- 125000006809 haloalkylaminocarbonyl group Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229940056881 imidacloprid Drugs 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 150000002547 isoxazolines Chemical class 0.000 description 3
- 229930014550 juvenile hormones Natural products 0.000 description 3
- 230000003902 lesions Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000005445 natural product Substances 0.000 description 3
- 229930014626 natural products Natural products 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- FSVSNKCOMJVGLM-UHFFFAOYSA-N octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O FSVSNKCOMJVGLM-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000002035 prolonged Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 150000003712 vitamin E derivatives Chemical class 0.000 description 3
- 230000003442 weekly Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- PJUIMOJAAPLTRJ-GSVOUGTGSA-N (R)-monothioglycerol Chemical compound OC[C@@H](O)CS PJUIMOJAAPLTRJ-GSVOUGTGSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- UNCVXXVJJXJZII-QLETUHIQSA-N 1K1CU6363A Chemical compound OC(=O)C(/C)=C/C=C/[C@@](C)([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@]1(C)[C@@H]2CC2=C1N1[C@@H](C(=C)C)C(=O)C3=C([C@@H](O)[C@@H]4C(OC(C)(C)C=C44)(C)C)C4=CC2=C31 UNCVXXVJJXJZII-QLETUHIQSA-N 0.000 description 2
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2H-imidazo[4,5-d][1,3]thiazole Chemical class C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102100017923 ACOT12 Human genes 0.000 description 2
- 101710008266 ACOT12 Proteins 0.000 description 2
- 229950008167 Abamectin Drugs 0.000 description 2
- 241000238682 Amblyomma americanum Species 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N Arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 239000005878 Azadirachtin Substances 0.000 description 2
- FTNJWQUOZFUQQJ-NDAWSKJSSA-N Azadirachtin Chemical compound C([C@@H]([C@]1(C=CO[C@H]1O1)O)[C@]2(C)O3)[C@H]1[C@]23[C@]1(C)[C@H](O)[C@H](OC[C@@]2([C@@H](C[C@@H]3OC(=O)C(\C)=C\C)OC(C)=O)C(=O)OC)[C@@H]2[C@]32CO[C@@](C(=O)OC)(O)[C@@H]12 FTNJWQUOZFUQQJ-NDAWSKJSSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 241000253350 Capillaria Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241000242722 Cestoda Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229960004782 Chlordiazepoxide Drugs 0.000 description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N Chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
- 241000933851 Cochliomyia Species 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 241001128004 Demodex Species 0.000 description 2
- 108010002156 Depsipeptides Proteins 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 239000005893 Diflubenzuron Substances 0.000 description 2
- QQQYTWIFVNKMRW-UHFFFAOYSA-N Diflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C=C1 QQQYTWIFVNKMRW-UHFFFAOYSA-N 0.000 description 2
- ILYCWAKSDCYMBB-OPCMSESCSA-N Dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 description 2
- QLFZZSKTJWDQOS-YDBLARSUSA-N Doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 2
- 241000498256 Enterobius Species 0.000 description 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N Etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 2
- 229960002541 Ethacrynic Acid Drugs 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- HJUFTIJOISQSKQ-UHFFFAOYSA-N Fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 2
- 239000005898 Fenoxycarb Substances 0.000 description 2
- 239000005899 Fipronil Substances 0.000 description 2
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N Fipronil Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229940100242 Glycol Stearate Drugs 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N Guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- 229940116364 Hard Fat Drugs 0.000 description 2
- 241001480843 Ixodes ricinus Species 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229950000961 Latidectin Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 241001113946 Linognathus vituli Species 0.000 description 2
- 229940057917 Medium chain triglycerides Drugs 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 229940014995 Nitroglycerin Drugs 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 241000790250 Otodectes Species 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- UVZZDDLIOJPDKX-ITKQZBBDSA-N Paraherquamide Chemical compound O1C(C)(C)C=COC2=C1C=CC1=C2NC(=O)[C@]11C(C)(C)[C@@H]2C[C@]3(N(C4)CC[C@@]3(C)O)C(=O)N(C)[C@]42C1 UVZZDDLIOJPDKX-ITKQZBBDSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N Phenethyl alcohol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004698 Polyethylene (PE) Substances 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229940070846 Pyrethrins Drugs 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N Quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 235000003846 Ricinus Nutrition 0.000 description 2
- 241000322381 Ricinus <louse> Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- JUVIOZPCNVVQFO-HBGVWJBISA-N Rotenone Natural products O([C@H](CC1=C2O3)C(C)=C)C1=CC=C2C(=O)[C@@H]1[C@H]3COC2=C1C=C(OC)C(OC)=C2 JUVIOZPCNVVQFO-HBGVWJBISA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 241000894243 Sericata Species 0.000 description 2
- CSMWJXBSXGUPGY-UHFFFAOYSA-L Sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 2
- 241001494139 Stomoxys Species 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N TBHQ Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- UBCKGWBNUIFUST-YHYXMXQVSA-N Tetrachlorvinphos Chemical compound COP(=O)(OC)O\C(=C/Cl)C1=CC(Cl)=C(Cl)C=C1Cl UBCKGWBNUIFUST-YHYXMXQVSA-N 0.000 description 2
- 229960000278 Theophylline Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N Tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 241000607216 Toxascaris Species 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 Zidovudine Drugs 0.000 description 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N Zygomycin A1 Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000642 acaricide Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000002506 adulticidal Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 229940087168 alpha Tocopherol Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000008361 aminoacetonitriles Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229960003942 amphotericin B Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 108060000449 aph-1 Proteins 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N carbon bisulphide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 2
- 229940019503 diflubenzuron Drugs 0.000 description 2
- 229960000465 dihydrotachysterol Drugs 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229960003997 doramectin Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 229940013764 fipronil Drugs 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 230000003370 grooming Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 description 2
- 125000004992 haloalkylamino group Chemical group 0.000 description 2
- 125000000232 haloalkynyl group Chemical group 0.000 description 2
- 125000005292 haloalkynyloxy group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000003752 hydrotrope Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- WTERNLDOAPYGJD-SFHVURJKSA-N monepantel Chemical compound C([C@@](C)(NC(=O)C=1C=CC(SC(F)(F)F)=CC=1)C#N)OC1=CC(C#N)=CC=C1C(F)(F)F WTERNLDOAPYGJD-SFHVURJKSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 2
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000002297 parasiticide Substances 0.000 description 2
- 229960001914 paromomycin Drugs 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229960005141 piperazine Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 239000002728 pyrethroid Substances 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001850 reproductive Effects 0.000 description 2
- 230000037335 skin penetration Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- ITCAUAYQCALGGV-XTICBAGASA-M sodium;(1R,4aR,4bR,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate Chemical compound [Na+].C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C([O-])=O ITCAUAYQCALGGV-XTICBAGASA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 229940029614 triethanolamine stearate Drugs 0.000 description 2
- 230000002034 xenobiotic Effects 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N α-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- ZCVAOQKBXKSDMS-PVAVHDDUSA-N (+)-trans-(S)-allethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(CC=C)C(=O)C1 ZCVAOQKBXKSDMS-PVAVHDDUSA-N 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N (+-)-(RS)-limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- GDLBFKVLRPITMI-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 description 1
- VNYBTNPBYXSMOO-UHFFFAOYSA-M (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate;bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1 VNYBTNPBYXSMOO-UHFFFAOYSA-M 0.000 description 1
- CAVQBDOACNULDN-KHFUBBAMSA-N (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-KHFUBBAMSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- FIWSRSRCWYARAJ-SQOFCNSWSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FIWSRSRCWYARAJ-SQOFCNSWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WGLYHYWDYPSNPF-RQFIXDHTSA-N (2R,3R,4S,5S,6S)-2-[[(2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy-4-hydroxy-3-(methylamino)-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-2-yl]oxy]-5-amino-6-(hydroxymethyl)oxane-3,4-diol;sulfuric acid Chemical compound OS(O)(=O)=O.O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O WGLYHYWDYPSNPF-RQFIXDHTSA-N 0.000 description 1
- OPCHFPHZPIURNA-MFERNQICSA-N (2S)-2,5-bis(3-aminopropylamino)-N-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- ZDOOQPFIGYHZFV-MSOLQXFVSA-N (2S,4R)-2-ethyl-4-[(4-phenoxyphenoxy)methyl]-1,3-dioxolane Chemical compound O1[C@@H](CC)OC[C@H]1COC(C=C1)=CC=C1OC1=CC=CC=C1 ZDOOQPFIGYHZFV-MSOLQXFVSA-N 0.000 description 1
- HBJOXQRURQPDEX-MHXMMLMNSA-N (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-ethylpiperidine-2-carboxamide Chemical compound C1[C@H](CC)CCN[C@@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 HBJOXQRURQPDEX-MHXMMLMNSA-N 0.000 description 1
- SHGAZHPCJJPHSC-XFYACQKRSA-N (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 1
- RLLPVAHGXHCWKJ-HKUYNNGSSA-N (3-phenoxyphenyl)methyl (1R,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-HKUYNNGSSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- DEQANNDTNATYII-MEUDYGGUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)NC(CO)C(O)C)C1=CC=CC=C1 DEQANNDTNATYII-MEUDYGGUSA-N 0.000 description 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 1
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
- NPUZFKMKEFBWLV-SNAWJCMRSA-N (E)-pent-2-ene Chemical group [CH2]C\C=C\C NPUZFKMKEFBWLV-SNAWJCMRSA-N 0.000 description 1
- FZRBKIRIBLNOAM-UHFFFAOYSA-N (E,E)-2-propynyl 3,7,11-trimethyl-2,4-dodecadienoate Chemical compound CC(C)CCCC(C)CC=CC(C)=CC(=O)OCC#C FZRBKIRIBLNOAM-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- 125000000606 (S)-methoprene group Chemical group 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N (Z)-but-2-enedioic acid;2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 125000006018 1-methyl-ethenyl group Chemical group 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- RPAJWWXZIQJVJF-UHFFFAOYSA-N 2,4-dichloro-6-(3,5-dichloro-2-hydroxyphenyl)sulfinylphenol Chemical compound OC1=C(Cl)C=C(Cl)C=C1S(=O)C1=CC(Cl)=CC(Cl)=C1O RPAJWWXZIQJVJF-UHFFFAOYSA-N 0.000 description 1
- UWNADWZGEHDQAB-UHFFFAOYSA-N 2,5-Dimethylhexane Chemical group CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- CZGIRAWWWHPJHM-UHFFFAOYSA-N 2-(3-methylpent-1-yn-3-yloxycarbonyl)benzoic acid Chemical compound CCC(C)(C#C)OC(=O)C1=CC=CC=C1C(O)=O CZGIRAWWWHPJHM-UHFFFAOYSA-N 0.000 description 1
- KXPXKNBDCUOENF-UHFFFAOYSA-N 2-(Octylthio)ethanol Chemical compound CCCCCCCCSCCO KXPXKNBDCUOENF-UHFFFAOYSA-N 0.000 description 1
- ISRUGXGCCGIOQO-UHFFFAOYSA-N 2-Isopropoxyphenyl N-methylcarbamate Chemical compound CNC(=O)OC1=CC=CC=C1OC(C)C ISRUGXGCCGIOQO-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-TUJWMRSMSA-N 2-[(2S)-butan-2-yl]-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-TUJWMRSMSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- FPQQSNUTBWFFLB-UHFFFAOYSA-N 2-chloro-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CCl FPQQSNUTBWFFLB-UHFFFAOYSA-N 0.000 description 1
- IWRFWZPCCDGEFJ-UXBLZVDNSA-N 2-cyanoethyl (1E)-N-(methylcarbamoyloxy)ethanimidothioate Chemical compound CNC(=O)O\N=C(/C)SCCC#N IWRFWZPCCDGEFJ-UXBLZVDNSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- OJCZPLDERGDQRJ-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 OJCZPLDERGDQRJ-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N 2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- YWDWYOALXURQPZ-UHFFFAOYSA-N 2-methyl-N-[3-(2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazol-6-yl)phenyl]propanamide Chemical compound CC(C)C(=O)NC1=CC=CC(C2N=C3SCCN3C2)=C1 YWDWYOALXURQPZ-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WAHLMMKQTIGONH-UHFFFAOYSA-N 3,3,3-tris(4-chlorophenyl)-1-(4-methylpiperazin-4-ium-1-yl)propan-1-one;chloride Chemical compound Cl.C1CN(C)CCN1C(=O)CC(C=1C=CC(Cl)=CC=1)(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 WAHLMMKQTIGONH-UHFFFAOYSA-N 0.000 description 1
- XJHDMGJURBVLLE-UHFFFAOYSA-N 3,5a,9-trimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g][1]benzofuran-2,8-dione Chemical compound C1CC2(C)C=CC(=O)C(C)=C2C2C1C(C)C(=O)O2 XJHDMGJURBVLLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- OOPDAHSJBRZRPH-UHFFFAOYSA-L 3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate;2-[(E)-2-(2,5-dimethyl-1-phenylpyrrol-3-yl)ethenyl]-N,N,1-trimethylquinolin-1-ium-6-amine Chemical compound C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C12=CC=CC=C2C=C(C([O-])=O)C(O)=C1CC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 OOPDAHSJBRZRPH-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NARHAGIVSFTMIG-UHFFFAOYSA-N 4-(dimethylamino)-2,2-diphenylpentanamide Chemical compound C=1C=CC=CC=1C(C(N)=O)(CC(C)N(C)C)C1=CC=CC=C1 NARHAGIVSFTMIG-UHFFFAOYSA-N 0.000 description 1
- XULACPAEUUWKFX-UHFFFAOYSA-N 4-chloro-2-(5-chloro-2-hydroxy-3-nitrophenyl)-6-nitrophenol Chemical compound C1=C(Cl)C=C([N+]([O-])=O)C(O)=C1C1=CC(Cl)=CC([N+]([O-])=O)=C1O XULACPAEUUWKFX-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 125000006058 4-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000000439 4-methylpentoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- KEEYRKYKLYARHO-UHFFFAOYSA-N 5-[(4,5-dimethoxy-2-methylphenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=C(OC)C(OC)=CC(C)=C1CC1=CN=C(N)N=C1N KEEYRKYKLYARHO-UHFFFAOYSA-N 0.000 description 1
- MHPUGCYGQWGLJL-UHFFFAOYSA-M 5-methylhexanoate Chemical compound CC(C)CCCC([O-])=O MHPUGCYGQWGLJL-UHFFFAOYSA-M 0.000 description 1
- HGZUXWNRGDQIPA-UHFFFAOYSA-N 6-$l^{1}-oxidanyl-3,5-dihydro-2H-pyrazine Chemical group [O]C1=NCC[N]C1 HGZUXWNRGDQIPA-UHFFFAOYSA-N 0.000 description 1
- SGXFBBAFIMCMPE-UHFFFAOYSA-N 7-hydroxy-3-(trifluoromethyl)pyrrolo[2,3-b]pyridine Chemical compound ON1C=CC=C2C(C(F)(F)F)=CN=C12 SGXFBBAFIMCMPE-UHFFFAOYSA-N 0.000 description 1
- PSGRLCOSIXJUAL-ZPQKBBRKSA-N 71YF100S3H Chemical compound CS(O)(=O)=O.C1=CC=C2C(C(OC3C[C@@H]4CC5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 PSGRLCOSIXJUAL-ZPQKBBRKSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229960005054 ACEPROMAZINE Drugs 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 229940035620 ACTH and synthetic analog preparations Drugs 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229940033488 ANTINEMATODAL AGENTS Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N Acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N Actinospectacin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229940023040 Acyclovir Drugs 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- 241001524031 Aedes sp. Species 0.000 description 1
- 229940057282 Albuterol Sulfate Drugs 0.000 description 1
- QGLZXHRNAYXIBU-WEVVVXLNSA-N Aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 229940024113 Allethrin Drugs 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N Alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- VWAUPFMBXBWEQY-ANULTFPQSA-N Altrenogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC=C)C=C3)C3=C21 VWAUPFMBXBWEQY-ANULTFPQSA-N 0.000 description 1
- 229960003805 Amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 241000238679 Amblyomma Species 0.000 description 1
- 229940114612 Aminopentamide Drugs 0.000 description 1
- 229960003556 Aminophylline Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N Aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960005260 Amiodarone Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N Amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004005 Amlodipine Besylate Drugs 0.000 description 1
- 229940088990 Ammonium Stearate Drugs 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960003683 Amprolium Drugs 0.000 description 1
- LCTXBFGHZLGBNU-UHFFFAOYSA-M Amprolium Chemical compound [Cl-].NC1=NC(CCC)=NC=C1C[N+]1=CC=CC=C1C LCTXBFGHZLGBNU-UHFFFAOYSA-M 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N Amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 208000006730 Anaplasmosis Diseases 0.000 description 1
- 241001147657 Ancylostoma Species 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N Anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 241001520752 Anopheles sp. Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- YBQWEUNEYYXYOI-UHFFFAOYSA-N Arsenamide Chemical compound NC(=O)C1=CC=C([As](SCC(O)=O)SCC(O)=O)C=C1 YBQWEUNEYYXYOI-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229960002274 Atenolol Drugs 0.000 description 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N Atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
- 229960003002 Atipamezole Drugs 0.000 description 1
- 229960002028 Atropine Sulfate Drugs 0.000 description 1
- 229950003616 Azaperone Drugs 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N Azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N Azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N BAY VP 2674 Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- PNVJTZOFSHSLTO-UHFFFAOYSA-N Baytex Chemical compound COP(=S)(OC)OC1=CC=C(SC)C(C)=C1 PNVJTZOFSHSLTO-UHFFFAOYSA-N 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N Benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- AVWWVJUMXRXPNF-UHFFFAOYSA-N Bephenium hydroxynaphthoate Chemical compound C=1C=CC=CC=1C[N+](C)(C)CCOC1=CC=CC=C1 AVWWVJUMXRXPNF-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N Bisphenol A Chemical class C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N Bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- OMWQUXGVXQELIX-UHFFFAOYSA-N Bitoscanate Chemical compound S=C=NC1=CC=C(N=C=S)C=C1 OMWQUXGVXQELIX-UHFFFAOYSA-N 0.000 description 1
- 229950002418 Bitoscanate Drugs 0.000 description 1
- 241000270299 Boa Species 0.000 description 1
- 241000972142 Boophis <genus> Species 0.000 description 1
- 229940097269 Borrelia burgdorferi Drugs 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- DAASOABUJRMZAD-UHFFFAOYSA-N Bromocyclen Chemical compound BrCC1CC2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl DAASOABUJRMZAD-UHFFFAOYSA-N 0.000 description 1
- NYQDCVLCJXRDSK-UHFFFAOYSA-N Bromofos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(Br)C=C1Cl NYQDCVLCJXRDSK-UHFFFAOYSA-N 0.000 description 1
- KWGUFOITWDSNQY-UHFFFAOYSA-N Bromophos-ethyl Chemical group CCOP(=S)(OCC)OC1=CC(Cl)=C(Br)C=C1Cl KWGUFOITWDSNQY-UHFFFAOYSA-N 0.000 description 1
- 229950009518 Bromoxanide Drugs 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 229950004965 Bunamidine Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N Buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229950000536 Butamisole Drugs 0.000 description 1
- 229960001590 Butorphanol Tartrate Drugs 0.000 description 1
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 1
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 239000008001 CAPS buffer Substances 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 102100003755 CCNO Human genes 0.000 description 1
- 101700047412 CCNO Proteins 0.000 description 1
- 229960002129 CEFIXIME Drugs 0.000 description 1
- JPKKQJKQTPNWTR-CHYDPLAESA-N CHEMBL3182372 Chemical compound O.OS(O)(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1.O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 JPKKQJKQTPNWTR-CHYDPLAESA-N 0.000 description 1
- 229950010946 CLIOXANIDE Drugs 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- RCKMWOKWVGPNJF-UHFFFAOYSA-N Carbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
- 229960005286 Carbaryl Drugs 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N Carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 229960000954 Carbenicillin indanyl sodium Drugs 0.000 description 1
- CFOYWRHIYXMDOT-UHFFFAOYSA-N Carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
- 229960001704 Carbimazole Drugs 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N Carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 229940074993 Carbon Disulfide Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- VEDTXTNSFWUXGQ-UHFFFAOYSA-N Carbophenothion Chemical compound CCOP(=S)(OCC)SCSC1=CC=C(Cl)C=C1 VEDTXTNSFWUXGQ-UHFFFAOYSA-N 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N Carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960001777 Castor Oil Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N Cefalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- 229960003408 Cefazolin Sodium Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N Cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960002417 Cefoperazone Sodium Drugs 0.000 description 1
- 229960004261 Cefotaxime Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N Cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960004445 Cefotetan Disodium Drugs 0.000 description 1
- 229960003016 Cefoxitin Sodium Drugs 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 229960000484 Ceftazidime Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N Ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 description 1
- 229960004467 Ceftiofur sodium Drugs 0.000 description 1
- 229940106164 Cephalexin Drugs 0.000 description 1
- 229940106193 Cephapirin Drugs 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- BIWJNBZANLAXMG-YQELWRJZSA-N Chloordaan Chemical compound ClC1=C(Cl)[C@@]2(Cl)C3CC(Cl)C(Cl)C3[C@]1(Cl)C2(Cl)Cl BIWJNBZANLAXMG-YQELWRJZSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N Chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229960002155 Chlorothiazide Drugs 0.000 description 1
- 229940046978 Chlorpheniramine Maleate Drugs 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229960001076 Chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001761 Chlorpropamide Drugs 0.000 description 1
- 229960004475 Chlortetracycline Drugs 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000359266 Chorioptes Species 0.000 description 1
- 229940107218 Chromium Drugs 0.000 description 1
- 229960001380 Cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N Cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- SHCRDCOTRILILT-VCAZWOOASA-N Cinerin II Natural products O=C(OC)/C(=C\[C@@H]1[C@@H](C(=O)O[C@@H]2C(C)=C(C/C=C\C)C(=O)C2)C1(C)C)/C SHCRDCOTRILILT-VCAZWOOASA-N 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229960003324 Clavulanic Acid Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N Clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N Clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960005098 Clidinium bromide Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N Clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 229960005351 Cloprostenol Sodium Drugs 0.000 description 1
- 229960001054 Clorazepate Dipotassium Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N Cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 240000007170 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 229960004415 Codeine Phosphate Drugs 0.000 description 1
- 241001126268 Cooperia Species 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N Corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 229940108999 Cosyntropin Drugs 0.000 description 1
- 108010091893 Cosyntropin Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- BXNANOICGRISHX-UHFFFAOYSA-N Coumaphos Chemical compound CC1=C(Cl)C(=O)OC2=CC(OP(=S)(OCC)OCC)=CC=C21 BXNANOICGRISHX-UHFFFAOYSA-N 0.000 description 1
- 229940013361 Cresol Drugs 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N Crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- XXXSILNSXNPGKG-ZHACJKMWSA-N Crotoxyphos Chemical compound COP(=O)(OC)O\C(C)=C\C(=O)OC(C)C1=CC=CC=C1 XXXSILNSXNPGKG-ZHACJKMWSA-N 0.000 description 1
- 241000490513 Ctenocephalides canis Species 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N Cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 Cyproheptadine Drugs 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- BSBSDQUZDZXGFN-UHFFFAOYSA-N Cythioate Chemical compound COP(=S)(OC)OC1=CC=C(S(N)(=O)=O)C=C1 BSBSDQUZDZXGFN-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 229960001894 DETOMIDINE Drugs 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N Danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960003710 Dantrolene Sodium Drugs 0.000 description 1
- 239000005892 Deltamethrin Substances 0.000 description 1
- OWZREIFADZCYQD-NSHGMRRFSA-N Deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 241000202828 Dermatobia hominis Species 0.000 description 1
- DYVLXWPZFQQUIU-WGNDVSEMSA-N Derquantel Chemical compound O1C(C)(C)C=COC2=C1C=CC1=C2NC[C@]11C(C)(C)[C@@H]2C[C@]3(N(C4)CC[C@@]3(C)O)C(=O)N(C)[C@]42C1 DYVLXWPZFQQUIU-WGNDVSEMSA-N 0.000 description 1
- 229950004278 Derquantel Drugs 0.000 description 1
- 229960002845 Desmopressin Acetate Drugs 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Destomysin Chemical compound OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- JXMXDKHEZLKQPB-UHFFFAOYSA-N Detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003949 Dexpanthenol Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229950010198 Diamfenetide Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N Diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 229960004706 Dichlorphenamide Drugs 0.000 description 1
- OEBRKCOSUFCWJD-UHFFFAOYSA-N Dichlorvos Chemical compound COP(=O)(OC)OC=C(Cl)Cl OEBRKCOSUFCWJD-UHFFFAOYSA-N 0.000 description 1
- 229950001327 Dichlorvos Drugs 0.000 description 1
- 229960001193 Diclofenac Sodium Drugs 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N Diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N Dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N Diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
- NOCJXYPHIIZEHN-UHFFFAOYSA-N Difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 description 1
- 229950001733 Difloxacin Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- CMZOLQQGUABKKN-STGYROPVSA-N Dimadectin Chemical compound O([C@H]1C[C@@H](C2)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@H](C)[C@@H](C(=C/C1)\C)OCOCCOC)[C@]12CC[C@H](C)[C@@H](C(C)C)O1 CMZOLQQGUABKKN-STGYROPVSA-N 0.000 description 1
- 229950004439 Dimadectin Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N Dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 Dimenhydrinate Drugs 0.000 description 1
- 229960001051 Dimercaprol Drugs 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N Dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229950001902 Dimevamide Drugs 0.000 description 1
- IYGXEHDCSOYNKY-RZHHZEQLSA-N Dinoprost tromethamine Chemical compound OCC(N)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O IYGXEHDCSOYNKY-RZHHZEQLSA-N 0.000 description 1
- VBKKVDGJXVOLNE-UHFFFAOYSA-N Dioxathion Chemical compound CCOP(=S)(OCC)SC1OCCOC1SP(=S)(OCC)OCC VBKKVDGJXVOLNE-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- DMBHHRLKUKUOEG-UHFFFAOYSA-N Diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 1
- 229940035422 Diphenylamine Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N Dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 241000935794 Dipylidium Species 0.000 description 1
- 241000935792 Dipylidium caninum Species 0.000 description 1
- UVGTXNPVQOQFQW-UHFFFAOYSA-N Disophenol Chemical compound OC1=C(I)C=C([N+]([O-])=O)C=C1I UVGTXNPVQOQFQW-UHFFFAOYSA-N 0.000 description 1
- 229960001863 Disopyramide Phosphate Drugs 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N Disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 229960002563 Disulfiram Drugs 0.000 description 1
- MNQDKWZEUULFPX-UHFFFAOYSA-M Dithiazanine iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CC)=C1C=CC=CC=C1N(CC)C2=CC=CC=C2S1 MNQDKWZEUULFPX-UHFFFAOYSA-M 0.000 description 1
- 229950005765 Dithiazanine iodide Drugs 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine hydrobromide Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 229940018602 Docusate Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N Domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- XFDJYSQDBULQSI-UHFFFAOYSA-N Doxapram Chemical compound C=1C=CC=CC=1C1(C=2C=CC=CC=2)C(=O)N(CC)CC1CCN1CCOCC1 XFDJYSQDBULQSI-UHFFFAOYSA-N 0.000 description 1
- 229960002955 Doxapram Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 210000001956 EPC Anatomy 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N Emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N Enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 Enalapril Drugs 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N Enalaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- RDYMFSUJUZBWLH-SVWSLYAFSA-N Endosulfan Chemical compound C([C@@H]12)OS(=O)OC[C@@H]1[C@]1(Cl)C(Cl)=C(Cl)[C@@]2(Cl)C1(Cl)Cl RDYMFSUJUZBWLH-SVWSLYAFSA-N 0.000 description 1
- 229960005153 Enoxaparin sodium Drugs 0.000 description 1
- 229960004842 Ephedrine sulfate Drugs 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 229940011916 Ethacrynate Sodium Drugs 0.000 description 1
- RIZMRRKBZQXFOY-UHFFFAOYSA-N Ethion Chemical compound CCOP(=S)(OCC)SCSP(=S)(OCC)OCC RIZMRRKBZQXFOY-UHFFFAOYSA-N 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N Ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229940083280 FD&C Blue #1 Aluminum Lake Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N Famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 Famotidine Drugs 0.000 description 1
- 210000003195 Fascia Anatomy 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N Felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 241000322646 Felicola Species 0.000 description 1
- JHJOOSLFWRRSGU-UHFFFAOYSA-N Fenchlorphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(Cl)C=C1Cl JHJOOSLFWRRSGU-UHFFFAOYSA-N 0.000 description 1
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N Fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
- 229960002428 Fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- WDQNIWFZKXZFAY-UHFFFAOYSA-M Fentin acetate Chemical compound CC([O-])=O.C1=CC=CC=C1[Sn+](C=1C=CC=CC=1)C1=CC=CC=C1 WDQNIWFZKXZFAY-UHFFFAOYSA-M 0.000 description 1
- NYPJDWWKZLNGGM-UHFFFAOYSA-N Fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N Fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N Flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004381 Flumazenil Drugs 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N Flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229940013399 Flumethasone Drugs 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 229960002464 Fluoxetine Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960002107 Fluvoxamine Maleate Drugs 0.000 description 1
- 229950005302 Fospirate Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N Furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960003883 Furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N Furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004666 Glucagon Drugs 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- MSWZFWKMSRAUBD-SPZCMYQFSA-N Glucosamine Chemical compound N[C@H]1C(O)OC(CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-SPZCMYQFSA-N 0.000 description 1
- 229960002849 Glucosamine Sulfate Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 229940014653 Glyburide Drugs 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N Glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 229940015042 Glycopyrrolate Drugs 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229960002146 Guaifenesin Drugs 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241001480796 Haemaphysalis Species 0.000 description 1
- 241000257224 Haematobia Species 0.000 description 1
- 241000790933 Haematopinus Species 0.000 description 1
- 241000243976 Haemonchus Species 0.000 description 1
- 229960003132 Halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N Halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229950002831 Haloxon Drugs 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N Hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical group CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N Hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229940097277 Hygromycin B Drugs 0.000 description 1
- 101700021161 IR12 Proteins 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- 229960004683 Imidocarb Drugs 0.000 description 1
- SCEVFJUWLLRELN-UHFFFAOYSA-N Imidocarb Chemical compound C=1C=CC(C=2NCCN=2)=CC=1NC(=O)NC(C=1)=CC=CC=1C1=NCCN1 SCEVFJUWLLRELN-UHFFFAOYSA-N 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N Imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229940060367 Inert Ingredients Drugs 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- 239000009471 Ipecac Substances 0.000 description 1
- 229940083603 Ipodate Sodium Drugs 0.000 description 1
- ZFHZUGUCWJVEQC-FPUQOWELSA-N Ipodate sodium Chemical compound [Na+].CN(C)\C=N\C1=C(I)C=C(I)C(CCC(O)=O)=C1I ZFHZUGUCWJVEQC-FPUQOWELSA-N 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L Iron(II) sulfate Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229940039009 Isoproterenol Drugs 0.000 description 1
- 229960005280 Isotretinoin Drugs 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- BMUKKTUHUDJSNZ-UHFFFAOYSA-N Isoxsuprine Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 description 1
- 229960004819 Isoxsuprine Drugs 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N Kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229940033992 Kaolin / pectin Drugs 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960004384 Ketorolac Tromethamine Drugs 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N Lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229960003639 Laurocapram Drugs 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N Levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 229960003918 Levothyroxine Sodium Drugs 0.000 description 1
- 229940059904 Light Mineral Oil Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N Lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N Lindane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- 229960004488 Linolenic Acid Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229960002394 Lisinopril Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium Ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 241000257166 Lucilia cuprina Species 0.000 description 1
- 206010025169 Lyme disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101700085088 MORC1 Proteins 0.000 description 1
- 229940078812 MYRISTYL MYRISTATE Drugs 0.000 description 1
- 229940091250 Magnesium supplements Drugs 0.000 description 1
- 239000005949 Malathion Substances 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N Malathion Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- BPFYOAJNDMUVBL-UHFFFAOYSA-N Marbofloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 229940041321 Meclizine Drugs 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- 229960002234 Melarsomine Drugs 0.000 description 1
- MGEOLZFMLHYCFZ-UHFFFAOYSA-N Melarsomine Chemical compound C1=CC([As](SCCN)SCCN)=CC=C1NC1=NC(N)=NC(N)=N1 MGEOLZFMLHYCFZ-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N Mepacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 229940041655 Meperidine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N Mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 239000005914 Metaflumizone Substances 0.000 description 1
- MIFOMMKAVSCNKQ-HWIUFGAZSA-N Metaflumizone Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)N\N=C(C=1C=C(C=CC=1)C(F)(F)F)\CC1=CC=C(C#N)C=C1 MIFOMMKAVSCNKQ-HWIUFGAZSA-N 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N Methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 Methazolamide Drugs 0.000 description 1
- 229960004011 Methenamine Drugs 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N Methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229940042048 Methimazole Drugs 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N Methocarbamol Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- 229960001620 Methohexital Sodium Drugs 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N Methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 Methoxyflurane Drugs 0.000 description 1
- YRHYCMZPEVDGFQ-UHFFFAOYSA-N Methyl decanoate Chemical compound CCCCCCCCCC(=O)OC YRHYCMZPEVDGFQ-UHFFFAOYSA-N 0.000 description 1
- 229940042115 Methylene blue Drugs 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M Methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- QRBVCAWHUSTDOT-UHFFFAOYSA-N Methyridine Chemical compound COCCC1=CC=CC=N1 QRBVCAWHUSTDOT-UHFFFAOYSA-N 0.000 description 1
- VOEYXMAFNDNNED-UHFFFAOYSA-N Metolcarb Chemical compound CNC(=O)OC1=CC=CC(C)=C1 VOEYXMAFNDNNED-UHFFFAOYSA-N 0.000 description 1
- 229960003793 Midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N Midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229940042472 Mineral Oil Drugs 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- PYCSFZRHAYWHQB-UHFFFAOYSA-N Mirasan Chemical compound CCN(CC)CCNC1=CC=C(C)C(Cl)=C1 PYCSFZRHAYWHQB-UHFFFAOYSA-N 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 229950003439 Monepantel Drugs 0.000 description 1
- KRTSDMXIXPKRQR-AATRIKPKSA-N Monocrotophos Chemical compound CNC(=O)\C=C(/C)OP(=O)(OC)OC KRTSDMXIXPKRQR-AATRIKPKSA-N 0.000 description 1
- 229960004715 Morphine Sulfate Drugs 0.000 description 1
- 241000257229 Musca <genus> Species 0.000 description 1
- 241001414919 Musca sp. Species 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- FGGFIMIICGZCCJ-UHFFFAOYSA-N N,N-dibutyl-4-hexoxynaphthalene-1-carboximidamide Chemical compound C1=CC=C2C(OCCCCCC)=CC=C(C(=N)N(CCCC)CCCC)C2=C1 FGGFIMIICGZCCJ-UHFFFAOYSA-N 0.000 description 1
- WLLGXSLBOPFWQV-UHFFFAOYSA-N N-Octyl bicycloheptene dicarboximide Chemical compound C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 description 1
- JNEZCZPNQCQCFK-UHFFFAOYSA-N N-[4-[2-[2-(4-acetamidophenoxy)ethoxy]ethoxy]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1OCCOCCOC1=CC=C(NC(C)=O)C=C1 JNEZCZPNQCQCFK-UHFFFAOYSA-N 0.000 description 1
- WRPRKPMHLLGGIZ-UHFFFAOYSA-N N-[4-bromo-2-(trifluoromethyl)phenyl]-3-tert-butyl-2-hydroxy-6-methyl-5-nitrobenzamide Chemical compound CC1=C([N+]([O-])=O)C=C(C(C)(C)C)C(O)=C1C(=O)NC1=CC=C(Br)C=C1C(F)(F)F WRPRKPMHLLGGIZ-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-M N-benzoylglycinate Chemical compound [O-]C(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-M 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 229950011528 Naftalofos Drugs 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N Neomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229940053050 Neomycin Sulfate Drugs 0.000 description 1
- 229960002362 Neostigmine Drugs 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N Neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- 229940053487 Niacinamide Drugs 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N Niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229960001920 Niclosamide Drugs 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N Nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 Nitrofurantoin Drugs 0.000 description 1
- 229960002460 Nitroprusside Drugs 0.000 description 1
- SGKGVABHDAQAJO-UHFFFAOYSA-N Nitroxynil Chemical compound OC1=C(I)C=C(C#N)C=C1[N+]([O-])=O SGKGVABHDAQAJO-UHFFFAOYSA-N 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N Nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229960004872 Nizatidine Drugs 0.000 description 1
- 229960004781 Novobiocin Sodium Drugs 0.000 description 1
- WWPRGAYLRGSOSU-RNROJPEYSA-M Novobiocin sodium Chemical compound [Na+].O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C WWPRGAYLRGSOSU-RNROJPEYSA-M 0.000 description 1
- 101710008205 OXT Proteins 0.000 description 1
- 102100017240 OXT Human genes 0.000 description 1
- 229960001494 Octreotide Acetate Drugs 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N Oleyl alcohol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- CKNAQFVBEHDJQV-UHFFFAOYSA-N Oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 1
- 229950008687 Oltipraz Drugs 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 229940023486 Oral Product Drugs 0.000 description 1
- 229940096978 Oral Tablet Drugs 0.000 description 1
- QIPQASLPWJVQMH-DTORHVGOSA-N Orbifloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(F)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F QIPQASLPWJVQMH-DTORHVGOSA-N 0.000 description 1
- 241000243795 Ostertagia Species 0.000 description 1
- 239000005950 Oxamyl Substances 0.000 description 1
- VRYKTHBAWRESFI-VOTSOKGWSA-N Oxantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CC(O)=C1 VRYKTHBAWRESFI-VOTSOKGWSA-N 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N Oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229950003126 Oxyclozanide Drugs 0.000 description 1
- JYWIYHUXVMAGLG-UHFFFAOYSA-N Oxyclozanide Chemical compound OC1=C(Cl)C=C(Cl)C=C1NC(=O)C1=C(O)C(Cl)=CC(Cl)=C1Cl JYWIYHUXVMAGLG-UHFFFAOYSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 Oxytocin Drugs 0.000 description 1
- CFKMVGJGLGKFKI-UHFFFAOYSA-N P-Chlorocresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
- 108060006375 POMC Proteins 0.000 description 1
- 102100008873 POMC Human genes 0.000 description 1
- 229940114930 POTASSIUM STEARATE Drugs 0.000 description 1
- 108060006601 PRM1 Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229950007337 Parbendazole Drugs 0.000 description 1
- UOZODPSAJZTQNH-VZXHOKRSSA-N Paromomycin II Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-VZXHOKRSSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940090663 Penicillin V Potassium Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- 229960002275 Pentobarbital Sodium Drugs 0.000 description 1
- 229960000490 Permethrin Drugs 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Petidina Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 Phenobarbital Drugs 0.000 description 1
- 229950000688 Phenothiazine Drugs 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N Phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N Phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- 229960003418 Phenoxybenzamine Drugs 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N Phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 229960005323 Phenoxyethanol Drugs 0.000 description 1
- 229960001802 Phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N Phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229940067107 Phenylethyl Alcohol Drugs 0.000 description 1
- IOUNQDKNJZEDEP-UHFFFAOYSA-N Phosalone Chemical compound C1=C(Cl)C=C2OC(=O)N(CSP(=S)(OCC)OCC)C2=C1 IOUNQDKNJZEDEP-UHFFFAOYSA-N 0.000 description 1
- 239000005921 Phosmet Substances 0.000 description 1
- LMNZTLDVJIUSHT-UHFFFAOYSA-N Phosmet Chemical compound C1=CC=C2C(=O)N(CSP(=S)(OC)OC)C(=O)C2=C1 LMNZTLDVJIUSHT-UHFFFAOYSA-N 0.000 description 1
- 229950001664 Phoxim Drugs 0.000 description 1
- 229960001898 Phytomenadione Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 241000242594 Platyhelminthes Species 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N Ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 229940069338 Potassium Sorbate Drugs 0.000 description 1
- CHHHXKFHOYLYRE-STWYSWDKSA-M Potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 229960003456 Pralidoxime chloride Drugs 0.000 description 1
- 229960001289 Prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N Prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 102000004659 Presynaptic Receptors Human genes 0.000 description 1
- 108010003717 Presynaptic Receptors Proteins 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N Primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N Procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N Prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- GGRLUNQHANDPSC-UHFFFAOYSA-N Promacyl Chemical compound CCCC(=O)CNC(=O)OC1=CC(C)=CC(C(C)C)=C1 GGRLUNQHANDPSC-UHFFFAOYSA-N 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- 229940055019 Propionibacterium acnes Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N Propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 229950000033 Proxetil Drugs 0.000 description 1
- 229960003908 Pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N Pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 241001649229 Psoroptes Species 0.000 description 1
- 241001649230 Psoroptes ovis Species 0.000 description 1
- ROVGZAWFACYCSP-VUMXUWRFSA-N Pyrethrin I Natural products CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-VUMXUWRFSA-N 0.000 description 1
- VJFUPGQZSXIULQ-HTNYLFFISA-N Pyrethrin II Natural products CC1(C)[C@H](\C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VJFUPGQZSXIULQ-HTNYLFFISA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229960002151 Pyridostigmine Bromide Drugs 0.000 description 1
- 229940079863 Pyrilamine Drugs 0.000 description 1
- QMHSXPLYMTVAMK-UHFFFAOYSA-N Pyrvinium Chemical compound C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1\C=C\C(=C1C)C=C(C)N1C1=CC=CC=C1 QMHSXPLYMTVAMK-UHFFFAOYSA-N 0.000 description 1
- 229960001077 Pyrvinium pamoate Drugs 0.000 description 1
- 229940079923 Quinacrine Drugs 0.000 description 1
- 229950002980 RAFOXANIDE Drugs 0.000 description 1
- NEMNPWINWMHUMR-UHFFFAOYSA-N Rafoxanide Chemical compound OC1=C(I)C=C(I)C=C1C(=O)NC(C=C1Cl)=CC=C1OC1=CC=C(Cl)C=C1 NEMNPWINWMHUMR-UHFFFAOYSA-N 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N Ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 Ranitidine Drugs 0.000 description 1
- VEMKTZHHVJILDY-FIWHBWSRSA-N Resmethrin Chemical compound CC1(C)[C@H](C=C(C)C)C1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-FIWHBWSRSA-N 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 206010039207 Rocky mountain spotted fever Diseases 0.000 description 1
- 229940080817 Rotenone Drugs 0.000 description 1
- 229940081973 S-Adenosylmethionine Drugs 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine zwitterion Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 101710028061 SLC25A26 Proteins 0.000 description 1
- 229940080236 SODIUM CETYL SULFATE Drugs 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- WKEDVNSFRWHDNR-UHFFFAOYSA-N Salicylanilide Chemical class OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 description 1
- 241000319984 Sarcoptes sp. Species 0.000 description 1
- 229940082568 Selenium Drugs 0.000 description 1
- 229940091258 Selenium supplements Drugs 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N Sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N Silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 229960003885 Sodium Benzoate Drugs 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M Sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 229960003212 Sodium propionate Drugs 0.000 description 1
- 229960001567 Sodium stibogluconate Drugs 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M Sodium thiopental Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N Sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 Sotalol Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N Spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 229960000912 Stanozolol Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Stearin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229960005202 Streptokinase Drugs 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000244174 Strongyloides Species 0.000 description 1
- 229940120904 Succinylcholine Chloride Drugs 0.000 description 1
- 229960004291 Sucralfate Drugs 0.000 description 1
- 229960001204 Sufentanil Citrate Drugs 0.000 description 1
- 229950008831 Sulfachlorpyridazine Drugs 0.000 description 1
- 229940035528 Sulfamethoxazole / Trimethoprim Drugs 0.000 description 1
- 229960001940 Sulfasalazine Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- YOEWQQVKRJEPAE-UHFFFAOYSA-L Suxamethonium chloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 description 1
- 102100009839 TEPP Human genes 0.000 description 1
- 101700024241 TEPP Proteins 0.000 description 1
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
- 229960003080 Taurine Drugs 0.000 description 1
- 239000005937 Tebufenozide Substances 0.000 description 1
- QYPNKSZPJQQLRK-UHFFFAOYSA-N Tebufenozide Chemical compound C1=CC(CC)=CC=C1C(=O)NN(C(C)(C)C)C(=O)C1=CC(C)=CC(C)=C1 QYPNKSZPJQQLRK-UHFFFAOYSA-N 0.000 description 1
- 239000005938 Teflubenzuron Substances 0.000 description 1
- 229960000195 Terbutaline Drugs 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- IDCBOTIENDVCBQ-UHFFFAOYSA-N Tetraethyl pyrophosphate Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 1
- 229950004468 Thiacetarsamide sodium Drugs 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960000340 Thiopental Sodium Drugs 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 229940035626 Thyrotropin Class in ATC Drugs 0.000 description 1
- 229940060693 Tiletamine / Zolazepam Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960004477 Tobramycin Sulfate Drugs 0.000 description 1
- 229960002872 Tocainide Drugs 0.000 description 1
- BUJAGSGYPOAWEI-UHFFFAOYSA-N Tocainide Chemical compound CC(N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-UHFFFAOYSA-N 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N Tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229940100613 Topical Solution Drugs 0.000 description 1
- 229940041677 Topical Spray Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 229950001807 Tribromsalan Drugs 0.000 description 1
- 229940016279 Trichlorfon Drugs 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- DUXYWXYOBMKGIN-UHFFFAOYSA-N Trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- BFWMWWXRWVJXSE-UHFFFAOYSA-M Triphenyltin hydroxide Chemical compound C=1C=CC=CC=1[Sn](C=1C=CC=CC=1)(O)C1=CC=CC=C1 BFWMWWXRWVJXSE-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N Tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 Tylosin Drugs 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229960004298 Vecuronium Bromide Drugs 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229960004982 Vinblastine Sulfate Drugs 0.000 description 1
- 229960002110 Vincristine Sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 229960002647 Warfarin Sodium Drugs 0.000 description 1
- RLQVKDVIBJCQGE-WDUCDQOOSA-N Win-25540 Chemical compound O=C1C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 RLQVKDVIBJCQGE-WDUCDQOOSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 229960004764 Zafirlukast Drugs 0.000 description 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L Zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L Zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N Zonegran Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- ROVGZAWFACYCSP-WIURDZCKSA-N [(1S)-2-methyl-4-oxo-3-[(2E)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C\C=C)C(=O)C1 ROVGZAWFACYCSP-WIURDZCKSA-N 0.000 description 1
- NZKIRHFOLVYKFT-WIURDZCKSA-N [(1S)-2-methyl-4-oxo-3-[(E)-pent-2-enyl]cyclopent-2-en-1-yl] (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound C1C(=O)C(C/C=C/CC)=C(C)[C@H]1OC(=O)[C@H]1C(C)(C)[C@@H]1C=C(C)C NZKIRHFOLVYKFT-WIURDZCKSA-N 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- FTFYNJYNMCKWAJ-JQOFMKNESA-F [(2R,3S,4S,5R)-2,4-bis($l^{1}-alumanyloxysulfonyloxy)-5-($l^{1}-alumanyloxysulfonyloxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-tris($l^{1}-alumanyloxysulfonyloxy)-6-($l^{1}-alumanyloxysulfonyloxymethyl)oxan-2-yl]oxyoxolan-3-yl]oxysulfonyloxyaluminum;hexadecahydr Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al])[C@H](OS(=O)(=O)O[Al])[C@@H](COS(=O)(=O)O[Al])O[C@H]1O[C@@]1(COS(=O)(=O)O[Al])[C@@H](OS(=O)(=O)O[Al])[C@H](OS(=O)(=O)O[Al])[C@@H](OS(=O)(=O)O[Al])O1 FTFYNJYNMCKWAJ-JQOFMKNESA-F 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- AHMMSNQYOPMLSX-CNQKSJKFSA-N [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] undec-10-enoate Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)OC(=O)CCCCCCCCC=C)[C@@H]4[C@@H]3CCC2=C1 AHMMSNQYOPMLSX-CNQKSJKFSA-N 0.000 description 1
- HIGSLXSBYYMVKI-UHDJGPCESA-N [(E)-(1-methylpyridin-2-ylidene)methyl]-oxoazanium;chloride Chemical compound [Cl-].CN1C=CC=C\C1=C/[NH+]=O HIGSLXSBYYMVKI-UHDJGPCESA-N 0.000 description 1
- FZSVSABTBYGOQH-XFFZJAGNSA-N [(E)-(3,3-dimethyl-1-methylsulfanylbutan-2-ylidene)amino] N-methylcarbamate Chemical compound CNC(=O)O\N=C(C(C)(C)C)\CSC FZSVSABTBYGOQH-XFFZJAGNSA-N 0.000 description 1
- FSAVDKDHPDSCTO-WQLSENKSSA-N [(Z)-2-chloro-1-(2,4-dichlorophenyl)ethenyl] diethyl phosphate Chemical compound CCOP(=O)(OCC)O\C(=C/Cl)C1=CC=C(Cl)C=C1Cl FSAVDKDHPDSCTO-WQLSENKSSA-N 0.000 description 1
- ICKMASVVMCGZLR-UHFFFAOYSA-N [2-[(4-chlorophenyl)carbamoyl]-4,6-diiodophenyl] acetate Chemical compound CC(=O)OC1=C(I)C=C(I)C=C1C(=O)NC1=CC=C(Cl)C=C1 ICKMASVVMCGZLR-UHFFFAOYSA-N 0.000 description 1
- ZXQYGBMAQZUVMI-BWHPXCRDSA-N [cyano-(3-phenoxyphenyl)methyl] (1S,3S)-3-[(Z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](\C=C(/Cl)C(F)(F)F)[C@@H]1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-BWHPXCRDSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- VKVOKQTWSYMEAI-UHFFFAOYSA-N acetyl 2-methylpropanoate Chemical compound CC(C)C(=O)OC(C)=O VKVOKQTWSYMEAI-UHFFFAOYSA-N 0.000 description 1
- 102000034433 acetylcholine receptors Human genes 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000006323 alkenyl amino group Chemical group 0.000 description 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000006319 alkynyl amino group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000005134 alkynylsulfinyl group Chemical group 0.000 description 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229960000971 altrenogest Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000001136 anti-cestodal Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000003717 antitrematodal agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical compound [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960000254 bephenium Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 229960001901 bioallethrin Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- KULDXINYXFTXMO-UHFFFAOYSA-N bis(2-chloroethyl) (3-chloro-4-methyl-2-oxochromen-7-yl) phosphate Chemical compound C1=C(OP(=O)(OCCCl)OCCCl)C=CC2=C1OC(=O)C(Cl)=C2C KULDXINYXFTXMO-UHFFFAOYSA-N 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 229960002326 bithionol Drugs 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 230000003139 buffering Effects 0.000 description 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- NVTRPRFAWJGJAJ-UHFFFAOYSA-L calcium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M caprate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960000717 carindacillin Drugs 0.000 description 1
- QFWPXOXWAUAYAB-XZVIDJSISA-M carindacillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 QFWPXOXWAUAYAB-XZVIDJSISA-M 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 229960003525 cefalexin Drugs 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 229960001020 ciclobendazole Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- SHCRDCOTRILILT-WOBDGSLYSA-N cinerin II Chemical compound CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C)C(=O)C1 SHCRDCOTRILILT-WOBDGSLYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 description 1
- 229960002483 decamethrin Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- YNKFCNRZZPFMEX-XHPDKPNGSA-N desmopressin acetate trihydrate Chemical compound O.O.O.CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 YNKFCNRZZPFMEX-XHPDKPNGSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- CUHVIMMYOGQXCV-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CNC=N1 CUHVIMMYOGQXCV-NSHDSACASA-N 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- BUKPHEZEZDMAPU-UHFFFAOYSA-N dibenzofuran-1-carbaldehyde Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C=O BUKPHEZEZDMAPU-UHFFFAOYSA-N 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 229960003974 diethylcarbamazine Drugs 0.000 description 1
- CTPKSRZFJSJGML-UHFFFAOYSA-N diethylcarbamothioyl N,N-diethylcarbamodithioate Chemical compound CCN(CC)C(=S)SC(=S)N(CC)CC CTPKSRZFJSJGML-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- XCBOKUAJQWDYNI-UHFFFAOYSA-N dimethyl (3,5,6-trichloropyridin-2-yl) phosphate Chemical compound COP(=O)(OC)OC1=NC(Cl)=C(Cl)C=C1Cl XCBOKUAJQWDYNI-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- KYCIUIVANPKXLW-UHFFFAOYSA-N dimethyl-(2-phenoxyethyl)-(thiophen-2-ylmethyl)azanium Chemical compound C=1C=CSC=1C[N+](C)(C)CCOC1=CC=CC=C1 KYCIUIVANPKXLW-UHFFFAOYSA-N 0.000 description 1
- 229960004280 dinoprost tromethamine Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- QCHSEDTUUKDTIG-UHFFFAOYSA-L dipotassium clorazepate Chemical compound [OH-].[K+].[K+].C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 QCHSEDTUUKDTIG-UHFFFAOYSA-L 0.000 description 1
- IITCWRFYJWUUPC-UHFFFAOYSA-N dipropyl pyridine-2,5-dicarboxylate Chemical compound CCCOC(=O)C1=CC=C(C(=O)OCCC)N=C1 IITCWRFYJWUUPC-UHFFFAOYSA-N 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- AXRWJSAOLNNBNI-UHFFFAOYSA-L disodium;2-[(4-carbamoylphenyl)-(carboxylatomethylsulfanyl)arsanyl]sulfanylacetate Chemical compound [Na+].[Na+].NC(=O)C1=CC=C([As](SCC([O-])=O)SCC([O-])=O)C=C1 AXRWJSAOLNNBNI-UHFFFAOYSA-L 0.000 description 1
- CGDDQFMPGMYYQP-UHFFFAOYSA-N disopyramide phosphate Chemical compound OP(O)(O)=O.C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CGDDQFMPGMYYQP-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229950007663 dithiazanine Drugs 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- WRZXKWFJEFFURH-UHFFFAOYSA-N dodecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WRZXKWFJEFFURH-UHFFFAOYSA-N 0.000 description 1
- 229960003218 dolasetron mesylate Drugs 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229950008597 drug INN Drugs 0.000 description 1
- 230000001984 ectoparasiticidal Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001586 eradicative Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- JISACBWYRJHSMG-UHFFFAOYSA-N famphur Chemical compound COP(=S)(OC)OC1=CC=C(S(=O)(=O)N(C)C)C=C1 JISACBWYRJHSMG-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- GBIHOLCMZGAKNG-CGAIIQECSA-N flucythrinate Chemical compound O=C([C@@H](C(C)C)C=1C=CC(OC(F)F)=CC=1)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 GBIHOLCMZGAKNG-CGAIIQECSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229950003154 fludrocortisone acetate Drugs 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- RYLHNOVXKPXDIP-UHFFFAOYSA-N flufenoxuron Chemical compound C=1C=C(NC(=O)NC(=O)C=2C(=CC=CC=2F)F)C(F)=CC=1OC1=CC=C(C(F)(F)F)C=C1Cl RYLHNOVXKPXDIP-UHFFFAOYSA-N 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 125000005291 haloalkenyloxy group Chemical group 0.000 description 1
- 125000006769 halocycloalkoxy group Chemical group 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- GBAWQJNHVWMTLU-UHFFFAOYSA-N heptenophos Chemical compound C1=CCC2C(OP(=O)(OC)OC)=C(Cl)C21 GBAWQJNHVWMTLU-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 101710007446 het-s Proteins 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- RNYJXPUAFDFIQJ-UHFFFAOYSA-N hydron;octadecan-1-amine;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH3+] RNYJXPUAFDFIQJ-UHFFFAOYSA-N 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 229940068812 inamrinone lactate Drugs 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229950005264 iopodic acid Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 229910000460 iron oxide Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 150000005605 isobutyric acids Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- WKNSDDMJXANVMK-XIGJTORUSA-N jasmolin II Chemical compound C1C(=O)C(C\C=C/CC)=C(C)[C@H]1OC(=O)[C@H]1C(C)(C)[C@@H]1\C=C(/C)C(=O)OC WKNSDDMJXANVMK-XIGJTORUSA-N 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 229930001540 kinoprene Natural products 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007650 limonene Natural products 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 229950004592 liothyronine Drugs 0.000 description 1
- SBXXSUDPJJJJLC-YDALLXLXSA-M liothyronine sodium Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 SBXXSUDPJJJJLC-YDALLXLXSA-M 0.000 description 1
- 229960002018 liothyronine sodium Drugs 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229950005239 lucanthone Drugs 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 229960000453 malathion Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002531 marbofloxacin Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- KDXZREBVGAGZHS-UHFFFAOYSA-M methohexital sodium Chemical compound [Na+].CCC#CC(C)C1(CC=C)C(=O)N=C([O-])N(C)C1=O KDXZREBVGAGZHS-UHFFFAOYSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- KZAUOCCYDRDERY-UITAMQMPSA-N methyl (1Z)-2-(dimethylamino)-N-(methylcarbamoyloxy)-2-oxoethanimidothioate Chemical compound CNC(=O)O\N=C(/SC)C(=O)N(C)C KZAUOCCYDRDERY-UITAMQMPSA-N 0.000 description 1
- GEPDYQSQVLXLEU-AATRIKPKSA-N methyl (E)-3-dimethoxyphosphoryloxybut-2-enoate Chemical compound COC(=O)\C=C(/C)OP(=O)(OC)OC GEPDYQSQVLXLEU-AATRIKPKSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- YRWLZFXJFBZBEY-UHFFFAOYSA-N methyl N-(6-butyl-1H-benzimidazol-2-yl)carbamate Chemical compound CCCCC1=CC=C2N=C(NC(=O)OC)NC2=C1 YRWLZFXJFBZBEY-UHFFFAOYSA-N 0.000 description 1
- OXLKOMYHDYVIDM-UHFFFAOYSA-N methyl N-[6-(cyclopropanecarbonyl)-1H-benzimidazol-2-yl]carbamate Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1CC1 OXLKOMYHDYVIDM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 235000001411 milk thistle Nutrition 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 229940038301 monosulfiram Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QNSIFYWAPWSAIJ-UHFFFAOYSA-N naftalofos Chemical compound C1=CC(C(N(OP(=O)(OCC)OCC)C2=O)=O)=C3C2=CC=CC3=C1 QNSIFYWAPWSAIJ-UHFFFAOYSA-N 0.000 description 1
- BUYMVQAILCEWRR-UHFFFAOYSA-N naled Chemical compound COP(=O)(OC)OC(Br)C(Cl)(Cl)Br BUYMVQAILCEWRR-UHFFFAOYSA-N 0.000 description 1
- RMHJJUOPOWPRBP-UHFFFAOYSA-N naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC=CC2=C1 RMHJJUOPOWPRBP-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 230000003533 narcotic Effects 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229950006977 niclofolan Drugs 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ASPOIVQEUUCDQT-UHFFFAOYSA-N nitroprusside Chemical compound O=N[Fe-2](C#N)(C#N)(C#N)(C#N)C#N ASPOIVQEUUCDQT-UHFFFAOYSA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229960004780 orbifloxacin Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 229960003068 ormetoprim Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960000462 oxamniquine Drugs 0.000 description 1
- XCGYUJZMCCFSRP-UHFFFAOYSA-N oxamniquine Chemical compound OCC1=C([N+]([O-])=O)C=C2NC(CNC(C)C)CCC2=C1 XCGYUJZMCCFSRP-UHFFFAOYSA-N 0.000 description 1
- 229960000535 oxantel Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 101700057139 oxyT Proteins 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 201000001181 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 229960003536 phenothrin Drugs 0.000 description 1
- 229960004331 phenoxymethylpenicillin Drugs 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- LUBJCRLGQSPQNN-UHFFFAOYSA-N phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- ATROHALUCMTWTB-OWBHPGMISA-N phoxim Chemical compound CCOP(=S)(OCC)O\N=C(\C#N)C1=CC=CC=C1 ATROHALUCMTWTB-OWBHPGMISA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960002164 pimobendan Drugs 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229960001635 pirlimycin Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229940104257 polyglyceryl-6-dioleate Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229940014329 polysulfated glycosaminoglycan Drugs 0.000 description 1
- 229960003508 ponazuril Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- BZNDWPRGXNILMS-VQHVLOKHSA-N propetamphos Chemical compound CCNP(=S)(OC)O\C(C)=C\C(=O)OC(C)C BZNDWPRGXNILMS-VQHVLOKHSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229940095050 propylene Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- VJFUPGQZSXIULQ-XIGJTORUSA-N pyrethrin II Chemical compound CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VJFUPGQZSXIULQ-XIGJTORUSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229960002778 pyrvinium Drugs 0.000 description 1
- 229910002059 quaternary alloy Inorganic materials 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000003252 repetitive Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940108410 resmethrin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- JMHCCAYJTTWMCX-QWPJCUCISA-M sodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 JMHCCAYJTTWMCX-QWPJCUCISA-M 0.000 description 1
- NCFTXMQPRQZFMZ-KHLPVGQYSA-M sodium;(6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)NC(C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-KHLPVGQYSA-M 0.000 description 1
- IFEJLMHZNQJGQU-KXXGZHCCSA-M sodium;(Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound [Na+].C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC([O-])=O)OC1=CC=CC(Cl)=C1 IFEJLMHZNQJGQU-KXXGZHCCSA-M 0.000 description 1
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 1
- QGMRQYFBGABWDR-OGFXRTJISA-M sodium;5-ethyl-5-[(2R)-pentan-2-yl]pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC[C@@H](C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-OGFXRTJISA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- XOXHILFPRYWFOD-UHFFFAOYSA-N sulfachloropyridazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=C(Cl)N=N1 XOXHILFPRYWFOD-UHFFFAOYSA-N 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 229960001531 suxamethonium Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- CJDWRQLODFKPEL-UHFFFAOYSA-N teflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC(Cl)=C(F)C(Cl)=C1F CJDWRQLODFKPEL-UHFFFAOYSA-N 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960001423 tetracosactide Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 150000005326 tetrahydropyrimidines Chemical class 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- YFNCATAIYKQPOO-UHFFFAOYSA-N thiophanate Chemical compound CCOC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OCC YFNCATAIYKQPOO-UHFFFAOYSA-N 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 1
- 229960004885 tiamulin Drugs 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- KVSKGMLNBAPGKH-UHFFFAOYSA-N tribromosalicylanilide Chemical compound OC1=C(Br)C=C(Br)C=C1C(=O)NC1=CC=C(Br)C=C1 KVSKGMLNBAPGKH-UHFFFAOYSA-N 0.000 description 1
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N tributyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 1
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium(0) Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- VEPSYABRBFXYIB-PWXDFCLTSA-M vecuronium bromide Chemical compound [Br-].N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 VEPSYABRBFXYIB-PWXDFCLTSA-M 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- SRBFZHDQGSBBOR-KKQCNMDGSA-N β-D-xylose Chemical compound O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N2300/00—Combinations or mixtures of active ingredients covered by classes A01N27/00 - A01N65/48 with other active or formulation relevant ingredients, e.g. specific carrier materials or surfactants, covered by classes A01N25/00 - A01N65/48
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/36—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N49/00—Biocides, pest repellants or attractants, or plant growth regulators, containing compounds containing the group, wherein m+n>=1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group, wherein A means a carbon atom or Y, n>=0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Provided are topical veterinary compositions comprising at least one parasiticidal isoxazoline compound of Formula (I), and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. A preferred active agent is 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalanecarboxamide. A preferred pharmaceutically acceptable carrier is liquid polyethylene glycol (PEG). ]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalanecarboxamide. A preferred pharmaceutically acceptable carrier is liquid polyethylene glycol (PEG).
Description
TITLE OF THE ION
PARASITICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT,
METHODS AND USES THEREOF.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a divisional application of New Zealand Patent ation No.
725115, the contents of which are incorporated herein by reference, which is a divisonal
application of New Zealand Patent Application No. 710442, which is a divisional application of
New Zealand Patent Application No. 622466. This application also claims the benefit of priority
to U.S. Provisional Application No. 61/533,308 filed September 12, 2011, which is orated
herein by reference in its entirety.
FIELD OF THE INVENTION
The present invention provides l veterinary itions comprising at least one
isoxazoline active agent for controlling ectoparasites and rasites in animals; the use of
these compositions against ectoparasites and/or endoparasites, and methods for preventing or
treating parasitic infections and infestations in animals.
BACKGROUND OF THE INVENTION
Animals such as mammals and birds are often susceptible to parasite
infestations/infections. These parasites may be ectoparasites, such as insects, and endoparasites
such as filariae and other worms. Domesticated animals, such as cats and dogs, are often ed
with one or more of the following ectoparasites:
- fleas (e.g. Ctenocephalides spp., such as Ctenocephalides felis and the like);
- ticks (e.g. Rhipicephalus spp., Ixodes spp., Dermacentor spp., Amblyoma spp., and the like);
- mites (e.g. Demodex spp., tes spp., Otodectes spp., and the like);
- lice (e.g. Trichodectes spp., Cheyletiella spp., Lignonathus spp. and the like);
- mosquitoes (Aedes spp., Culux spp., Anopheles spp. and the like); and
- flies (Hematobia spp., Musca spp., Stomoxys spp., Dematobia spp., mia spp. and the
like).
Fleas are a particular problem because not only do they adversely affect the health of the
animal or human, but they also cause a great deal of psychological stress. Moreover, fleas are
also vectors of pathogenic agents in animals and , such as dog tapeworm (Dipylidium
caninum).
W0 20131039948 PCT/U8201210547l9
Similarly, ticks are also harmful to the physical and psychological health of the animal or
human. However, the most serious problem associated with ticks is that they are the vector of
pathogenic agents in both humans and animals. Major diseases which are caused by ticks include
borrelioses (Lyme disease caused by Borrelia burgdorferi), babesioses (or asmoses caused
by Babesia spp.) and rickettsioses (also known as Rocky Mountain spotted fever). Ticks also
release toxins which cause ation or paralysis in the host. Occasionally, these toxins are
fatal to the host.
se, farm animals are also susceptible to te infestations. For example, cattle
are ed by a large number of parasites. A parasite which is very prevalent among farm
animals is the tick genus Rhipicephalus, especially those of the species microplus (cattle tick),
decoloratus and annulatus. Ticks such as Rhipicephalus microplus (formerly Boophilus
microplus) are particularly difficult to control because they live in the pasture where farm
animals graze. This species of ticks is considered a one-host tick and spends immature and adult
stages on one animal before the female es and falls off the host to lay eggs in the
environment. The life cycle of the tick is approximately three to four weeks. In addition to cattle,
Rhipicephalus microplus may infest found on buffalo, horses, donkeys, goats, sheep, deer, pigs,
and dogs. A heavy tick burden on animals can decrease production and damage hides as well as
transmit diseases such as babesiosis (“cattle fever”) and anaplasmosis caused by protozoan
parasites.
s and humans also suffer from endoparasitic infections ing, for example,
helminthiasis which is most frequently caused by a group of parasitic worms categorized as
ccstodes (tapeworm), nematodes (roundworm) and odes (flatworm or flukes). These
parasites adversely affect the nutrition of the animal and cause severe economic losses in pigs,
sheep, horses, and cattle as well as affecting domestic animals and poultry. Other tes which
occur in the gastrointestinal tract of s and humans include Ancylostoma, Nccator, s,
yloides, Trichinella, Capillaria, Toxocara, Toxascaris, Trichiris, Enterobius and parasites
which are found in the blood or other tissues and organs such as filarial worms and the extra
intestinal stages of Strogyloides, Toxocara and Trichinella.
Recently, isoxazole and isoxazoline-containing compounds have been demonstrated to be
effective t parasites that harm animals. For example, US 2010/0234219 A1 (to DuPont)
PCT /US2012/054719
discloses oline compounds according to a (I) below, which are active t
ectoparasites and/or endoparasites.
w (I)
In addition, published patent application nos. US 2010/0254960 Al, A2, WO
2007/123855 A2, Al, US7951828 & US7662972, US 2010/0137372 Al, US
2010/0179194 A2, US 2011/0086886 A2, US 2011/0059988 Al, US 2010/0179195 Al and WO
2007/075459 A2 and U.S. Patent Nos. 7,951,828 and 972 describe various other
parasiticidal isoxazoline compounds. bes l localized isoxazoline
formulations comprising glycofurol.
Notwithstanding the compositions comprising isoxazoline active agents alone or in
combination with other active agents described in the documents above, there is a need for
veterinary compositions and methods with improved efficacy, bioavailability, and um of
coverage to protect animals t endoparasites and/or ectoparasites. Optimal compositions
should provide contact and/or systemic activity, be efficacious, have a quick onset of activity,
have a long duration of activity, and be safe to the animal recipient and their human owners. This
invention addresses this need.
ORATION BY REFERENCE
Any foregoing applications, and all documents cited therein or during their prosecution
("application cited documents") and all documents cited or referenced in the application cited
documents, and all documents cited or referenced herein ("herein cited documents"), and all
documents cited or nced in herein cited documents, together with any manufacturer's
instructions, descriptions, product specifications, and product sheets for any products mentioned
herein or in any document incorporated by reference herein, are hereby incorporated herein by
reference, and may be employed in the practice of the ion.
Citation or identification of any document in this application is not an admission that
PCT /US2012/054719
such document is available as prior art to the present invention.
SUMMARY OF THE INVENTION
The present ion is directed to topical compositions compnsmg at least one
isoxazoline, alone or in combination with other active agents, and their use to control parasites in
or on warm-blooded animals and birds. In accordance with this ion, it has been discovered
that these compositions generally show desirable bioavailability, and can provide contact and/or
ic activity. The compositions also provide desirable safety profiles toward the warmblooded
and bird animal recipients. In addition, it has been discovered that a single
administration of such compositions generally provides potent activity against one or more
rasites, while also g to provide fast onset of activity, long duration of ty, and/or
desirable safety profiles.
The invention encompasses uses or veterinary uses of the isoxazoline compositions for
the treatment or prophylaxis of parasitic infections and ations of animals ( either wild or
domesticated), including livestock and companion animals such as cats, dogs, , chickens,
sheep, goats, pigs, turkeys and cattle, with the aim of g these hosts of parasites ly
encountered by such animals.
In a particularly preferred embodiment, the composition is a topical spot-on formulation.
In another preferred embodiment particularly well suited for livestock animals, the composition
is a topical pour-on formulation. The invention also includes other topical itions
comprising an isoxazoline active agent including sprays, aerosols, foams and the like.
In some embodiments, the topical nary composition comprises a pharmaceutically
acceptable carrier wherein the carrier comprises a diester of a dicarboxylic acid, a glycol ester, a
glycol ether, a fatty acid ester, a polyethylene glycol, or hylene glycol ester, an oil, an
alcohol, a glycerol ester, a glycerol ether, propylene glycol, ethylene , a glycol ate,
dimethyl isosorbide, N-methylpyrrolidone, or a mixture thereof.
In one embodiment, the diester of a dicarboxylic acid is a diester of a C6-C 16 dicarboxylic
acid including, but not limited to, diethyl sebacate or diisopropyl adipate.
In another embodiment of the invention, the pharmaceutically acceptable carrier of the
compositions comprises mixture of a diester of a dicarboxylic acid and a propylene glycol ester,
a fatty acid ester, a polyethylene glycol ester, a polyethylene glycol, an oil, a C6-C20 long-chain
PCT /US2012/054719
aliphatic alcohol, a C1-C8 alcohol, glycol ether, or a combination thereof.
In certain embodiments, the pharmaceutically acceptable carrier of the topical veterinary
ition of the invention further comprises a mixed ester of sucrose and acetic and isobutyric
acid, a low melting wax, a hard fat or a block co-polymer of ethylene oxide and ene oxide,
or a combination thereof.
In another ment, the pharmaceutically acceptable earner compnses dimethyl
isosorbide, glycerol formal, propylene carbonate, triacetin, diethyleneglycol monoethyl ether,
polyethylene glycol 400 or benzyl alcohol, or a mixture thereof.
The invention also es methods for the treatment or tion of parasitic
infections and infestations in animals, sing administering an effective amount of a
composition comprising at least one isoxazoline to the . Surprisingly, it has been found
that the inventive compositions and formulations described herein exhibit superior broad
spectrum efficacy against harmful ectoparasites more rapidly, and over a long duration compared
to compositions known in the art.
In one embodiment, the invention provides topical nary compositions comprising
effective amounts of at least one isoxazoline of formula (I) below, in combination and a
pharmaceutically or veterinarily acceptable liquid carrier, where variables A1, A2, A3, A4, As, A6,
B 1 B 2 B 3 1 2 3 .
, , , R , R , R , R 4, Rs, W are d fie 1ne d here1n.
w (I)
In some embodiments, the topical veterinary compositions and methods comprise 4-[5-
[3-chloro(trifluoromethyl)phenyl]-4,5-dihydro(trifluoromethyl)isoxazolyl]-N-[2-oxo-
2-[(2,2,2-trifluoroethyl)amino]ethyl]naphthalenecarboxamide as the active agent.
In other embodiments, the compositions may further comprise one or more additional
active agents. In one embodiment, the compositions comprise at least one macrocyclic lactone
active agent, including, but not d to, avermectins or ycins. In some embodiments,
PCT/U82012/054719
the avermectin or milbemycin active agent is eprinomectin, ivermectin, ctin, milbemectin,
milbemycin D, ycin oxime, or moxidectin.
In another embodiment, the topical compositions of the invention include a combination
of an isoxazoline active agent with the neonicotinoid active agent yram.
In other embodiments, the compositions and s of the invention may further
comprise an insect growth regulator (IGR) active agent, including but not limited to, methoprene,
pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, or novaluron. In another preferred
embodiment, the compositiOns of the invention comprise a neonicotinoid active agent such as
nitcnpyram. In other embodiments, the compositions and methods comprise at least one of
IO thiabendazole, oxibendazole, mebendazole, fenbendazole, oxfendazole, albendazole,
triclabendazole, febantel, levamisole, pyrantel, morantel, praziquantel, closantel, lon, an
amino acetonitrile active agent, or an aryloazol-Z-yl cyanoethylarnino active agent.
It is an object of the invention to not encompass within the invention any previously
known product, process of making the product, or method of using the product such that the
Applicants reserve the right and hereby disclose a disclaimer of any previously known product,
s, or method. It is r noted that the invention does not intend to encompass within the
scope of the invention any product, process, or making of the product or method of using the
product, which does not meet the Evritten description and ment ements of the
USPTO (35 U.S.C. §112, first paragraph) or the EPO (Article 83 of the EPC), such that
Applicants reserve the right and hereby disclose a imer of any previously described
product, s of making the product, or method of using the product.
These and other embodiments are disclosed or are obvious from and encompassed by, the
following Detailed Description.
BRIEF PTION OF THE DRAWINGS
Fig. I is a plot showing the long lasting efficacy of a spot-on composition comprising
Compound A against Ctenocepha/idesfelis fleas in cats le 9).
Fig. 2 is a plot showing the long lasting efficacy of a pour-on composition comprising
Compound A against Rhipicephalus (Boophi/zis) microplus in cattle based on the number of ticks
dropped (Example 15).
PCT/U82012/054719
Fig. 3 is a plot showing the long lasting efficacy of a pour-on composition comprising
Compound A against Rhipicephalus (Boophz'lus) microplus in cattle based on the weight of ticks
that drop (Example 15). _
DETAILED DESCRIPTION
The present invention provides novel and inventive topical compositions comprising at
least one isoxazoline nd together with a pharmaceutically acceptable carrier or diluent
that is suitable for topical application to an animal.
In some embodiments of the invention, the compositions preferably include spot-on or
pour-on formulations that are applied to a localized area on an animal. Topical spray, aerosol or
IO foam formulations, which typically include the active agent in lower concentrations, are also
encompassed by the invention. These formulations provide surprisingly effective protection of
the animals t parasites for an extended period of timefThe formulations also provide
extremely rapid killing of parasites infesting s. _
Also ed are s and uses for the treatment and/or prophylaxis of parasitic
ions and infestations of animals, comprising administering an effective amount of a
formulation of the invention to the animal.
The invention includes at least the following features:
(a) topical veterinary formulations that exhibit superior activity against animal tes
comprising at least one isoxazoline active agent together with a pharmaceutically acceptable
carrier or t that is suitable for l ation to an animal;
(b) topical veterinary compositions that exhibit superior long lasting efficacy that
comprise at least one oline compound of formula (I) described herein er with a
pharmaceutically acceptable carrier or t that is suitable for topical application'to an animal;
(c) topical Veterinary compositions that exhibit superior long lasting efficacy that
comprise at least one isoxazOline active agent in combination with one or more other active
agents together with a pharmaceutically acceptable carrier or diluent that is suitable for topical
ation to an animal;
(d) topical veterinary compositions comprising an effective amount of an isoxazoline
active agent together with a pharmaceutically acceptable r or diluent that is suitable for
PCT/U82012/054719
topical ation to an animal, wherein the carrier does not comprise glycofurol;
(e) topical veterinary compositions comprising an effective amount of an isoxazoline
active agent together with a pharmaceutically acceptable carrier or diluent that is suitable for
topical application to an animal, wherein the carrier is not a binary mixture of propylene glycol
and glycerol formal; _ _
’ i (f) methods for the treatment or prevention of parasitic infections and infestations in an
animal comprising administering an effective amount of a composition comprising at least one
isoxazoline ’active’agent together with a ceutically able carrier or diluent;
(g) methods for the treatment or prevention of parasitic infections and infestations in an
IO animal comprising administering an effective amount of a composition comprising at least one
isoxazoline active" agent with a pharmaceutically acceptable earfier or diluent that is suitable for
l application to an animal_{
(h) methods for the treatment or prevention of parasitic ions and ations in an
animal comprising administering an effective amount of a topical ition comprising at
least one isoxazoline active agent in combination with one or more other active agents together
with a pharmaceutically acceptable carrier or diluent that is suitable for topical ation to an
animal;
(i) use of veterinary compositions comprising at least one oline compound,
including a compound of formula (I), together with a pharmaceutically acceptable carrier or
t in the prevention or treatment of animal parasites.
In this disclosure and in the claims, terms such 39 LL
as “comprises, comprising,"
“containing” and “having” and the like can have the meaning ascribed to them in US. Patent law
and can mean “includes.” “including,” and the like; “consisting ially of” or “consists
essentially” likewise has the meaning ascribed in US. Patent law and the term is open-ended,
allowing for the presence of more than that which is recited so long as basic or novel
characteristics of that which is recited is not changed by the ce of mere than that which is
recited, but excludes prior art embodiments.
Definitions “
firmsused herein will have their customary meaning in the art unless specified
otherwise. The organic moieties ned in the definitions of the variables of formula (I) are -
like the term n — collective terms for individual listings of the individual group members.
PCT/U82012/054719
The prefix Cn-Cm indicates in each case the possible number of carbon atoms in the group.
The term “animal” is used herein to include all mammals, birds and fish and also include
all vertebrate animals. Animals include, but are not d to, cats, dogs, cattle, chickens, cows,
deer, goats, horses, llamas, pigs, sheep and yaks. It also includes an dual animal in all
stages—of development. including embryonic and fetal . In some embodiments, the animal
will be a non-human animal.
' ' The term “fatty acid” refers
to carboxylic acids having from 4 to 26 carbon atoms.
The terms “fatty l” or “long-chain tic alcohol” refer to aliphatic alcohols
containing from 6 to 20 carbon atoms.
IO The term “low melting” refers to substances that are solids at room temperature but melt
into liquids below 50° C.
’The term “alkyl” refers to saturated straight, branched, cyclic, primary, secondary or
tertiary hydrocarbons, including those having 1 to 20 atoms. In some embodiments, alkyl groups
will include C1-C12, Cl-Cm, C1-C3, C1-C6 or C1-C4 alkyl . Examples of C1-Cm alkyl
include, but are not limited to, methyl, ethyl, , l-methylethyl, butyl, l-methylpropyl, 2-
mcthylpropyl, 1,1-dimcthylcthyl, , l-mcthylbutyl, 2-mcthylbutyl, 3-mcthylbutyl, 2,2-
dimethylpropyl, l-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl,
2-methylperityl, 3-metliylpentyl, 4-methylpentyl, “1,l“-dimethylbutyl, 1,25dimethylbutyl, 1,3-
dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, l-ethylbutyl, 2-
ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, l-ethyl-l-methylpropyl, l-ethyl
methylpropyl, heptyl, octyl, 2-ethylhexyl, nonyl and decyl and their isomers. C1-C4-alkyl means
for example methyl, ethyl, propyl, 1-methylethyl, butyl, l-methylpropyl, 2-methylpropyl or 1,]-
dimethylethyl. * i V " _ ' W *
Cyclic alkyl groups or “cycloalkyl”, which are encompassed by alkyl include those with
3 to 10 carbon atoms having single or multiple condensed rings. In some embodiments,
cycloalkyl groups e C4LC7 or C3-C4 cyclic alkyl groups. Non-limiting examples of
cycloalkyl groups include tyl, cyclopropyl, cyclobutyl, cntyl, cxyl,
cycloheptyl, cyclooctyl and the like. ' '
The alkyl groups described herein can be unsubstituted or substituted with one or more
moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl,
acyloxy, amino, alkyl- or lamino, amido, arylamino, alkoxy, aryloxy, nitro, cyano, azido,
PCT/U82012/054719
thiol, imino, sulfonie acid, e, yl, sulfanyl, sulfinyl, sulfamonyl, ester, onyl,
phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime,
hydrazine, carbamate, phosphoric acid, phosphate, onate, or any other viable functional
group that does not inhibit the biological ty of the compounds of the invention, either
unprotected, or protected as necessary, as known to those skilled in the art, for example, as
taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons; Third
Edition, 1999, hereby incorporated by reference.
Terms including the term “alkyl” such as “alkylcycloalkyl,” “cycloalkylalkyl,”
“alkylamino,” or “dialkylamino” will be tood to se an alkyl group as defined above
IO linked to the other functional group, where the group is linked to the compound h the last
group listed, as understood by those of skill in the art.
The term “alkenyl” refers to both straight and ed carbon chains which have at least
one carbon-carbon double bond. In some embodiments, alkenyl groups may include C2-Czo
alkenyl groups. In other embodiments, alkenyl includes C2-C12, C2-Cm, C2-C8, C2-C6 or C2-C4
alkenyl groups. In one embodiment of alkenyl, the number of double bonds is 1-3, in another
embodiment of alkenyl, the number of double bonds is one or two. Other ranges of carbon-
carbon double bonds and carbon numbers are also contemplated depending on the location of the
alkenyl moiety on the molecule. “CZ-Clo-alkenyl” groups may include more than one double
bond in the chain. Examples include, but are not limited to, l, enyl, 2-propenyl, 1-
methyl-ethenyl, l-butenyl, 2-butenyl, 3-butenyl, l-methyl-l-propenyl, 2-methyl-l-propenyl, l-
methylpropenyl, 2-methylpropenyl; l-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-
methyl-l-butenyl, 2-methylbutenyl, 3-methyl-l-butenyl, 1-methylbutenyl, 2-methyl
butenyl, 3-methylbutenyl, l-meth'ylbuteny‘l, 2-methylbutenyl, 3-methylbutenyl, 1,1-
dimethyl-Z-propenyl, 1,2-dimethyl-l4propenyl,i1,2-dimethylpropenyl, l-ethyl-l-propenyl, 1-
ethyl-2Fpropenyl, nyl, 2-hexenyl, 3-hexeny1, 4-hexenyl, iS-liexenyl, l-methyl-l-pentenyl,
2-methyl-llpentenyl, 3-methylpentenyl, 4-methyl-l-pentenyl, l-methyl-Z-pentenyl, 2-methyl-
2-pcntcnyl, 3-methylpentenyl, 4—mcthylpentenyl, 1-methylpentenyl, 2-methyl
pentenyl, 3-methylpenfenyl, 4-methylpentenyl, l-methylpenteny1, 2-methylpentenyl,
ylpentenyl, 4-methyl—4-pentenyl, 1,1-dimethylbutenyl, 1,1-dimethylbutenyl, 1,2-
dimethyl-l-butenyl, 1,2-dimethylbutenyl, 1,2-dimethylbutenyl, 1,3-dimethyl-l-butenyl,
1,3-dimethylbutenyl, 1,3 -dimethylbutenyl, 2,2-dimethylbutenyl, 2,3-dimethyl- l -butenyl,
WO 39948 PCT/U82012/054719
2,3-dimethylbutenyl, 2,3-dimethylbutenyl, 3,3-dimethyl-l-butenyl, 3,3-dimethylbutenyl,
l-ethyl-l-butenyl, 1-ethylbutenyl, l—3-butenyl, lbutenyl, 2-ethylbutenyl, 2-
ethylé3-butenyl, 1,1,2-trimethyl-24propenyl, l-l-methyl-Z-propenyl, l-ethylmethyl
propenyl and 1-ethylmethylpropenyl.
“Alkynyl” refers to both straight and ed carbon chains which have at least one
earbon-carbOn triple bond. In one embodiment of alkynyl, the number of triple bonds is 1-3; in
another embodiment of alkynyl, the number of triple bonds is one or two. In some embodiments,
l groups e from C2-Czo alkynyl groups. In other embodiments, alkynyl groups may
include , C2-Clo, C2-C8, C2-C5 or C2-C4 alkynyl groups. Other ranges of carbon-carbon
IO triple bonds and carbon numbers are also contemplated depending on the location of the alkenyl
moiety on the molecule. For example, the term ”CZ-Cld-alkynyl” as used herein refers to'a
straight-chain or branched unsaturated hydrocarbon group having 2 to 10 carbon atoms and
containing at least one triple bond, such as ethynyl, prop-l-yn-l-yl, prop-Z-yn-l-yl, n-but-l-ynl-yl
, n-but-l-ynyl, n-but-l-ynyl, n-but-Z-yn-l-yl, n-pent-l-yn-l-yl, -l-ynyl, n-
pent-l-ynyl, n-pent-l-yn-S-yl, n-pent-Z-yn-l-yl, n-pentynyl, n-pent-Z-yn-S-yl, 3-
methylbut-l-ynyl, 3-methylbutynyl, n-hex-l-yn-l-yl, n-hex-l-ynyl, n-hex-l-ynyl,
n-hex-l-yn-S-yl, n-hex-l-ynyl, n-hexyn-l-yl, n-hexynyl, Z-yn-S-yl, n-hex-Z-
ynyl, 'n-hexyn-l-yl, 'n-hexynyl, 3-methylpent-l-ynyl, 3-methylpent-l-ynyl, 3-
methylpent-l-ynyl, 3-methylpentynyl, 4-methylpentynyl, 4-methylpentynyl
or 4-methylpentynyl and the like.
The term lkyl” refers to an alkyl group, as defined herein, which is substituted by
one or more n atoms. For example C1-C4—haloalkyl includes, but is not limited to,
chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl,
trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, l-chloroethyl,
l-bromoethyl, l-fluoroethyl, 2-fluoroethyl, 2,2-difluor0ethyl, 2,2,2-trifluoroethyl, 2-chlor042-
fluoroethyl, 2-chloro-2,Z-difluoroethyl, 2,2-dichlorofluoroethyl, 2,2,2—trichloroethyl,
pcntafluorocthyl and the like.
The term “haloalkenyl” refers to an alkenyl group, as defined herein, which is substituted
by one or more halogen atoms.
The term “haloalkynyl” refers to an alkynyl group, as defined herein, which is substituted
by one or more halogen atoms.
PCT/U82012/054719
“Alkoxy” refers to alkyl-O-, wherein alkyl is as defined above. Similarly, the terms
“alkenyloxy, 3? $6alkynyloxy,” “haloalkoxy,” lkenyloxy,” “haloalkynyloxy,3) alkoxy,”
“cycloalkenyloxy,” “halocycloalkoxy,” and “halocycloalkenyloxy” refer to the groups alken'yl-
0-, alkynyl-O-, haloalkyl-O-, haloalkenyl-O-_, kynyl-O-, eyeloalkyl-O-, cycloalkenyl-O-,
haloeyeloalkyl-O-, and halocycloalkenyl-O-, respectively, wherein alkenyl, alkynyl, haloalkyl,
haloalkenyl, haloalkynyl, cyeloalkyl, cyeloalkenyl, halocycloalkyl, and halocycloalkenyl are as
defined above. Examples of C1-C6-alkoxy include, but are not limited to, methoxy, ethoxy,
C2H5-CH20-, (CH3)2CHO-, n-butoxy, Csz-CH(CH3)O-, (CH3)2CH-CH20-‘ (CH3)3CO-, n-
pcntoxy, ylbutoxy, 2-methylbutoxy, 3-mcthylbutoxy, mcthylpropoxy,
IO l,2—dimethy|propoxy, 2,2-dimethyl-propoxy, l-ethylpropoxy, xy, l-methylpen’toxiy, 2-
methylpentoiy, hylpentoxy, 4-methylpentoxy, _ 1,1-dimethylbutoxy, 1,2-dimethylbutoxy,
1,3—dimethylbutoxy, 2,2-dimethylbutoxy, 7 methylbutoxy, methylbutoxy, l-
ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, l-ethyl-lmethylpropoxy
, 1-ethylmethylpropoxy and the like.
The term “alkylthio” refers to alkyl-S-, wherein alkyl is as defined above. Similarly, the
terms “haloalkylthio,” “eyeloalkylthio,” and the like, refer to haloalkyl-S- and cyeloalkyl-S-
where haloalkyl and eyeloalkyl are as defined above.
The term “alkylsulfinyl” refers to alkyl-S(O)-, wherein alkyl is as defined above.
Similarly, the term “haloalkylsulfinyl” refers to kyl-S(O)- where haloalkyl is as defined
above.
The term “alkylsulfonyl” refers to alkyl-S(O)2-, wherein alkyl is as defined above.
Similarly, the term “haloalkylsulfonyl” refers to haloalkyl-S(O)z- where haloalkyl is as defined
above.
The term alkylamino and dialkylamino refer to alkyl-NH- and )2N- where alkyl is
as defined above. Similarly, the terms “haloalkylamino” refers to haloalkyl-NH- where haloalkyl
is as defined above.
The terms “alkylcarbonyl,” “alkoxycarbonyl,” aminocarbonyl,” and
“dialkylaminocarbonyl” refer ‘ alkylamino-C(O)-
to alkyl-C(O)-, alkoxy-C(O)-, and
dialkylamino-C(O)- where alkyl, alkoxy, alkylamino and dialkylamino are as defined above.
Similarly, the terms “haloalkylearbonyl,” “haloalkoxyearbonyl,” "‘haloalkylaminoearbonyl,” and
“dihaloalkylaminocarbonyl” refer to the groups haloalkyl-C(O)-, haloalkoxy-C(O)-,
PCT/U82012/054719
haloalkylamino-C(0)- and dihaloalkylamino-C(O)- where haloalkyl, haloalkoxy, haloalkylamino
and dihaloalkylamino are as defined above.
“Aryl” refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms
having a single ring or multiple condensed rings. In some embodiments, aryl groups include C6-
Cm aryl . Aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl,
tetrahydronaphtyl, phenyleyelopropyl and indanyl. Aryl groups may be ’unsubstituted or
substituted by one or more moieties selected from halogen, cyano, nitro, hydroxy, mercapto,
amino, alkyl, alkenyl, alkynyl, eyeloalkyl, eyeloalkenyl, haloalkyl, haloalkenyl, haloalkyhyl,
halocycloalkyl, halocycloalkcnyl, alkoxy, alkenyloxy, alkynyloxy, koxy, haloalkenyloxy,
IO haloalkynyloxy, eyclOalkoxy, cycloalkenyloxy, haloCycloalkoxy, halocycloalkcnyloxy, alkylthio,
haloalkylthio, cycloalkylthio, halocycloalkylthio, alkylsulfinyl, lsulfinyl, alkynyl-sulfinyl,
haloalkylsulfinyl. haloalkenylsulfinyl, haloalkynylsulfmyl, alkylsulfonyl, alkenylsulfonyl,
alkynylsulfonyl, haloalkyl-sulfonyl, haloalkenylsulfonyl, haloalkynylsulfonyl, alkylamino,
alkenylamino, alkynylamino, yl)amino, di(alkenyl)-amino, di(alkynyl)amino, or
trialkylsilyl.
The terms “aralkyl” or “arylalkyl” refers to an aryl group that is bonded to the parent
compound through a diradical alkylene bridge, (-CH2-)n, where n is 1-12 and where “aryl” is as
defined above.
“Heteroaryl” refers to a monovalent ic group of from 1 to 15 carbon atoms,
ably from 1 to 10 carbon atoms, having one or more oxygen, nitrogen, and sulfur
heteroatoms within the ring, preferably 1 to 4 heteroatoms, or 1 to 3 heteroatoms. The nitrogen
and sulfur heteroatoms may optionally be oxidized. Such aryl groups can have a single
ring (e.g., pyridyl or furyl) or multiple sed rings ed that the point of attachment is
thrbugha heteroaryl ring atom. Preferred heteroaryls' include pyridyl, pifidazinyl, pyrimidinyl,
pyrazinyl, triazinyl, pyrrolyl, indolyl, quinolinyl, isoquinolinyl, quin’azolinyl,’ quinoxalinnyl,
l, thiophenyl, fiiryl, pyrrolyl, imidazolyl‘, oxazolyl, isOxazolyl, isothiazolyl, pyrazolyl
bcnzofuranyl, and bcnzothiophcnyl. Heteroaryl rings may be unsubstituted or tuted by one
or more moieties as described for'aryl above.
“Heterocyclyl,” “heterocyclic” or “heterocyclo” refer to fully saturated or unsaturated,
cyclic groups, for example, 3 to’7 membered monocyclic or 4 to 7 membered monocyclic; 7 to
11 membered bicyclic, or 10 to 15 membered lic ring systems, which have one or more
PCT/U82012/054719
oxygen, sulfur or nitrogen heteroatoms in ring, preferably 1 to 4 or 1 to 3 heteroatoms. The
nitrogen and sulfur heteroatoms may optionally be oxidized and the en heteroatoms may
optionally be quaternized. The heterocyclic group may be attached at any heteroatom or carbon
atom of the ring or ring system and may be unsubstituted or tuted by one or more moieties
as described for aryl groups above.
Exemplary monoéyclic heterocyclic groups include, but are not limited to, pyrrolidinyl,
pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl,
oxazolidinyl, isoxazolinyl; is0xazolyl, thiazolyl, thiadiazolyl, lidinyl, 'isothiazolyl,
isothiazolidinyl, furyl, tctrahydrofuryl, thicnyl, oxadiazolyl, pipcridinyl, pipcrazinyl, 2-
IO oxopiperazinyl, 2-0Xopiperidinyl, yrrol0dinyl, 2-oxoazepinyl, azepinyl,‘ 4-piperidonyl,
pyridinyl, pyrazinyl, pyrimidinyl, pyridaiinyl, tetrahydropyranyl; morpholinyl, thiamorpholinyl,
thiamorphélinyl sulfoxide, rpholinyl ‘ 1,3-dioxolane
sulfone,’ and tetrahydro-l,l-
hienyl, triazolyl, triazinyl, and the like.
Exemplary bicyclic heterocyclic groups include. but are not limited to, indolyl,
benzothiazolyl, azolyl, benzodioxolyl, benzothienyl, quinuclidinyl, quinolinyl, tetra-
hydroisoquinolinyl, isoquinolinyl, idazolyl, bcnzopyranyl, indolizinyl, bcnzofuryl,
chromonyl, coumarinyl, bcnzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, opyridyl,
ridinyl (such as furo[2,3-c]pyridinyl, fi1r0[3,2-b]pyridinyl]or furo[2;3-b]pyridinyl),
dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydrooxo-quinazolinyl),
tetrahydroquinolinyl and the like.
Exemplary lic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl,
acridinyl, phenanthridinyl, xanthenyl, and the like.
V Halogen
means the atoms fluorine, chlorine, bromine and iodine. The designation of
“halo” (e.g. as illustrated in the term haloalkyl) refers to all degrees of substitutions from a single
substitution to a perhalo substitution (e.g. as illustrated with methyl as chloromethyl (-CHzCl),
dichloromethyl (-CHC12), trichloromethyl (-CC13)).
Stcrcoisomcrs and polymorphic forms
It will be appreciated by those of skill in the art that certain compounds within the
itions of the invention may exist and be isolated as optically active and c forms.
Compounds having one or more Chiral centers, including at a sulfur atom, may be present as
single enantiomers or diastereomers or as es of enantiomers and/or diastereomers. For
PCT/U82012/054719
example, it is well known in the art that ide compounds may be optically active and may
exist as single enantiomers or racemic mixtures. In addition, compounds within the compositions
of the invention may include one or more chiral centers, which results in a theoretical number of
optically active s. Where compounds within the compositions of the invention e n
chiral centers, the compounds may comprise up to 2" optical isomers. The t invention
encompasses the specific enantiomers or diastereomers ofeach compound as well as mixtures of
different enantiomers and/or diastereomers of the nds of the invention that possess the
useful properties described herein. The optically active forms can be prepared by, for example,
tion of the c forms by selective llization techniques, by synthesis from
IO optically active precursors, by chiral synthesis, by chromatographic separation using a chiral
stationary phase or by enzymatic resolution. _ _
The compounds Within the compositions of present invention may also be present in
different solid forms such as different crystalline forms or in the form of an amorphous solid.
The present invention encompasses different crystalline forms as well as ous forms of the
inventive nds.
In addition, the compounds within the compositions of the invention may exist as
es or solvates, in which a certain stoichiometric amount of water or a solvent is associated
with the molecule in the crystalline form. The compositions of the invention may include
hydrates and solvates of the active agents. In some embodiments, the compositions of the
invention may include up to 15% (w/w), up to 20% (w/w), or up to 30% (w/w) of a particular
solid form.
Salts
Also contemplated within the scope of the invention are acid or base salts, where
applicable, of the compounds of the invention provided for herein.
The term "acid salt" contemplates salts of the compounds with all pharmaceutically
acceptable inorganic or organic acids“. Inorganic acids include mineral acids such as hydrohalic
acids such as hydrobromic acid and hydrochloric acid, sulfuric acid, phosphoric acids and nitric
acid. Organic acids include all pharmaceutically acceptable aliphatic, alicyclic and aromatic
carbOXylic acids, dicarboxylic acids, tricarboxylic acids and fatty acids. In one embodiment of
the acids. the acids are straight chain or branched, ted 0r rated C1-C20 aliphatic
carboxylic acids, which are optionally substituted by halogen or by hydroxyl groups, or C6-C12
PCT/U82012/054719
aromatic ylic acids. Examples of such acids are carbonic acid, formic acid, acetic acid,
propionic acid, isopropionic acid, valcric acid, et-hydroxy acids such as glycolic acid and lactic
acid, chloroacetic acid, benzoic acid, e sulfonic' acid, and salicylic acid. Examples of
dicarboxylic acids include oxalic acid, malic acid, succinic acid, tartaric acid, fumaric acid, and
maleic acid. An example of a tricarboxylic acid is citric acid. Fatty acids e all
pharmaceutically acceptable saturated or unsaturated tic or aromatic carboxylic acids
having 4 to 24 carbon atoms. es include butyric acid, isobutyric acid, sec-butyric acid,
lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and steric
acid. Other acids include gluconic acid, eptonic acid and lactobionic acid.
The term “base salt” contemplates salts of the compounds with all pharmaceutically
acceptable inorganic or c bases, including hydroxides, carbonates or bicarbonates of alkali
metal or alkaline earth metals. Salts formed with such bases include, for example, the alkali
metal and alkaline earth metal salts, including, but not limited to, as the lithium, sodium,
potassium, magnesium or calcium salts. Salts formed with organic bases include the common
hydrocarbon and heterocyclic amine salts, which include, for example, ammonium salts (NH4' ),
alkyl- and dialkylammonium salts, and salts of cyclic amines such as the morpholine and
piperidine salts.
In one embodiment. the invention provides l veterinary compositions comprising
effective amounts of at least one isoxazoline of formula (I) belOw, in‘ combination—and a
pharmaceutically or vcterinarily acceptable liquid carrier:
A6” \ 4 O—N
wherein
AKA], A“, A4, A5 and A6 are independently CR3 or N, provided that at most 3 of Al,
A2, A3, A4, A5 and A6 are N; - I -
B], B2 and B3 are independently CR2 or N;
PCT/U82012/054719
W is O or S;
R1 is alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl or cycloalkylalkyl, each
optionally substituted with one or more substituents independently selected from R6;
each R2 is independently H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio,
haloalkylthio, alkylsulfinyl. haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylamino,
dialkylamino, alkoxycarbonyl, —CN‘or —N02; '
each R3 is independently H, halogen, alkyl, haloalkyl, cycloalkyl, halocycloalkyl,
alkoxy, haloalkoxy, hio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl,
haloalkylsulfonyl, alkylamino, lamino, —CN or —NOz;
IO R4 is H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, lkylalkyl,
alkylcarbonyl or alkoxycarbonyl; ' ' V ' V
I R5 is H, OR"), NRHR'2 or Q]; or alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl
or cycloalkylalkyl, each optionally tuted with one or more substituents independently
selected from R7; or
R4 and R5 are taken together with the nitrogen to which they are attached to form a
ring containing 2 to 6 atoms of carbon and optionally one additional atom cd from the
group consisting of N, S and 0, said ring optionally substituted with 1 to 4 substituents
independently selected from the group consiSting of alkyl, n, —CN, —NOZ and alkoxy;
each R6 is independently halogen, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl,
—CN or —NOZ;
each R7 is independently n; alkyl, cycloalkyl, alkoxy, alkylthio, alkylsulfinyl,
alkylsulfonyl, alkylamino, dialkylamino, cycloalkylamino, alkylcarbonyl, alkoxycarbonyl,
alkylaminocarbonyl, dialkylaminocarbonyl, haloalkylcarbohyl, haloalkoxycarbonyl.
haloalkylaminocarbonyl, dihaloalkylaminocarbonyl, hydroxy, —NH2, —CN or —N02; or Q2;
each R8 is independently halogen, alkoxy, haloalkoxy, hio, haloalkylthio,
alkylsulflnyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylamino, dialkylamino,
alkoxycarbonyl, —CN or —N02_;
each R9 is independently halogen, alkyl, haloalkyl, lkyl, halocycloalkyl, alkoxy,
haloalkoxy, alkylthio, kylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl,
haloalkylsulfonyl; alkylamino, dialkylamino, —CN, —N02, phenyl or pyridinyl;
PCT/U82012/054719
R10 is H; or alkyl, alkenyl, alkynyl, cycloalkyl, alkyleycloalkyl or cycloalkylalkyl,
each optionally substituted with one of more halogen;
7 R11
is H, alkyl, alkenyl, alkynyl, icycloalkyl, alkylcycloalkyl, cycloalkylalkyl,
alkylcarbonyl or alkoxycarbonyl;
R12 is H; Q3; or alkyl, alkenyl, alkynyl, lkyl, alkyleyeloalkyl or
cycloalkylalkyl, each optionally substituted with one or more substituents independently
selected from R7; or
RH and R12 are taken together with the nitrogen to which they are attached to form a
ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the
IO group consisting of N, S and 0, said ring optionally substituted with l to 4 substituents
independently ed from the group ting of alkyl, halogen, —CN, —NOz and alkoxy;
Q' is a phenyl ring, a 5- or 6-mernbered heterocyclie ring, or an 8-, 9- or '10-
membered fused bieyclic ring system optionally containing one to three heteroatoms selected
from up to l 0, up to 1 S and up to 3 N, each ring or ring system optionally substituted with
one or more substituents independently selected from R8;
each Q2 is independently a phenyl ring or a 5- or 6-membered heterocyclie ring, each
ring optionally substituted with one or more substituents independently selected from R9;
_ Q3 is a phenyl ring or a 5- or 6-membered heterocyclie ring, each ring optionally
substituted with one or more substituents independently selected from R9; and
n is 0, l or 2.
In one embodiment, the invention provides topical veterinary compositions sing
ive amounts of at least one isoxazoline of formula (1) below, in combination and a
pharmaceutically or narily acceptable liquid carrier:
A5 '
O—N A” \A4
W (1)
wherein:
PCT/U82012/054719
A', A2, A3, A4, A5 and A6 are independently CR3 or N, provided that at most 3 of A',
A2, A3, A4, A5 and A6 are N;
8‘, B2 and B3 are independently CR2 or N;
W is O or S;
R1 is C1-C6 alkyl, C2-C(, alkenyl, C2-C(, alkynyl, C3-C6 cycloalkyl, C4-C7 ycloalkyl
or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents
independently selected from R6;
each R2 is independently H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6
haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C l-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl,
IO C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C5 alkylamino, C2-C6 dialkylamino, C2-C4
carbonyl, —'CN or —NO2;
each R3 is independently H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-
C6 halocycloalkyl, C 1- C6 alkoxy, C1-C6 koxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-
C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C7-C6 alkylsulfonyl, Cl-C6 kylsulfonyl, C l-C(,
alkylamino, C2-C6 dialkylamino, —CN or —NO2;
R4 is H, C 7-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7
alkylcycloalkyl, C4-C7 cycloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl;
' R5 '
is H, on”, NRI'R'Z or Q‘; or (:.'.C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6
cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with
one or more substituents independently selected from R7; or
R4 and R5 are taken together with the nitrogen to which they are ed to form a
ring ning 2 to 6 atoms of carbon and optionally one additional atom selected from the
group ting of N, S and 0, said ring optionally substituted with 1 to 4 substituents
independently selected from the group consisting of C1-C2 alkyl, halogen, —CN, —NO2 and
' 7 ' 7
C1-C2alkoxy;
each' R6 is independently halogen, C1-C6 alkyl, C1-C6 alkoxy, C 7-C6 alkylthio, C1-C6
alkylsulfinyl, C 1-C6 ulfonyl, —CN or —NO2;
I each R7 is independently halogen; C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6
alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 alkylamino, Cz-Cg dialkylamino, C3-
C6 'cycloalkylamino, C2—C7‘ alkylcarbonyl, C2-C7 alkoxycarbonyl, C2-C7 alkylarninocarbonyl,
C3-C9 dialkylaminocarbonyl, C2-C7 kylcarbonyl, C2-C7 haloalkoxycarbonyl, C2-C7
PCT/U82012/054719
haloalkylaminocarbonyl, C3-C9 dihaloalkylaminocarbonyl, hydroxy, —NH2, —CN or —N02;
or Q2;
each R8 is independently halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-
C6 haloalkylthio, C1- C6 alkylsulfinyl, C1-C5 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6
haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, C2-C4 alkoxycarbonyl, —CN or —
N02;
each R9 is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 lkyl, C3-C6
halocycloalkyl, C1-C6 ’alkoxy, C1-C6’haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6
alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1- C6 alkylsulfonyl, C 1-C6 haloalkylsulfonyl, C 1—C6
IO alkylamino, C2-C6 dialkylamino —CN, —N02, phenyl or pyridinyl;
R10 is H; or C1-C6 alkyl, C2-C5 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl C4-C7
alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one of more halogen;
R” is H, C1C6 alkyl, C2-C6 alkenyl C2C6 alkynyl, C3C6 cycloalkyl, C4C7
alkylcycloalkyl, C4-C7 cycloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl;
R” is H; Q3; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7
alkylcycloalkyl or C4-C7 cycloalkylalkyl, each ally substitutcd with one or morc
substituents independently selected from R7; or
RH and R12 are taken together with the nitrogen to which they are attached to form a
ring ning 2 to 6 atoms of carbon and optionally one onal atom selected from the
group consisting of N, S and 0, said ring optionally substituted with l to 4 tuents
independently ed from the group consisting of C1-C2 alkyl, halogen, —CN, —N02 and
C1-Cz alkoxy;
Q1 is a phenyl ring, a 5- or 6-membered heterocyclic ring. or an 8-, 9- or 10-
membered fused bicyclic ring system optionally containing one to three heteroatoms selected
from up to l 0, up to 1 S and up to 3 N, each ring or ring system optionally substituted with
one or more substituents independently selected from Rs;
each Q2 is indcpcndcntly a phcnyl ring or a 5- or 6-mcmbcrcd hctcrocyclic ring, cach
ring optionally substituted with one or more substituents independently ed'f‘rom Rgi
Q3 is a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally
substituted with one or more substituents independently selected from R9; and
nisO,lor2.
PCT/U82012/054719
In one embodiment of formula (I), W is O. In another embodiment, W is S.
In r embodiment of formula (I), A', A2, A3, A4, A5 and A6 are each CR3.
In another ment of formula (I), B1 B2 and B3 are each CR2.
In still another embodiment of formula (I), W is O and Al, A2, A3, A4, A5 and A6 are
each CR3.
In yet another embodiment of formula (I), W is O; A', A2, A3, A4, A5 and A6 are each
CR3; and B1, B2 and B3 are each CR2 .
In another embodiment of formula (1), Al, A2, A3, A4, A5 and A6 are each CH.
In another embodiment of formula (I), B', B2 and B3 are each CR2; and R2 is H,
IO halogen, C1-C6 alkyl or C1-C6 haloalkyl.
In still another embodiment of formula (I), R1 is C1-C3 alkyl optionally substituted by
_ i
one or more of R6;
R2 is independently H, n, C1-C6 kyl, C1-C6 haloalkoxy or —CN; and
each R3 is independently H, halogen, C1-C6 alkyl, Cl-C6 haloalkyl, C3-C6 cycloalkyl,
C3-C6 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -CN or —N02.
In still another embodiment, the invention provides a composition comprising an
oline of a (I) wherein:
W is O or S; R4 is H or C1-C6 alkyl; R5 is —CH2C(O)NHCH2CF3; each of
A'=A2=A-‘=A4=A5=A6 is CH;
R1 is C1-C6 alkyl each optionally substituted with one or more substituents independently
selected from R6;
R6 is halogen or C1-C6 alkyl; and
B' 133 are independently CH, C-halogen, C-C.-C6 alkyl, C-Cl-CGhaloalkyl, or C-
, B2, and
_ i
C1-C6 alkoxy.
In another embodiment of formula (I), B], B2 and B3 are independently CR2;
W is O;
R4 is H, C1-C6 alkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl; and
R5 is H, NR'IR12 or Q; or C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C4 lkyl,
C4-C7 alkylcycloalkyl or C4-C 7 cycloalkylalkyl, each optionally substituted with one or more of
R7. . a a _ a
PCT/U82012/054719
In still another embodiment of formula (1), RI is C1-C3 alkyl optionally substituted with
halogen;
each R2 is independently H, CF3, OCFg, halogen or —CN;
each R3 is independently H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C 1-C4
' I
alkoxy or —CN; and
each R7 is independently halogen, C1-C4 alkyl, C1-C4 , C1-C4 alkylthio, C1-C4
alkylsulfinyl, C1-C4 alkylsulfonyl, C2-C4 alkylcarbonyl, C2-C4 alkoxyearbonyl, C2-C5
alkylamin0carbonyl, C2-C5 haloalkylearbonyl, C2-C5 haloalkoxycarbonyl, C2-C5
haloalkylaminoearbonyl, -NH2, -CN or N02; 01' Q2.
IO In yet another embodiment of a (I), R4 is H;
R5 is C1-C4 alkyl optionally substituted with one or more R7;
each R7 is independently halogen or Q2; and
each Q2 is independently phenyl, pyridinyl or thiazolyl.
In still another embodiment of formula (I). R1 is CF3;
A', A2, A3, A4, A5 and A6 are each CR3;
B2 is CR2; and
each R3 is independently H, C1-C4 alkyl or —CN.
In another embodiment, B2 is CH;
BI and B3 are each CR2 where each R2 is independently halogen or C1-C3 haloalkyl;
A', A2, A3, A4, A5 and A6 are each CR3;
R3 is H; and
n is 2.
In still r embodiment of a (I). R1 is CF};
A', A2, A3, A4, A5 and A6 are each CR3;
B2 is CH;
each of B1 and B3 are CR2;
each R3 is independently H or C1-C4 alkyl;
each R2 is independently halogen or C1-C3 haloalkyl;
R4 is H;
R5 is C1-C4 alkyl optionally substituted with one or more R7; and
PCT/U82012/054719
R‘ is C2-C7 alkylcarbonyl, C2-C7 alkoxycarbonyl, C2-C7 alkylaminocarbonyl, C3-C9
dialkylaminocarbonyl, C2-C7 haloalkylcarbonyl, C2-C7 haloalkoxycarbonyl, C2-C7
haloalkylaminocarbonyl, C3-C9 dihaloalkylaminocarbonyl. ' '
In yet another embodiment of formula (l), R1 is CF3;
Al. A2, A3, A4. A5 and A6 are each CH;
B2 is CH;
each of B1 and B3 are CR2;
each R2 is independently halogen or C1-C3 haloalkyl;
R4 is H;
IO R5 is C1-C4 alkyl optionally substituted with one or more R7; and
R‘7 is Cz-C 7 alkylarninocarbonyl, C3-C9 dialkylaminocarbonyl, C2-C7
haloalkylaminocarbonyl or C3-C9 dihaloalkylaminocarbonyl.
In a preferred embodiment, a topical composition comprising an isoxazoline active agent of
formula (I) is provided, n:
R1 is CF3;
W is O;
A', A2, A3, A4, A5 and A6 are each CH;
132 is CH;
BI is chloro;
132 is CF3;
R4 is H;
R5 is CH2C(O)NHCH7CF3; and
n is 2.
In a red embodiment, the isoxazoline nd is 4-[5-[3-chloro
(trifluoromethyl)phenyl]-4,5-dihydro(trifluoromethyl)isoxazolyl]-N-[2-oxo[(2,2,2-
trifluoroethyl)amino]ethyl]naphthalanecarboxamide (Compound A).
In anothcr embodiment, the compositions of the invention may include one or more
compounds of the isoxazolines disclosed in , WO' 2007/075459 and US
2009/0133319, and US 2009/0143410, , WO 02809,
, WO 85216 and US 2007/0066617 and , all of which
are incorporated herein by reference in their entirety.
PCT/U52012/054719
In other preferred embodiments, the invention provides topical compositions comprising
an isoxazoline active agent bed in WC 2009/02451A2 and A1, both
incorporated herein by reference in their entirety, in combination with a pharrnaceutically
acceptable carrier or diluent.
In another red embodiment, the invention es topical compositions comprising
compound ll-l described in W0 2009/02451A2, which has the structure:
mt; ‘3‘“ 3’ M"
i 33% We. H's;
, 3 "'3
t Ls
‘ 3,-
'. «f {ig 5;.
K. v.~\-§.\
in combination with a pharmaceutically acceptable r or diluent bed herein.
In still another embodiment the invention provides topical compositions comprising one
or more of the isoxazoline compounds of formulae 1.001 to 1.025 and 2.001 to 2.018 described
in WO 2011075591 in combination with a pharmaceutically acceptable carrier described :
(2)9 4%/ :N//%N B3
BYE]\\B2R15
0 .N_/
Compounds 1.001 to 1.025
Compound in:1:a- - RT LCMS
«a in) No. (Z) I 5" EH3: (“11“) Method
3,5-C12 m a: H CH3C(O)NHCH3CF3 5 k) 1“)
1.002 2 O :1: oI oE c:1: CH3CF3 u. N u. N DJ k).—
1.003 3.5- (CFg): (" I]: (I‘: :1: (K CH2C02C‘H3 HJ1 \C N CO"
1.004 3,5-(CF3)2 O :1: oI CHzCOZH V' 00 U.) .NO\l
1.005 3,5-(CF3)3 0 :1: om: $32: oneIII, QI 0H CH2C(O)NHCH3CF3 E .N '— J:-
3,5-(CF3)3 on I-H can:‘1: 00:1: 000 CH2C(O)NHCH3CF3 0\ £1! 0 N . _. 00
1.007 3,5-(CF3)2 '3 CH2CHQSCH3 I90UI N . DJ
3,5-(CF3)2 C-H 9:i: 0 H CH2C(O)NHCH3CF3 648 1" —- 00
PCT/U52012/054719
9:1: on U1 00A Ix) I‘QJ)
”P:1: O o
1.011 (‘0‘ III:
0“”? :z: 90‘.” :1::1:: (:1 :L'. Gonna‘ =:1:::1:::1: s OC N NC
1.012 0 :1:
1.013 3,5-C12 - 9C3It: U1 1— O\ h) Ix) O\
1.014 3-C].5-CF; - O:1: CH2C(O)NHCH3CF;
1.015 noI: W?I:
1.016 00
1.017 3,5-C12 00000000— IE’I‘IZIII 00‘? :1::1::1: 0000($ng 099::m E!0 N —- N
3,5-C12 - 0 Z(I? N .— \1
1.019 OE(D n UIU1 flu:to N ,_. 00
1.020 OO z('5 noI}: 0CD )NHCH;CF3
1.021 C-:1: 0:1: 0Z(D 0.:1: an E(D
1022 3,5-(CF3)2 0Z0 CH2CH2$CH3
1.023 3-Cl.5-CF3 rpm:m 90:n: 0ZO rpm :12: rpm33(DO )NHCH3CF3
1.024 3-Cl,5-CF; E 0C- :L‘ ‘9LI: 0 z('D CH2CF;
1.025 3-C1,5-CF3 C-H 0x I 7‘Z(O..Qa('D (7I (-s Z CD\ CHgCHgSC-H3
N0. III-nl—l-105 13.4 B3 132 R15 R'6 MH' (mm) Method
2001 ‘
. cmuochuzcm --
2.002
2.003
2.004 1
2.005
2.006 -_--
2.007 CH2C(O)NHCH2CF_~, --
2.008 --_--
2.009 --_--
2.010 ‘
,. 2(‘(O)NHCH2CF3 --
2.011
2.012 - c-H--_--
PCT/U82012/054719
on on CH.C(0)NHCH,CF. --
2.014 - - -_--
2.015 —--‘ ‘ -_--
2.016 - - cnzc<o>Nchzcm --
2.017 —-- - - -_--
2.018 - - -_--
In one embodiment, the invention es a topical composition comprising at least one
isoxazoline of formula (I) in combination at least one other active agent, and a phannaeeutieally
acceptable carrier or diluent.
Additional veterinary/pharmaceutical active ingredients may be used with the
compositions of the invention. _ In some ments, the additional active agents may include,
but are not limited to, aearieides, anthelminties, anti-parasitics and insecticides. Anti-parasitic
agents can include both ectoparasiticidal and/or endoparasiticidal agents.
Veterinary pharmaceutical agents that may be included in the compositions of the
invention are well-known in the art (see e.g. Plumb’ Veterinary Drug Handbook, S‘h Edition, ed.
Donald C. Plumb, Blackwell Publishing, (2005) or The Merck Veterinary Manual, 9‘h Edition,
(January 2005)) and include but are not limited to aearbose, acepromazine e,
acetaminophen, aeetazolamide, aeetazolamide sodium, acetic acid, aeetohydroxamie acid,
acetylcysteine, acitretin, acyclovir, azole, albuterol sulfate, anil, rinol,
alprazOlam, altrenogest, amantadine, amikaein sulfate, aproie acid, aminopentamide
hydrogen sulfate, aminophylline/theophylline, amiodarone, ptyline, amlodipine besylate,
ammonium chloride, ammonium molybdenate, amoxieillin, clavulanate potassium, amphotericin
B desoxycholate, amphotericin B lipid-based, ampicillin, amprolium, ds (oral), antivenin,
apomorphione, apramycin sulfate, ascorbic acid, asparaginase, aspiring, atenolol, atipamezole,
atraeuriitm besylate, atropine sulfate, , hioglueose, azaperone, azathioprine,
azithromycin, baelofen, barbituates, pril, betamethason‘e, bethanechbl de, bisacodyl,
bismuth subsalieylate, bleomyein sulfate, boldenone undecylenate, bromides, bromoeriptine
mesylate, budenoside, buprenorphine, buspirone, busulfan, butorphanol tartrate, cabergoline,
calcitonin , calcitrol, calcium salts, captopril, carbenicillin indanyl sodium, carbimazole,
carboplatin, eamitine, carprofen, carvedilol, eefadroxil, cefazolin sodium, cefixime, clorsulon,
cefoperazone sodium, cefotaxime , cefotetan disodium, cefoxitin sodium, oxime
proxetil, ceftazidime, ceftiofur sodium, ceftiofur, ceftiaxone sodium, cephalexin, cephalosporins,
_ 26 _ _ _
PCT/U82012/054719
cephapirin, charcoal (activated), chlorambucil, mphenicol, chlordiazepoxide,
chlordiazepoxide +/- clidinium bromide, chlorothiazide, chlorpheniramine maleate,
chlorpromazine, chlorpropamide, chlortetracycline, nic gonadotrdpin (HCG), chromium,
cimetidine, ciprofloxacin, cisapride, cisplatin, citrate salts, clarithromycin, clemastine te,
clenbuterol, clindamycin, clofazimine, clomipramine, claonazepam, clonidine, cloprostenol
sodium, clorazepate dipotassium, clorsulon, cloxacillin, codeine phosphate, colchicine,
corticotropin (ACTH), cosyntropin, cyclophosphamide, cyclosporine, cyproheptadine,
cytarabine, azine, dactinomycin/actinomycin 7D, arin sodium, danazol, dantrolene
sodium, dapsonc, dccoquinatc, dcfcroxaminc mcsylatc, dcracoxib, dcslorclin acctatc,
IO desmopressin acetate, corticosterone te, detOmidine, dexamethasone, dexpanthenol,
dexraaioxane, dextran, diazepam, diazoxide (oral), dichlorphenamide, diclofenac sodium,
dicloxacillin, diethylcarbamaiine citrate, diethylstilbestroln (DES), difloxacin, n,
dihydrotachysterol (DHT), diltiazem, dimenhydrinate, dimercaprol/BAL, dimethyl sulfoxide,
dinoprost tromethamine, diphenylhydramine, disopyramide phosphate, dobutamine,
docusate/DSS, dolasetron mesylate, domperidone, dopamine, ctin, doxapram, doxepin,
doxorubicin, clinc, cdctatc calcium disodium.calcium EDTA, cdrophonium chloride,
enalapril/enalaprilat, enoxaparin sodium, enrofloxacin, ephedrine sulfate, epinephrine,
epoetin/erythropoietin, eprinomectin, antel, erythromycin, esmolol, estradiolicypionate,
ethacrynic acid/ethacrynate sodium, ethanol (alcohol), etidronate , etodolac, etomidate,
euthanasia agents w/pentobarbital, famotidine, fatty acids (essential/omega), felbamate, fentanyl,
ferrous sulfate, fllgrastim, finasteride, fipronil, icol, fluconazole, flucytosine,
fludrocortisone acetate, flumazenil, flumethasone, n meglumine, fluorouracil (S-FU),
fluoxetine, fluticasone propionate, fluvoxamine maleate, izole (4-MP), furazolidone,
furosemide, gabapentin,“ gemcitabine, gentamicin sulfate, glimepiride, ide, glucagon,
glucocorticoid agents, gluCosamine/chondroitin sulfate, ine,’glyburide, glycerine ,
glycopyrrolate, gonadorelin, grisseofulvin, guaifenesin,‘halothane,hemoglobin glutamer—ZOO
(OXYGLOBINCEXRD, heparin, hctastarch, hyaluronatc sodium, hydrazalinc, hydrochlorothiazidc,
odone bitartrate, hydrocortisone, hydromorphone, hydroxyurea, hydroxyzine, ifosfamide,
imidacloprid, imidocarb dipropinate, impenem-cilastatin sodium, imipramine, inamrinone
lactate, insulin, eron alfal2a (human recombinant), iodide (sodium/potassium), ipecac
(syrup), ipodate sodium, iron n, isoflurane, isoproterenol, isotretinoin, isoxsuprine,
PCT/U82012/054719
itraconazole, ivermectin, kaolin/pectin, ketamine, ketoconazole, ketoprofen, ketorolac
tromethamine, lactulose, leuprolide, levamisole, levetiracetam, levothyroxine sodium, ine,
lincomycin, liothyronine sodium, lisinopril, lomustine (CCNU), lufenuron, lysine, magnesium,
mannitol, marbofloxacin, mechlorethamine, meclizine, meclofenamic acid, medetomidine,
medium chain triglycerides, medroxyprogesterone acetate, megestrol acetate, melarsomine,
nin, can, melphalan, meperidine, mercaptopurine, meropenem, metformin,
methadone, methazolamide, methenamine ate/hippurate, methimazole, methionine,
methocarbamol, methohexital sodium, methotrexate, ’methoxyflurane, methylene blue,
phcnidatc, mcthylprcdnisolonc, mctoclopramidc, mctoprolol, mctronidaxolc, mcxilctinc,
IO mibolerlone, midazolam’milbemycin oxime, mineral oil, minocycline, misoprostol, mitotane,
mitoxantrone, morphine sulfate, moxidectin, naloxone, mandrolone decanoate, naproxen,
narcotic (opiate) agonist analgesics, neomycin sulfate, neostigmine, niacinamide, nitazo‘xanide,
nitenpyram, nitrofurantoin, nitroglycerin, nitroprusside sodium, nizatidine, novobiocin sodium,
nystatin, octreotide acetate, olsalazinc sodium, omeprozole, ondansetron, opiate antidiarrheals,
orbifloxacin, lin sodium, oxazepam, oxibutynin chloride, oxymorphone, oxytretracycline,
oxytocin, pamidronatc disodium, pancrcplipasc, pancuronium e, paromomycin sulfatc,
parozetine, pencillamine, general information penicillins, llin G, penicillin V potassium,
pentazocine, pentobarbital sodium, pentosan polysulfafe sodium, péntoxifyllinerergolide
mesylate, phenobarbital, phenoxybenzamine, utazone, phenylephrine,
phenypropanolamine, oin sodium, pheromones, parenteral phosphate,
phytonadione/vitamin K-l, pimobendan, piperazine, pirlimycin, piroxicam, polysulfated
glycosaminoglycan, ponazuril, potassium chloride, pralidoxime chloride, prazosin,
prednisolone/prednisone, primidone, procainamide, rbazine, prochlorperazine,
propantheline“ bromide, propionibacteriumacnes injection, “propofol, propranolol, protamine
e, pseudoephedrine, um hydrophilic mucilloid, pyridostigmine bromide, pyrilamine
e,“ pyriméthamine, “quinacrine, quinidine, ranitidine, in, s-adenosyl-methionine
(SAMc), salinc/hypcrosmotic ve, sclamcctin, sclcgilinc /l-dcprcnyl, scrtralinc, mcr,
sevoflurane, silymarin/milk thistle, sodium bicarbonate, sodium polystyrene ate, sodium
stibogluconate, sodium sulfate, sodum thiosulfate, somatotropin, sotalol, spectinomycin,
spironolactone, stanozolol, streptokinase, ozocin, succimér, succinylcholine chloride,
sucralfate, sufentanil citrate, sulfachlorpyridazine sodium, sulfadiazine/trimethroprim,
sulfamethoxazole/trimethoprim, sulfadimentoxine, imethoxine/ormetoprim, sulfasalazine,
taurine, tepoxaline, terbinafline, terbutaline e, testosterone, tetracycline, thiacetarsamide
sodium, thiamine, anine, thiopental sodium, thiotepa, thyrotropin, tiamulin, ticarcilin
um, tiletamine /zolazepam, tilmocsin, nin, tobramycin sulfate, tocainide, tolazoline,
telfenamie acid, topiramateftramadol, trimcinolone acetonide, ine, trilostane, trimepraxine
tartrate w/prednisolone, tripelennamine, tylosin, urdosiol, valproic acid, vanadium, vanedmycin,
vasopressin, vecuronium bromide, verapamil, vinblastine sulfate, vincristine sulfate, vitamin
E/selenium, warfarin sodium, xylazine, yohimbine, zafirlukast, zidovudine (AZT), zinc
acetate/zinc sulfate, zonisamide and mixtures thereof.
IO In one embodiment of the invention, arylpyrazole compounds such as pyrazoles,
known in the art may be combined with the isovaoline compounds in the topical compositions
of the invention. Examples of such arylpyrazole compounds include but are not limited to those
described in US. Patent Nos. 6,001,384; 6,010,710; 6,083,519; 6,096,329; 6,174,540; 6,685,954
and 6,998,131 (all of which are incorporated herein by reference, each assigned to Merial, Ltd.,
Duluth, GA).
In another embodiment of the invention, one or more macrocyclic cs or lactams,
which act as an acaricide, anthelmintic agent and/or insecticide, can be added to the
compositions of the invention.
The macrocyclic lactoncs e, but are not limited to, ctins such as abamectin,
dimadectin, doramectin, emameetin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin
and ML-1,694,554, and milbemycins such as milbemeetin, milbemycin D, moxidectin and
etin. Also included are the 5-oxo and 5-oxime derivatives of said avermectins and
milbemyeins. Examples ofcombinations Of arylpyrazoleeompounds With’maeroeyclie lactoncs
include but are not“ d to those described in US. Patent Nos. 6,426,333; 6,482,425;
6,962,713 and 6,998,131 (all incorporated herein by reference - each assigned to Merial, Ltd.,
Duluth, GA). _ ' ‘
The macrocyclic lactone compounds are known in the art and can easily be obtained
commercially or through synthesis techniques known in the art. nce is made to the widely
available technical and commercial literature. For avermectins, ivennectin and tin,
reference may be made, for example, to the work “Ivermectin and Abamectin”, 1989, by M.H.
Fischer and H. Mrozik, William C. ll, published by er Verlag., or Albers-
WO 39948 PCT/U82012/054719
Schonberg et a1. (1981), “Avermectins Structure Determination”, J. Am. Chem. Soc., 103, 4216-
4221. For doramectin, “Veterinary Parasitology”, vol. 49, No. 1, July 1993, 5-15 may be
consulted. For milbemycins, reference may be‘ made, inter alia, to Davies H.G. et al., 1986,
“Averrneetins and Milbemycins”, Nat. Prod. Rep., 3, 87-121, Mrozik H. et al., 1983, Synthesis
of Milbemycins from Avermectins, Tetrahedron Lett., 24, 5333-5336, US. Patent No. 4,134,973
and EP 0 677 054.
Macrocyclic es are either natural products or are semi-synthetic derivatives thereof.
The structure of the avcrmcctins and milbemycins are closely related, e.g., by sharing a complex
16-membered macrocyclic c ring. The natural product ctins are disclosed in US.
IO Patent No. 4,310,519 and the 22,23-dihydro avermectin compounds are disclosed in US. Patent
No. 4,199,569. Mention is also made Of US. Patent Nos. 4,468,390, 5,824,653, EP 0 007 812
Al, U.K. Patent Specification 1 390 336, EP 0 002 916, and New d Patent No. 237 086,
inter alia. Naturally occurring milbemycins are described in US. Patent No. 3,950,360 as well
as in the various references cited in “The Merck Index” 121h ed., S. ri, Ed., Merck & Co.,
Inc. Whitehouse Station, New Jersey (1996). Latidectin cribed in the “International
Nonproprictary Names for Pharmaceutical Substances (INN)”, WHO Drug Information, vol. 17,
no. 4, pp. 263- 286, (2003). Semisynthetic derivatives of these classes of compounds are well
known“ in the art and are described, for example, in US. Patent Nos. 5,077,308, 4,859,657,
4,963,582, 4,855,317, 4,871,719, 4,874,749, 4,427,663, 4,310,519, 4,199,569, 596,
711, 4,978,677, 4,920,148 and EP 0 667 054.
In preferred embodiment of the invention, the invention comprises a topical composition
sing an isoxazoline compound in combination with a class of acarieides or insecticides
known as insect growth regulaters (IGRs). Compounds belonging to this group are well known
to the practitioner and represent a wide range of different chemical classes. ‘These nds all
act by’interfering with the development or growth of the insect pests. Insect growth regulators
are described, fer e, in US. Patent Nos. 3,748,356, 3,818,047, 4,225,598, 4,798,837,
4,751,225, EP 0 179 022 or UK. 2 140 010 as well as US. Patent Nos. 6,096,329 and 6,685,954
(all orated herein by reference).
In one embodiment the IGR is a compound that mimics juvenile hormone. es of
juvenile hormone mimics include azadirachtin, diofenolan, fenoxycarb, hydroprene, kindprene,
PCT/U82012/054719
methoprene, pyriproxyfen, ydroazadirachtin and ro-2(2-chloromethyl-propyl)
(6-iodopyridy1methoxy)pyridazine-3(2H)-one.
In a particularly preferred embodiment, the compositions of the invention comprise an
isoxazoline compound of formula (I) in combination with methoprene or pyriproxyfen and a
pharmaceutically acceptable carrier. It has been surprisingly found that compositions Comprising
an isoxazoline compound of formula (I) in combination with methoprerie or pyriproiyphen
exhibit superior long lasting efficacy that is not table based on the activity of each active
alone. 7
In another embodiment, the IGR nd is a chitin synthesis inhibitor. Chitin
IO synthesis tors include chlorofluazuron, cyromazine, diflubenzuron, fluazuron,
flucyeloxuron, flufenoxuron, hexaflumoron, lufenuron, tebufenozide, teflubenzuron, triflumoron,
novaluron, 1-(2,6-difluorobenzoyl)—3-(2-fluoro(trifluoromethyl)phenylurea, l-(2,6-difluoro-
benzoyl)(2-fluoro(I,1,2,2-tetrafluoroethoxy)-phenylurea and I-(2,6-difluorobenzoyl)(2-
fluorotrifluoromethyl)phenylurea.
In yet another embodiment of the ion, adulticide insecticides and acaricides can
also be added to the composition of the invention. These include pyrethrins (which include
n I, cinerin II, jasmolin I, jasmolin II, pyrethrin I, pyrethrin II and mixtures thereof) and
pyrethroids, and carbamates including, but are not limited to, benomyl, olate, carbaryl,
carbofuran, iocarb, metolcarb, promacyl, propoxur, aldicarb, rboxim, oxamyl,
thiocarboxime and thiofanox.
In some embodiments, the itions of the invention may include one or more
antinematodal agents including, but not limited to, active agents in the benzimidazoles,
imidazothiazoles, tetrahydropyrimidines, and organophosphate class of compounds. In some
embodiments, benzimidazolés including, but not limited to, thiabendazole, ciambendazole,
parbendazole, oxibendazole, mebendazole, azole, fenbendazole, oxfendazole,
albendazole, cyclobendazole, febantel, thiophanate and its o,o-dimethyl ue may be
included in the compositions.
In other embodiments, the compositions may include an imidazothiazole compounds
including, but not limited to, tetramisole, sole and butamisole. In still other embodiments,
the itions of the invention may include tetrahydropyrimidine active agents including, but
not limited to, pyrantel, oxantel, and morantel. Suitable organophosphate active agents include,
PCT/U82012/054719
but are not limited to, coumaphos, trichlorfon, haloxon, naftalofos and dichlorvos, heptenophos,
mevinphos, monocrotophos, TEPP, and tetrachlorvinphos.
In other embodiments, the itions may include the matodal compounds
phenothiazine and piperazine as the neutral compound or in various salt forms,
diethylcarbamazine, s such as disophenol, cals such as arsenamide, ethanolamines
such as bephenium, thenium closylate, and methyridine; e dyes ing pyrvinium
de, pyrvinium pamoate and dithiazanine iodide; isothiocyanates including bitoscanate,
n , phthalofyne, and various natural products including, but not limited to,
hygromycin B, a-santonin and kainic acid.
In other embodiments, the compositions of the invention may include antitrematodal
agents. Suitable antitrematodal agents—include, but are not limited to, the miracils such as miracil
D and mirasan; praziquantel, clon’azepam and its 3-methyl derivative, oltipraz, lucanthone,
hycanthonc, oxamniquine, nate, niridazolc, nitroxynil, s bisphenol compounds
known in the art including hexachlorophene, bithionol, bithionol sulfoxide and menichlopholan;
various salicylanilide compounds including tribromsalan, oxyclozanide, clioxanide, rafoxanide,
nide, bromoxanide and closantel; triclabendazole, diamfenetide, clorsulon, hetolin and
emetine.
'Anticestodal nds may also be advantageously used in the compositions of the
invention including, but not limited to, arecoline in various salt forms, bunamidine, niclosamide,
canatc, paromomycin and paromomycin II.
In yet other embodiments, the compositions of the invention may include other active
agents that are ive against arthropod parasites. Suitable active agents include, but are not
limited to, bromocyclen, chlordane, DDT, endosulfan, lindane, methokychlor, ene,
bromophos, bromophos-ethyl, carbophenothion, chlorfenvinphos, yrifos, crotoxyphos,
cythioate, diazinon, dichlorenthion,, diemthoate, dioxathion, ethion, famphur, fenitrothion,
fenthion, fospirate, iodofenphos, malathion, naled, phosalone, phosmet, phoxim, propetamphos,
ronnel, stirofos, allethrin, cyhalothrin, cyperrnethrin, deltamethrin, fenvalerate, flucythrinate.
permethrin, phenothrin, pyrethrins, resmethrin, benzyl benzoate, carbon disulfide, crotamiton,
diflubenzuron, diphenylamine, disulfiram, isobornyl thiocyanato e, methoprene,
monosulfiram, pirenonylbutoxide, rotenone, triphenyltin acetate, triphenyltin hydroxide, deet,
dimcthyl phthalate, and the compounds l,5a,6,9,9a,9b-hcxahydro-4a(4I-I)-
PCT/U82012/054719
dibenzofurancarboxaldehyde (MGK-l 1 ), thylhexyl)-3a,4,7,7a-tetrahydro-4,7-methano-1H-
isoindole-1,3(2H)dione (MGK-264), yl-2,5-pyridinedicarboxylate (MGK-326) and 2-
(octylthio)ethanol 74). ' _
In a particularly preferred embodiment, the topical compositions of the invention will
include perrhethrin in combination with the isoxazoline active agent.
An antiparasitic agent that can be combined with the compound of the invention to form
a composition can be a biologically active e or protein including, but not limited to,
depsipeptides, which act at the neuromuscular’ junction by stimulating ’presynaptic receptors
belonging to the sccrctin receptor family resulting in the paralysis and death of parasites. In one
IO embodiment of the depsipeptide, the depsip’eptide is side (see ’Willson et al.,
Parasitology, Jan. 2003, I26(Pt 1):79-86).
In another embodiment, the compositions of the ion may comprise an active agent
from the neonicotinoid class of pesticides. The otinoids bind and inhibit insect specific
nic acetylcholine receptors. In one embodiment, the neonicotinoid insecticidal agent that
can be combined with an isoxazoline compound to form a topical composition of the invention is
imidacloprid. Imidacloprid is a well-known neonicotinoid active agent and is the key active
ingredient in the l parasiticide products Advantage'fi, Advantage® II, K9 Advantix®, and
K9 Advantix® I] sold by Bayer Animal Health. Agents wof this class are described, for example,
in US. Patent No. 4,742,060 or in EP 0 892 060.
In another embodiment, the topical compositions of the invention may se
nitenpyram, another active agent of the neonicotinoid class of pesticides. Nitenpyram has the
following chemical structure and is the active ingredient in the oral product CAPSTARTM Tablets
sold by Novartis Animal Health.
Nitenpyram is active against adult fleas when given daily as an oral tablet. Nitenpyram
works by interfering with normal nerve transmission and leads to the death of the insect.
yram has a very fast onset of action against fleas. For example. CAPSTARTM Tablets
begin to act t fleas in as early as 30 minutes after administration and is indicated for use as
often as once a day. However, nitenpyram is only known to be effective when administered orally as
PCT/U82012/054719
a systemic parasiticide, as with CAPS'I‘ARTM Tablets. Therefore, it is surprising and cted that
the l compositions of the invention sing a ation of “nitenpyram with an
isoxazoline active agent t the very fast onset’of action of nitenpyram because this active agent
is not known to be 'active when administered topically. The l compositions of the invention
comprising a combination of a long-lasting isoxazoline active agent with a very fast acting active
agent such as the neonicotinoid active agent nitenpyram provide optimal speed of onset and long
lasting activity against ectoparasites.
' Nitenpyram has a very low log octanol-water partition coefficient of -0.64 and a
relatively high solubility in water of 840 g/L at 20° C and pH of 7 (see Supplement to
IO Compendium 0n Continuing Education/or the practicing veterindrian, vol. 23, n0.’3(a), march
2001), indicating that it is not a likely candidate for topical delivery. Based on the very low log p
of nitenpyram and the very high water solubility, one of skill in the art would have a very high
level of cism that this active agent could be effectively delivered in a topical composition.
The effectiveness of topical compositions of the invention that comprise nitenpyram are all the
more cted in view of the physicochemical properties of the compound.
In another preferred embodiment of the invention, topical compositions comprising at
least one isoxazoline compound in combination with an IGR and a otinoid active agent are
provided. In still anothef preferred embodiment, the invention es topical compositions
comprising an isoxazoline compound of Formula (I) together with an IGR that mimics juvenile
e and nitenpyram. In yet another preferred embodiment, the invention provides topical
spot-on or pour-on compositions comprising 4-[5-[3-chloro(trifluoromethyl)phenyl]-4,5-
dihydro-S-(trifluoromethyl)isoxazolyl]-N-[2-oxo[(2,2,2-trifluoroethyl)amino]ethyl]- l -
naphthalanecarboxamide' (Compound A) in combination with (S)-methoprene or pyriproxyfen
and nitenpyram. H M
In another ment, the topical itions of the invention provide topical n
or pour-on compositions that comprise 4-[5-[3Schloro-S-(trifluoromethyl)phenyl]-4,“5-dihydro
(trifluoromethyl)isoxazolyl]-N-[2-oxo[(2,2,2-trifluoroethyl)amino]ethyl]
naphthalanecarboxamide (Compound A) in combination with nitenpyram, (S)-methoprene or
pyriproxyfen and an avermectin or milbemyein compound. In yet another embodiment of the
invention, topical compositions are provided that comprise 4-[5—[3-chloro
(trifluoromethyl)phenyl]-4,5-dihydro(trifluoromethyl)isoxazolyl]-N-[2-oxo[(2,2,2-
PCT/U82012/054719
trifluoroethyl)amino]ethyl]naphthalanecarboxamide (Compound A) in combination with
nitenpyram and/or (S)-methoprene or pyriproxyfen and/or an avermeetin or milbemycin
compound and/or praziquantel. In this embodiment, the presence of an avermectin or
milbemycin compound and/or praziquantel provides potent activity against endoparasites in
addition to activity against ectoparasites. i
In certain ments, an insecticidal agent that can be combined with the compositions
of the ion is a semicarbazone, such as metaflumizone.
In r embodiment, the compositions of the invention may ageously include a
combination of isoxazolinc compounds known in the art. These active agents are described in
IO W0 2007/079162, W0 2007/075459 and US 2009/0133319, W0 2007/070606 and US
2009/0143410, , WO 02809, W0 2009/024541, and
US 2007/0066617 and W0 2008/122375, all of which are incorporated herein by reference in
their entirety.
In r embodiment of the invention, nodulisporic acid and its derivatives (a class of
known acaricidal, anthelmintic, anti-parasitic and insecticidal ) may be added to the
compositions of the invention. These compounds are used to treat or prevent ions in
humans and animals and are described, for example, in US. Patent No, 5,399,582, 5,962,499,
6,221,894 and 6,399,786, all of which are hereby incorporated by reference in their entirety. The
compositions may include one or more of the known nodulisporic acid derivatives in the art,
including all stereoisomers, such as those described in the patents cited above.
In another embodiment, anthelmintic compounds of the amino acetonitrile class (AAD)
of compounds such as monepantel (ZOLVIX), and the like, may be added to the compositions of
the invention. These compounds are described, for example, in W0 2004/02470’4 and US.
Patent No. 280 (incorporated by reference); Sager et“ al., Veterinary Parasitology, 2009,
159, 49-54; Kaminsky et al.,Nature VOL 452, 13 March 2008, 176-181. The compositions of the
invention may also include aryloazol-Z-yl cyanoethylamino compounds such as those bed
in US Patent No. 8,088,801 to 8011 et al., which is incorporated herein in its ty, and
thioamide derivatives of these compounds, as described in US. Patent No. 7,964,621, which is
incorporated herein by reference.
The compositions of the invention may also be combined with rquamide
compounds and derivatives of these nds, including derquantel (see 0stlind et al.,
WO 39948 PCT/U82012/054719
Research in nary e, 1990, 48, 260-61; and Ostlind et al., l and Veterinary
Entomologv, 1997, 11, 407-408). The paraherquamide family of compounds is a known class of
compounds that include a spirodioxepino indole core with aetivity against certain parasites (see
Tet. Lett. 1981, 22, . Antibiotics 1990, 43, 1380, and J. Antibiotics 1991, 44, 492). In
addition, the structurally related marefortine family of compounds, such as marcfortines A-C, are
also known and may be combined with the formulations of the ion (see J. Chem. Soc. —
Chem. Comm. 1980, 601 and Tet. Lett. 1981, 22, 1977). Further references to the
paraherquamide derivatives can be found, for example, in WC 91/0996], WO 92/22555, WO
97/03988, WO 01/076370, W0 09/004432, US. Patent 5,703,078 and US. Patent 5,750,695, all
IO of which are hereby incorporated by reference in their entirety.
In general, the additional active agent is included in the composition in an amount of
between about 0.1 ug and about 1000 mg. More typically, the additional active agent may be
included in an amount of about 10 pg to about 500 ing, about 1 mg to about 300 mg, about 10
mg to about 200 mg or about 10 mg to about 100 mg.
In other embodiments of the invention, the additional active agent may be included in the
composition to deliver a dose of about 5 ug/kg to about 50 mg/kg per weight of the . In
other embodiments, the additional active may be present in an’amount sufficient to deliver
a dose of about 0.01 mg/kg to about 30 mg/kg, about 0:1 mg/kg to about 20 mg/kg, or about 0.1
mg/kg to about 10 mg/kg of weight of animal. In other embodiments, the onal active agent
may be present in a dose of about 5 gag/kg to about 200 ug/kg or about 0.1 mg/kg to about 1
mg/kg of weight of animal. In still another embodiment ofthe invention, the additional active
agent is included in a dose between about 0.5 mg/kg to about 50 mg/kg.
The topical compositions of the invention,iwhieh include at least an isoxazoline active
agent and a pharmaceutically acceptable carrier that is suitable for topical ation to an
animal, have been surprisingly discovered to be stable and ive t a broad spectrum of
eetoparasites for an extended period of time. '
In a preferred embodiment of the inventive compositions, the topical composition will be
in the form‘ of a liquid solution or suspension that comprises a pha‘rmaeeutie‘ally acceptable
carrier or diluent that is suitable for application to the skin of an animal. Topical, dermal and
subdermal formulations can include emulsions, creams, ointments, gels, pastes, powders,
shampoos, pour-on formulations, ready-to-use formulations, spot-on solutions and suspensions.
PCT/U82012/054719
In a preferred embodiment of the invention, topical compositions suitable for l
administration to a localized area of an animal are provided, ing compositions in the form
of spot-on or pour-on compositions. In another embodiment, the topical compositions will be in
the form of a spray formulation, an aerosol or a foam formulation suitable for administration to
an . In Some embodiments, the liquid on or suspension ations comprising
isoxazoline active agents will be in a form’that can be sprayed’on via a metered dose pump or a
metered dose aerosol.
Isoxazoline active , such as those of Formula (I), are ically active such that
the ectoparasite is affected when taking a blood meal from the host. Accordingly, a minimum
IO concentration of the compounds in the systemic circulation of the animal is required. However,
in some situations the isoxazoline active agent may also be active by contacting the parasite on
the surface of the animal. Thus, in some embodiments, topical application or the inventive
compositions can allow for the active agents to be delivered and distributed throughout the hair
coat topically and/or may also provide distribution of the active agent via the sebaceous glands
of the animals. When the compound is distributed hout sebaceous glands, the sebaceous
glands can act as a oir, whereby there can be a long-lasting effect, c.g. at least one month
or longer. For example, Cochet and co-workers reported the distribution of fipronil, a I-
arylpyrazole compound, to the stratum comeum, the viable epidermis and the sebaceous glands
and epithelial layers of beagle dogs after spot-on administration (see Cochet et al., Eur. J. Drug
Metab. Pharmacokinet.., 1997, 22(3), 211-216). Using 14C radiolabeled drug, the publication
demonstrated that l is displaced from the point of application and distributed to the whole
skin, where it was persistently detected for up to 56 days after treatment.
Topical application of the inventive compositiOns enables effective delivery of the active
agent transdermaIly through the skin into the systemic circulation at a concentration sufficient to
provide ent y against ectoparasites. In another preferred embodiment, the
compositions of the invention aChieve distribution of the active agent both topically over the hair
coat of the animal and also transderrnally into the blood stream. In this embodiment, the topical
compositions provide a high level of efficacy at unexpectedly low plasma concentrations of the
isoxazoline active agent.
The outer layer of the mis, the m comeum, forms the major barrier to both the
egress of water and the ingress of xenobiotics into the circulatory system. It is a unique
PCT/U82012/054719
membrane comprised of dead thin flat cells, comeocytes, which are filled with dense keratin,
between which is a lipid-rich layer comprised of numerous lipid bilayers. The general sus
is that most xenobiotics pass through the lipid-rich layer between the flat cells. Delivering an
active through the skin ts a significant challenge, given the role of the skin as a barrier for
keeping foreign substances out. In 'order for an active—ingredient to pass through the stratum
comeum, it must pass sequentially across bilayers and ore cross many hydrophilic-
lipophilic interfaces. Because of the efficient barrier of the skin, transdermal delivery is only
typically appropriate for potent compounds that e only a small dosage.
Only materials which have good solubility properties in both oils and water will be able
IO to effectively pass across the skin With relative ease. One of the major problems in treating the
skin or using the skin to deliver a substance into the systemic Circulation arises from the
requirement that the active has to possess the correct physicochemical ties to allow it to
reach the site of action or circulation. If it is extremely hydrophilic it will reside on the skin
surface. If it is extremely lipophilic it will pass into the lipid-rich layer n the cells and
will have difficulty penetrating . Only compounds that are small, have balanced solubility
in oils and water and a log (octanol—water partition coefficient) of ~2 (log P) will pass through
the stratum comeum and into the ic circulation to any significant degree (see Kenneth B.
Sloan (ed.) (1992) Prodrugs: Topical and Ocular Drug Delivery, p.6, Marcel , New
York). Examples include ne and nitroglycerin (GTN). However even these are not
absorbed to a large degree. Thus, many compounds are not suitable for transdermal delivery
e of their inherent physicochemical properties.
It will be understood that the ability of an active agent to be distributed either topically or
transdermally is dependent both on the physicochemical characteristics of the nd and
also on the non-active excipients of the formulation, which may induce penetration of the active
agent into the skin. While there is no general method to r any active agent either topically
over the hair coat of an animal or transdermally to an animal, some techniques for enhancing the
penetration of active agents into the skin of animals are known. Substances termed ation
enhancers,’ 9 are typically used in compositions designed to deliver drugs transdermally to
increase the amount of the active that is delivered into the systemic circulation. Permeation
enhancers constitute various classes of compounds including certain solvents such as
dimethylsulfoxide (DMSO), pyrrolidones, ethanol, propylene glycol, ethyl acetate,
PCT/U82012/054719
dimethylacetamide, and others that are capable of disrupting the barrier function of the stratum
comeum. Other substances have also been shown to increase the flux of certain active agents
through the skin. These include lipophilic compounds such as laurocapram (Azone); fatty acids
or alcohols such as oleic acid, oleyl alcohol, linoleic acid and the like; certain fatty acid esters
such as isopropyl ate, methyl noanoate, methyl caprate and others. Mixtures of n
tion enhancers with propylene glycol are also known to improve the delivery of certain
active ingredients. For example, see Pharmaceutical Skin Penetration Enhancement edited by
h A. Walters and Jonathan Hadgraft, Marcel Dekker, Inc. New York, 1993; ISBN 0
9017-0.
IO In some ments of the invention, the itions are ated to control the
rate of permeation of the isoxazoline compound in order to maintain efficacious levels of the
active in the plasma for a prolonged period of time and significantly extend the duration of
efficacy. Thus, in one embodiment, the topical compositions of the ion are formulated with
a carrier system that induces the containment of the isoxazoline active s) within the skin to
achieve a reservoir effect and controls the permeation rate of the compound into the systemic
circulation over a longer period of time. In this manner, the invention es topical
compositions that exhibit sing long lasting efficacy against ectoparasites. It must be noted
that “this approach is only applicable to potent active agents thatgmay achieve the desired
ticidal efficacy with low plasma concentrations, since less potent compounds would not be
able to establish an efficacious concentration.
It has been found that the topical compositions of the present invention comprising an
isoxazoline active agent in a carrier comprising a lipophilic solvent or lipophilic solvent system
result in superb efficacy against ectopar’asites’for an extended duration of time. Although not
wishing to “be bound by , it is believed that non-active ents in certain topical
formulations of the invention prOmote the containment of the isoxazoline active agent within the
skin for longer periods of time while allowing the active agent to constantly diffuse into the
circulatory system at a rate that provides the required concentration of the active in the blood
stream to be'efficacious against ectoparasites fora longer period of time. This is contrary to the
approaches used with typical topical formulations that are designed to enhance the passage of
active agents through the skin of an animal into the systemic circulation quickly to n the
desired biological effect. Thus, in one embodiment the present invention utilizes non-active
2012/054719
excipients that discourage the fast permeation of isoxazoline active agents into the systemic
circulation.
In one embodiment, the invention provides topical compositions sing an
isoxazoline active agent in a ceutically acceptable carrier wherein the carrier does not
include a compound that enhances the permeation of the isoxazoline active agent. In another
embodiment, the invention provides topical compositions comprising an isoxazoline active agent
and a pharmaceutically acceptable r wherein the carrier comprises a solvent or solvent
system’that promotes the containment of the isoxazoline active agent in the skin of the animal for
a longer period of time.
IO In one embodiment of the ion sing a carrier that extends the duration of
efficacy of the topical compositions, the carrier may comprise a solvent selected from carboxylic
acid esters, diesters of dicarboxylic acids, fatty acid esters or diesters of fatty diacids, Or a
combination thereof, including, but not limited to, isopropyl palmitate, isostearyl lactate,
diisopropyl adipate, dibutyl adipate, diethyl sebacate, dibutyl sebacate, octyl palmitate,
polyethyleneglycol (PEG) stearate and cetearyl octanoate; oils including, but not limited to,
mineral oil, crides, triglycerides, jojoba oil, lecithin and castor oil, or a combination
thereof; long chain tic alcohols such as isostearyl alcohol and the like; fatty alcohols and
their esters, ding for example, cetyl alcohol, cetearyl l and the like, or a combination
thereof; polyethylene glycols of different molecular weight ranges ing, but not limited to,
PEG 300, PEG 400, PEG 600 and PEG 1000, or a combination thereof; and glycol ethers
including, but not limited to, leneglycol monoethyl ether (Transcutol’m), butyl diglycol,
ene glycol monomethyl ether, propylene glycol monoethyl ether, ylene glycol n-
butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether’and dipropylene
glyCol monomethyl ether, or a combination thereof; or a combination Of two or more of these
Solvents.
Exeipients that may also promote the containment of the active agent in the skin for
longer periods of time and may be included in the compositions of the invention include, but are
not limited to, mixed esters ofsucrose and carboxylic acids including sucrose acetate yrate
(SAIB) and the like; low temperature melting waxes, hydrogenated vegetable oils,
caprylic/capric glycerides; glycerol esters, including for example, triacetin, glycerol monooleate,
ol monolinoleate, glycerol stearate, glyceryl distearate and the like; triglycerides, including
PCT/U82012/054719
for example, caprylic, capric/ myristic/ stearic triglyceride; therrnoreversible polymers, such as
Pluronic and poloxamers, including for example, Lutrol F127 by itself or in mixture with other
poloxamers; or a ation thereOf.
In another embodiment of the invention the ceutically acceptable carrier for the
topical itions comprise a mixture of a diester of a dicarboxylic acid alone or in
co’mbination’with one or more of additional solvents listed above, and/0r an “oily” lipophilic
substance, including a liquid or low melting lipophilic active agent such as (S)-methoprene,
pyriproxyfen and/or’perme’thrin; and/or a mixed ester of e and carboxylic acids including a
mixed ester of sucrose and acetic and isobutyric acids such as sucrose acetate isobutyrate
IO (SAIB), and/or low melting waxes and/or hard fats.
Although not wishing to be bound by theory, the ion of certain lipophilic solvents
in the topical compositions of the invention e the residence time of the oline active
agent within the skin while allowing an effective concentration of the active agent to pass slowly
into the atory system to achieve the desired efficacy for longer s of time.
In a preferred embodiment, the diester of a dicarboxylic acid is diethyl sebacate or
diisopropyl adipatc. In another embodiment, the blend of solvents comprising a dicarboxylic
acid ester comprises a glycol or polyglycol, or a glycol or ycol ether or ester including, but
not limited to, ethylene glycol“(EG),' propylene glycol “(PG)‘, liquid polyoxyethylene glycols
(PEGs) of various grades including PEG 400, EG or PG monocaprylate, EG or PG caprylate,
EG or PG monolaurate, EG or PG dicaprylate/dicaprate, diethyleneglycol monoethyl ether
(DGME, Transcutol'zm), butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol
monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether,
propylene glycol monomethyl ether, propylene glycol monOethyl ether, and the like, or a
combination thereof; an ether including, but not limited to, dimethyl isosorbide; an ester or di-
ester including, but not limited to, triaCetin, lauryl lactate; and other solvents including glycerol
formal, or mixtures thereof.
In preferred embodiments, the carrier for the topical compositions comprises a dialkyl
ester of a dicarboxylic acid such as diethyl sebacate, diisopropyl sebacate, diisopropyl adipate,
dibutyl adipate, or a ation thereof, alone or in ation with solvents selected from:
' _
a) a propylene glycol (PG) ester ing PG monocaprylate, PG ate, PG
urate, PG dicaprylate / ate, or a combination thereof;
PCT/U82012/054719
b) an ether solvent ing yl isosorbide, diethylene glycol monoethyl
ether (also known as DGME or Transcutol®), or a combination thereof;
0) a carboxylic acid ester including, but not limited to, triacetin, lauryl lactate,
isopropyl palmitate, diisopropyl sebacate, or a combination f; and
d) other “oily” or lipophilic organic solvents including glycerol formal and the
like.
In some embodiments, the amount the additional solvents ed with the carboxylic
acid ester or diester of a dicarboxylic acid are present in an amount of at least about 1% (v/v), at
least about 5% (v/v), at least about 9.0% (v/v), at least about 13% (v/v), at least about 17% (v/v)
IO or at least about 20% (v/v). Preferably the additional solvents will be in an amount of at least
about 9% (v/v).
In other embodiments, the additional solvents will be present in an amount of about 5-
70% (v/v), about 10-60% (v/v), about 10-50% (v/v), about 15-60% (v/v) or about 15-50% (v/v).
In preferred embodiments, the additional solvents will be present in an amount of about 20-70%
(v/v), about 20-60% (v/v), about 20-50% (v/v) or about 25-50% (v/v).
The pharmaceutically acceptable carrier may include suitable carriers or diluents
commonly used in the formulation art including aqueous or organic solvents or mixtures of
solvents. These organic solvents may be found, for example, in Remington Pharmaceutical
es, 21St Edition (2005). Other solvents and/or additives that may be used in the topical
itions include, but are not limited to, PEG ethers and PEG esters including, but not
limited to, PEG esters of carboxylic acids and dicarboxylic acids and PEG esters of fatty acids,
glycerol esters including triacetin, caprylic/capric cerides (Miglyol 8123‘) and the like;
ol ethers includingnglycerol formal; propylene glycol dicaprylate/dicaprate (Miglyol 840®),
lauryl lactate, triacetin, diisopropyl e (DIPA, also knownas CERAPHYL 230), diisobutyl
e, dimethyl isosorbide (DMI), tributyl citrate, oleic acid; carboxylic acid esters
including esters of diacids, ketones including acetone, methylisobutyl ketone (MIK), methyl
ethyl ketone, and the like; acetonitrile, C1-C1; alcohols including benzyl alcohol, methanol, ethyl
alcohol, isopropanol, and butanol; aromatic ethers such "as anisole; amides including
dimethylacetamide, thylacetamide and dimethylformamide; dimethyl sulfoxide
(DMSO), ethylene glycol, propylene glycol, a glycol carbonate including, but not limited to,
propylene carbonate and, butylene ate; 2-pyrrolidone, N-methylpyrrolidone, C1-C1; alkyl
PCT/U82012/054719
esters of carboxylie acids including butyl or octyl acetate and benzyl e; C1-C12 alkyl esters
of dicarboxylic acids; aryl esters including benzyl te, ethyl benzoate and the like; and
diethyl phthalate, or a miXture of at least two of these solvents.
However, in one ment, the invention provides topical compositions comprising at
least one isoxazoline active agent, ally in combination with one or_ more additional active
agents, in a pharmaceutically acceptable carrier, wherein the carrier does not comprise
glyeofurol. In r embodiment, the pharmaceutically acceptable carrier of the topical
Compositions does not comprise a binary mixture of propylene glycol and glycerol formal. ’
As vehicle or diluent, mention may also be made of plant oils such as, but not limited to
IO soybean oil, groundnut oil, castor oil, corn oil, cotton oil, olive oil, grape seed oil, sunflower oil,
etc.; mineral eils such as, but not limited to, petrolatum, paraffin, ne, etc.; aliphatic or cyclic
hydrocarbons including limonene or alternatively, for example, medium-chain ’(such as C3 to
C12) triglycerides, or mixtures f.
In one ment, solvents and/or additives that control the permeation rate of the
active may be added to a composition comprising one of the formulation carriers described
herein, including carriers comprising a dialkyl ester of a dicarboxylic acid such as dicthyl
sebacate or the like. In another embodiment, solvents and/or additives that control the
permeation rate of the active may be added to carriers comprising other ts described herein
or may be used alone in the composition.
It will be appreciated by those skilled in the art that the skin of different animals will be
different in nature and may be more or less permeable to the isoxazoline active agent. For
example, the retainment of the isoxazoline active agent on the skin of a cat may be more difficult
than dogs. Accordingly. in some situations with certain animals the topical compositions of the
invention will utilize'solvents that enhance the permeation of the “isoxazoline active agent
through the skin of the animal rather than solvents and excipients that retain the active agent on
the skin of the animal for longer periods of time. Thus, in another embodiment of the invention,
topical compositions are provided that include ts that e the permeation of
iséxazoline active agents through the skin of the animal. These solvents provide a greater
proportion of the active agent through the skin and thereby improve the efficacy and on of
time. In this embodiment, the permeation enhancing solvent s a greater proportion of the
isoxazoline active agent through the skin into the ic circulation. It will be appreciated by
PCT/U82012/054719
those of skill in the art that this effect allows a greater level of efficacy at lower doses of the
. Selected solvents that enhance the permeation of the isoxazoline active agent e, but
are not d to, dimethyl bide; and glycol ethers including, but "not limited to,
diethyleneglycol monoethyl ether (DGME, utol®), butyl diglyeol, dipropylene glycol n-
butyl ether, neglchl monoethyl ether, ethyleneglycol monOmethyl ether, dipropylene
glycol monomethyl ether, propylene glycol monOmethyl ether, propylene glycol monOethyl
ether, and the like. Other solvents that enhance the permeation of the isoxazoline active agent
bed below may also be used in the compositions.
In one embodiment of the invention, the pharmaceutically acceptable carrier of the
IO formulation may comprise Cs-Czo long-chain aliphatic alcohols or esters f. In another
embodiment, the r comprises C1-C1; alcohols or esters thereof, C1-C4 alcohols or esters
thereof or C3-C8 alcohols or esters thereof. In some embodiments, the esters formed with the
alcohol include esters of C1-C1; carboxylic acids or diacids, or esters of C6-C16 ylic acids
or diacids. Esters include, but are not limited to, acetates such as ethyl acetate and the like; and
esters of 0-02 alcohols and a diearboxylic acid or a hydroxy-substituted carboxylic acids.
In another embodiment, the pharmaceutically acceptable r ses C4-C22 fatty
acids or esters thereof, including esters with C6-C20 long chain alcohols, Cl-C 12 alcohols, C1-C4
alcohols or C3-Cg alcohols; Clo-"C13 saturated fatty acids or esters thereof, including esters with
C6-C20 long chain alcohols, C1-C12 alcohols, C1-C4 alcohols or C3-C3 alcohols; Clo-C13
rated fatty acids or esters thereof, including esters with C6-C20 long chain alcohols, C l—C 12
alcohols, C1-C4 alcohols or C3-C3 alcohols; monoesters or diesters of C6-C16 aliphatic carboxylic
acids and carboxylie diaeids, including esters with C6-C20 long chain alcohols, C1-C12 alcohols,
C1-C4 alcohols or C3-C3 alcohols, or mixtures thereof. In other embodiments, the carrier may
include C1-Clo, C1-C8 or C1-C6 alcohols or esters thereof.
In another embodiment, the compositions of the invention comprise aromatic alcohols or
esters thereof. In one preferred embodiment, the topical compositions of the ion may
include benzyl alcohol as a solvent.
In another embodiment, preferred solvents include C1-C12 alkyl esters of carboxylic acids
such as butyl acetate, octyl acetate, lauryl lactate or isopropyl palmitate, and C1-C12 alkyl esters
of dicarboxylic acids, including diisopropyl adipate, diethyl‘s'ebacate and diisopropyl sebacate. In
other embodiments, the carrier may e C1-C10, C1-C8 or C1-C6 alkyl esters of carboxylic
PCT/U82012/054719
acids or C1-Clo, C1-C3 or C1-C6 alkyl diesters or dicarboxylic acids. In one embodiment, the
carboxylic acid or dicarboxylic acid is a C4-C2; fatty acid or dicarboxylic acid. In another
embodiment, the carboxylic acid or dicarboxylic acid is a C1-C1; ylic acid or diearboxylic
acid. In other embodiments, the carboxylic acid or dicarboxylic acid is a C1-Clo, C1-C3 or C1-C6
carboxylic acid or dicarboxylic acid.
In some preferred ments, the carrier or diluent e a derivative of glycerol
including, but not limited to, ol monoesters (e.g. monoglycerides), glycerol rs (e.g.
diglycerides), glycerol triesters' (e.g. cerides such as triacetin), or glycerol formal, or
mixtures thereof. Glycerol formal is a mixture of 5-hydroxy—l,3-dioxanc and 4-hydroxymethyl-
IO 1,3- ane (approximately 60:40), which are cyclic ether compounds derived from glycerol
and having 2 oxygen atoms in the ring structure and substituted by alcohol group. Glycerol
Formal is a low Odor and low toxic solvent for a wide variety of applications in’pharmaceutical
and cosmetics industry including anti-parasite veterinary formulations.
In r embodiment of the ion, the organic solvents may comprise diisopropyl
adipate, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, 2-
pyrrolidone, ylpyrrolidone, diethylenc glycol monoethyl ether, triacctin, butyl acetate,
benzyl alcohol, octyl acetate, propylene carbonate, oleic acid, or a mixture of at least two of
H A
these solvents.
In some embodiments of the invention, the carrier comprises yl isosorbide.
Dimethyl isosorbide (DMI) is a high purity solvent and carrier which offers a safe, effective
delivery enhancement mechanism for active ingredients in personal care products and
pharmaceutical formulations. In addition dimethyl isosorbide is sometimes used as an epidermal
penetration enhancer to provide enhanced penetration of active agents to the mis. It may
also provide delivery of active agents into—the skin while avoiding crystallization of the active
agent, which will severely the effectiveness of the ation. Dimethyl Isosorbide is
e in a variety of ingredients including water, cottonseed oil, isopropanol, isopropyl
ate, propylene glycol, polysorbate 20, and polysorbate 80.
In Other embodiments, the carrier or diluent may comprise a glycol derivative including,
but not limited to, propylene glycol, ethylene glycol; glycol ethers and polyglyeol ethers
including, but not limited to, butyl diglycbl, propylene glycol monomethyl—ether, propylene
glycol monoethyl ether, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether,
PCT/U82012/054719
ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, and diethylene glycol
monoethyl ether (DGME or Transcutol‘ai').
In a preferred embodiment, the topical compositions of the invention comprising
isoxazoline active agent(s) are dissolved in a pharmaceutically acceptable carrier comprising one
or more solvents. In some embodiments of the invention solvents include, but are not limited to,
dimethyl isosorbide (DMI), glycerol formal (methylidinoglycerol or glycerin formal), tin,
liquid polyethyleneglyeols ing PEG 400, diisopropyl adipate (DIPA), pyl palmitate,
silicone fluid including SILICONE FLUID 200 and ne Fluid lest and /or ne Fluid
Zest and the like; propylene glycol (or other aliphatic dihydric ls), benzyl alcohol,
IO propylene glycol esters including propylene glycol dicaprylate / dicaprate, propylene carbonate,
propylene glycol monocaprylate, “propylene glycol dicaprylate, propylenew glycol monolaurate
and propylene glycol dilaurate; alkyl esters “of dicarboxylic acids including diethyl sebacate
(DES), diisopropyl sebacate; and esters or diesters of fatty acid, or combinations thereof.
In an embodiment of the invention, the compositions of the ion may include
tants. The surfactants may be anionic, cationic, non-ionic or amphoterie surfactants.
Anionic surfactants include, but are not limited to, alkaline tcs; calcium stearate;
triethanolamine stearate; sodium abietate; alkyl sulfates; sodium dodeeylbenzenesulphonate,
sodium dioctylsulphosuceinate; fatty acids, and the like. Examples of ic surfactantiinelude,
but are not d to, water-soluble nary ammonium salts of formula;
eetyltrimethylammonium bromide and oetadecylamine hydrochloride. Non-ionic surfactants that
may be used in the compositions e, but are not limited to, polyoxyethylenated (PEGylated)
esters including, but not limited to, sorbitan esters and fatty acid esters; polyethylene glycol
stearate, polpoyethylenated derivatives of castor oil, polyglycerol esters, yethylenated
fatty alcohols, polyoxyethylenated fatty acids, and eopolymers of ethylene oxide and propylene
oxide including, but not limited to, block co-polymers Of ethylene oxide and propylene Oxide
such as poloxamers and the like (e.g. Lutrol® F grades and L grades from EASF including
Lutrol® F68, F87, F 108 and F 127 and others), and the like;. Further example of surfactants
include, but are not limited to, CAPRYOLTM 90 (propylene glycol“ monoeaprylate),
CAPRYOLTM PGMC (propylene glycol monoeaprylate) which are oily liquids having an HLB
(hydrophilic-lipophilie balance) of 6 and 5, respectively. lly they can be used as a co-
surfactant in microemulsions and as a solubilizer/penetration enhancer.
WO 39948 PCT/U82012/054719
As used herein, HLB values have the following general meanings: compounds with a
HLB value of < 10 tend to be lipid soluble (water insoluble) and solvents with a HLB > 10 tend
to be water soluble. tants having HLB between 4 and 8 are typically useful as anti-foaming
agents. Surfactants having HLB from 7 to 11 may be useful as W/O (water in oil) emulsifiers.
HLB of 12 to 16 typically indicates a surfactant may be useful in oil in water emulsions, and
HLB of II to 14 is indicative of a wetting agent. HLB of 12 to 15 is typical of detergents, and
HLB of 16 to 20 indicates a solubilizer or hydrotrope. There is significant an overlap of
ranges/uses, and a skilled person well understands that the HLB value alone cannot be used to
predict whether a particular surfactant will serve a specific purpose (e.g. anti-foaming agent,
IO emulsifier, wetting agent, solubilizer, hydrotrope). Therefore, in general, determination of a
suitable system of solvent, active agent, surfactant(s) and other excipients necessarily involves
non-routine experimentation and inventive effort.
The compositions may also include tants such as oleoyl macrogolglycerides
(polyoxylglycerides, for example, LABRAFIL‘K‘ MI944CS and IL‘E‘ M2125CS both
having an HLB of 4). These compounds may also be used, for example, as oily phase for
emulsions, microemulsions, and as penetration enhancers.
In another embodiment, the polyoxylglycerides may include polyethyleneglycol
caprylic/caprylic glycerides such as LABRAS'O—LB) (HLB of '14. Topically it is used. as a
surfactant in microemulsions, and can also act as a solubility/penetration enhancer in l
formulations.
In another embodiment the surfactant is LAUROGLYCOLTM90 (propylene glycol
monolaurate) having an HLB of 5. It is a eo-surfactant for mulsions in topical
formulations and can also act as a lizer/penetration er in topical formulations. In
some embodiments, the surfactant is PLUROL® OLEIQUE CC497 (polyglyceryl oleate), having
7 V
an HLB of 6.
Certain ts suitable for topical formulations may be characterized as having good
ing properties while other solvents for l formulations may be characterized by an
ability to “enhance tion of active agents through the skin barrier into the systemic
circulation (see for example, Pharmaceutical Skin Penetration Enhancement, edited by Jonathan
Hadgraft and Kenneth A. Walters, Marcel Dekker, Inc. New York 1993). In some ces,
solvents suitable for l formulations may include both good spreading and good permeation
PCT/U82012/054719
characteristics. DIPA, diisopropyl sebacate, DES and l 840 have both good spreading and
permeation characteristics. Transcutol, DMI, lauryl lactate, propylene glycol caprylate,
ene glycol monocaprylate and propylene glycol monolaurate have good permeation
enhancing properties but are not considered to have particularly good spreading properties. In
certain embodiments of the invention. the compositions will comprise mixtures of ts that
will enhance the spreading ability and/or the permeation enhancing ability of the composition.
In some embodiments of the invention, formulations are provided wherein the carrier
comprises solvents that exhibit both good spreading and permeationcharacteristics including, but
not limitcd to, DIPA, diisopropyl scbacatc, DES and Miglyol® 840. In othcr cmbodimcnts, the
IO invention provides formulations n the carrier comprises ts that exhibit good
spreading characteristics. In still another embodiment of the invention, formulations are provided
\vherein the carrier vehicle comprises solvents that enhance the permeation of the active agent
through the skin into the systemic circulation.
In one ment, the composition exhibits long lasting efficacy and provides
protection against parasites in domestic animals for at least one month. In one embodiment, the
composition ses a carrier that includes a solvent system comprised of a carboxylic acid
alkyl ester or diester of a dicarboxylic acid. In another embodiment, the composition comprises
a blend of solvents comprising a ylic acid alkyl ester or a diester of a dicarboxylic acid.
In another embodiment, the compositions of the invention t very long lasting
efficacy of at least 90% against fleas and/or ticks that for a period of at least 1 month, at least 2
months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months against fleas
and/or ticks. In one ment, the long-lasting composition comprises a carrier that includes a
carboxylic acid alkyl ester or a diester ’of a dicarboxylic acid, including diethyl sebacate and
diisopropyl adipate. In r embodiment, the long-lasting composition ses a
carboxylic acid’alkyl ester or a diester of a dicarboxylic acid combined with an co-solvent
including, but not limited to, a propylene glycol (PG)'ester including PG monocaprylate, PG
caprylatc, PG monolauratc and PG dicaprylatc/dicapratc; lcncglycol hyl cthcr
(DGME, Transcutol‘fi’), mineral oil, triglycerides, diglycerides, isostearyl l, isostearyl
lactate, dibutyl adipate, l sebacate; polyethylene glycols (PEGs) including PEG 400, PEG
stearate; lecithin, r oil and castor oil derivatives, film formers, myristyl myristate,
dimethiconol argenine, sucrose acetyl isobutyrate, and the like, or a combination thereof.
PCT/U82012/054719
In still r embodiment, the long-lasting compositions that provide an efficacy of at
least 90% against fleas and/or ticks for at least 1 month, at least 2 months, at least 3 , at
least 4 , at least 5 , or at least 6 months, comprise a carrier vehicle that includes
dimethyl isosorbide. As mentioned above, DMl is a known permeation enhancer, and use of this
solvent in some topical formulations of the invention results in increased delivery of the active
agent into the systemic circulation. In particular, it was found that the use of DM1 in topical
formulations for cats ed in surprising efficacy for up to at least 3 months, at least 4 months,
at least 5 months or even at least 6 months, against fleas.
In yet another embodiment, the long-lasting compositions that provide an y of at
IO least 90% t fleas and/or ticks comprises a“ glycol ether including, but not limited to,
diethyleneglycol monoethyl ether (DGME, Transcutol®), butyl diglyeol, dipropylene glycol n-
butyl ether, neglchl monoethyl ether, ethyleneglycol mOnOmethyl~ ether, diptopylene
glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl
ether, and the like.
As discussed above, isoxazoline active agents such as those of Formula (I), and in
ular 4-[5-[3-chloro(trifluoromcthyl)phenyl]-4,5-dihydro(trifluoromcthyl)
isoxazolyl]-N-[2-oxo[(2,2,2-trifluoroethyl)amino]ethyl]- l -naphthalanecarboxamide
(Compound A), are systemically active such that the ectoparasite is affected when taking a blood
meal from the host. ingly, a minimum concentration of the compounds in the systemic
circulation of the animal is required to effectively control ectoparasites such as ticks and fleas. It
was surprisingly found that the topical formulations of the invention comprising an isoxazoline
active agent provide excellent efficacy t fleas and ticks at unexpectedly very low plasma
concentrations. In some embodiments, the topical compositions of the invention comprising
selected solvents and excipients, including dialkyl esters of dicarboxylic acids such as diethyl
sebacate and the like, result in constant low levels of the active agent over a prolonged period of
time. In some embodiments, the concentration of the active agent in the plasma that is sufficient
to obtain at least 90% efficacy against flcas and/or ticks is less than or equal to about 200 ng/mL
or less than or equal to about] 50 ng/mL. In other preferred embodiments, the concentration of
the isoxazoline active agent in the plasma required to attain 90% efficacy against fleas and/or
ticks is less than or equal to about 100 ng/mL, less than or equal to about 75' ng/mL or even less
than or equal to about 50 ng/mL. In other embodiments of the invention, the concentration of the
PCT/U82012/054719
isoxazoline active agent in the plasma required to attain 90% efficacy against fleas and ticks is
about 75-100 ng/mL, about 50-75 ng/mL or about 30-50 ng/mL.
Furthermore, it was also surprisingly found that'the concentration of the isoxazoline
active agent (Compound A) in the plasma required to attain an efficacy of at least 90% against
certain tick species ed to an untreated control or a control group treated with a placebo
was cantly less than the plasma concentration required to attain 90% cy from r
mode of administration that achieves high systemic exposure, such as oral or injectable
administration. It was found that the concentration of the isoxazoline active agent required to
achieve 90% efficacy against the tick species A. anzericammz, D. variabilis and R. sanguineus in
IO dogs was about 42%; 36% and 32% lower than the concentration required from oral
administration (see Example 13). This effect is surprising and unexpected for an active agent that
is active against ectoparaSites through ingestion of a blood meal, as with the isoxazolineclass of
compounds. Although not wanting to be bound by theory, the lower plasma concentration
required to e 90% efficacy from the l itions of the invention may indicate
that the compositions provide protection against ectoparasites by acting both topically on the
e of the animal and systemically. The improved efficacy of the topical compositions of the
invention against these tick species at significantly lower plasma concentrations may allow for a
longer duration of efficacy based on the ability of the non-active excipients in the inventive
compositions to provide a slow delivery of ive amounts of isoxazoline active agents into
the blood stream from the site of application.
As mentioned above, it was surprisingly discovered that the addition of certain other
active agents with the isoxazoline active agent in the topical compositions of the ion
significantly enhanced the long lasting cy of the corripositionsfFor example, inclusion of
an IGR active agent such as the juvenile hormone mimic methoprene in the l compositions
resulted in significantly longer lasting efficacy against ectoparasites. Thus; in one preferred
embodiment the invention provides very long lasting topical “compositions comprising at least
one oline active agent in combination with an insect growth regulator (IGR) active agent.
Preferably, the IGR will be a juvenile hormone mimic including azadirachtin, diofenélan,
fenoxycarb, hydroprene, kinoprene, pyriproxyfen, tetrahydroazadirachtin or 4-chloro(2-
chlorO-Z-methy[propyl)(6-iodopyridylmethoxy)pyridizin-3(2H)-one, as discussed herein.
More preferably, the IGR will be rene or pyriproxyfen. As described in the non-limiting
PCT/U82012/054719
examples, the inclusion of the IGR (S)-methoprene with the isoxazoline active agent resulted in
significantly longer lasting efficacy. This effect is sing and unexpected, as methoprene is
not an adulticide'(see Examples 1-3). _ ' _ _
In another embodiment of the invention, it was surprisingly discovered that inclusion of a
neonicotinoid active agent such as nitenpyram in the topical compositions of the invention
significantly increased’the speed of kill’of the compositions against fleas. Thus, a topical
composition sing nitenpyram in combination with an isoxazoline active agent and
optiénally an IGR active agent and/or other oily active agents and/or active agents With low
mclting points such as pcrmcthrin, provide cfficacy of at lcast 90% against flcas as carly as 12
IO hours after administration of the l formulation and also provide king lasting efficacy. In yet
other embodiments of the invention, the topical compositions provide efficacy'of at least 90%
against fleas as early as 9 hours or 6 hours afier administration. In one embodiment of the
invention, the compositions comprising a combination of nitenpyram and an isoxazoline active
agent provide efficacy of at least 90% against fleas as early as 12 hours, 9 hours or 6 hours after
treatment and an efficacy of at least 90% for a period of at least 1 month. In other embodiments,
the compositions comprising a combination of nitenpyram and an isoxazoline activc agcnt
provide efficacy of at least 90% as early as 12 hours, 9 hours or 6 hours after treatment and an
efficacy of at least 90% for a period of at least 2 months or at least 3 months, or . The fast
acting and long lasting protection provided by a combination of the neonicotinoid nitenpyram
and an isoxazoline active agent is very surprising and unexpected because yram is only
known to be effective when stered orally, as with the product CAPSTARTM Tablets.
In other ments, the compositions of the invention may be in the form of oil-in-
water or water-in-oil emulsions. In some embodiments the oily phase may be a vegetable oil, for
example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of
thesef Suitable emulsifying agents e naturally-occurring pholsphafides, for example, soy
bean, lecithin, and esters or l esters derived from fatty acids and hexitol anhydrides, fOr
cxamplc, sorbitan mono olcatc, and condensation products of thc said partial cstcrs with cthylcnc
oxide”, for e, polyoxyethylene sorbitan mono oleate, and the like. In some embodiments,
the emulsions may also contain preservatives.
In r embodiment of the formulation, the ition of the invention is in the form
of a microemulsion. Microemulsions are well suited as the liquid r vehicle. Microemulsions
PCT/U82012/054719
are typically quaternary systems comprising an aqueous phase, an oily phase, a surfactant and a
co-surfactant. They are y translucent and isotropic liquids. Microemulsions are composed
of stable dispersions of micrddroplets of the aqueous phase in the oily phase or conversely of
microdroplets of the oily phase in the aqueous phase. The size of these microdroplets is typically
less than—200 nm (1000 to 100,000 nrri for emulsions). The interfacial film is composed of an
alternation of surface-active (SA) and co-surface-active (Co-SA) molecules which, by lowering
the interfacial tension, allows the microemulsion to be formed spontaneously.
In one embodiment of the oily phase, the oily phase’can be formed from mineral or
vegetable oils, from unsaturated polyglycosylatcd idcs or from triglycerides, or
IO alternatively from mixtures of such compotmds.‘ In one embodiment of the oily phase, the oily
phase comprises of cerides. In r embodiment of the oily phase, the triglycerides are
medium-chain triglycerides, for example C3-C10 caprylic/capric‘ triglycerideI In another
embodiment, the oily phase will represent a % v/v range selected from the group consisting of
about 1 to about 20%; about 2 to about 15%; about 7 to about 10%; and about 8 to about 9% v/v
of the microemulsion;
The aqueous phase typically includes, for example water or glycol derivatives, such as
propylene , glycol , polyethylene glycols or glycerol. In one embodiment of the
glycol derivatives, the glycol is selected from the group consisting of propylene glycol,
lene glycol monoethyl ether, dipropylene glycol hyl ether and mixtures thereof.
Generally, the aqueous phase will represent a proportion from about 1 to about 10% v/v or about
1 to about 4% v/v in the microemulsion.
' ‘SurfaCtants
for the microemulsion typically include diethylene glycol hyl ether,
dipropyelene glycol monomethyl ether, polyglycolyzed Cg-Cm glycerides or polyglyceryl-6
dioleate, or a combination of these surfactants. In addition to these surfactants, them-surfactants
include chain alcohols, such as ethanol and propanol. Additionally, poloxamers and
Pluronic F127 can be used as tants. “ “ “
Some nds are common to the three components discussed above, i.c., aqueous
phase, surfactant and co-surfactant. However, it is well within the skill level of the practitioner to
use different compounds for each component of the same formulation.
Oily suspensions may be forniulated by suspending the active ingredient in a vegetable
oil, for example, s oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid
WO 39948 2012/054719
paraffin, and the like. The oily suspensions may contain a thickening agent, for example,
x, hard paraffin or cetyl alcohol, and the like. These compositions may be ved by
the addition of an anti-oxidant such as ascorbic acid or other know—n preservatives. _
Aqueous suspensions may contain the active agents in admixture with excipients suitable
for the manufacture of aqueous suspensions. Such excipients include ding agents, for
example, sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethyICellulose,
sodium alginate, polvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting
agents may be a naturally-eccurring atide, for example in, or condensation products
of an alkylcnc oxide with fatty acids, for example polyoxycthylcnc stcaratc, or condensation
IO products of ethylene oxide with long ‘chain aliphatic alcohols, for example,
heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters
derived from fatty acids and a hexitol s polyoxycthylene sorbitol mono-oleate, or
condensation products of ethylene oxide, with l esters derived from fatty acids and hexitol
anhydrides, for example polyethylene sorbitan mono-oleate. The aqueous suspensions may also
contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or
more coloring agcnts.
Colorants may be added to the inventive formulations. Colorants contemplated by the
present invention are'those commonly known in the art. Specific colorants include,“ for example,
dyes, FD&C Blue #1 Aluminum Lake, caramel, colorant based upon iron oxide or a mixture of
any of the foregoing. Especially preferred are organic dyes and titanium dioxide. Preferred
ranges include fi'om about 0.01% to about 2% (w/v), more preferably from about 0.01% to about
0.5% (w/v).
In preferred embodiment, the compositions of the invention are in the form of a n
formulation that is d to a localized“ area on an animal, rather than the entire coat “of the
animal or a large portion of the animal’s coat. In one embodiment of a zed region, the
location is betheen the shoulders. The spot-on formulation according to the present invention
provide long-lasting and broad—spectrum efficacy against rasitcs and/or cndoparasitcs
ivhen the so1ution ‘is applied toithe . The spot-on formulations provide for topical
administration of a concentrated solution, suspension, microemulsion or on for
ittent application to localized area on the animal, generally between the two shoulders.
Spot-on formulations are well known techniques for topically delivering certain
PCT/U82012/054719
antiparasitic agents to a d area of the host. However, not all compounds are suited for
formulation in spot-on formulations because the physicochemical characteristics of the active
agent may not allow effective distribution of the compound topically or transderrnally. US.
Patent Nos. 536, 6,395,765; 329; 7,262,214; 6,426,333; 6,482,425; 713;
6,998,131; and 7,531,186, all incorporated herein by reference, describe spot-on ations.
W0 01/957715, also incorporated’ herein by reference, describes a method for controlling
ectoparasites in small s as well as upting or preventing the diseases caused by
arthropods in small rodents, which comprise applying topical formulations, such as spot-on
compositions, to the skin, or hair of the rodents.
IO Spot-on formulations may be prepared by dissolving the active ingredients into the
pharmaceutically or nary acCeptable vehicle. Alternatively, the spot-on formulation can be
prepared by encapsulation of the active ingredients to leave a film of the therapeutic agent on the
surface of the animal. These formulations will vary with regard to the weight of the eutic
agent in the ation depending on the species of host animal to be treated, the severity and
type of infection and the body weight of the host.
For spot-on formulations, the pharmaceutically acceptable carrier may be a liquid carrier
vehicle as described , and other carriers described in the art, for example in US. Patent
No. 6,395,765 and other patents listed in the previous paragraph. In some embodiments, the
liquid carrier vehicle can optionally contain a crystallization inhibitor such as the crystallization
inhibitors described below, or mixtures thereof, to inhibit the ion of crystals or precipitate
of the active ents.
The veterinarily acceptable carrier will generally comprise a diluent or vehicle in which
the active agents are soluble. It will be apparent to those of skill in the art that the carrier or
diluent of the topical compositions mustibe able to deliver the active agents to the targeted
location without’the active agents precipitating from solution or forming crystals. In Some
embodiments, the carrier or diluent of mpdsitions will be suitable to avoid precipitation or
crystallization of the active agents. In other embodiments, the compositions may include a
crystallization inhibitor component in addition to the carrier or diluent. “
Crystallization inhibitors which are useful for the ion include but are not limited to:
(a) polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and of
vinylpyrrolidone, 2-pyrrolidone including N-methylpyrrolidone, dimethylsulfoxide, polyethylene
PCT/U82012/054719
glycols, co-polymers of polyoxyethylene and polyoxypropylene, benzyl alcohol, mannitol,
glycerol, sorbitol or polyoxyethylenated esters of an; lecithin or sodium
carboxymethylcellulose; or‘ acrylic derivatives, such as polymers derived from acrylic monomers
including polyacrylates or polymethacrylates; and, a solvent as described herein that inhibits the
crystallization of the active agent, and r compounds;
(b) anionic surfaCtants, such as alkaline stearates (e.g. sodium, potassium or
ammonium stearate); calcium stearate or triethanolamine stearate; sodium abietate; alkyl
sulfates, which include but are not limited to sodium lauryl sulfate and sodium cetyl sulfate;
sodium dodccylbcnzcncsulfonatc or sodium dioctyl sulphosuccinatc; or fatty acids (c.g. coconut
IO oil);
(c) cationic surfactants, such as water-soluble quaternary ammonium salts of formula
N+R'R"R"'R""Y_, in which the R radicals are identical‘or different optionally hydroxylatcd
hydrocarbon radicals and Y7 is an anion of a strong acid, such as halide, e and sulfonate
; cetyltrimethylammonium bromide is one of the cationic tants which can be used;
(d) amine salts of formula N+HR'R"R"' Y", in which the R radicals are identical or
different optionally hydroxylatcd hydrocarbon radicals and Y" is the anion of a mineral or
organic acid; octadecylamine hydrochloride is one of the cationic surfactants which can be used;
(e) non-ionic surfactants, such as optionally polyoxyethylenated esters of an,
e.g. Polysorbate 80, or polyoxyethylenated alkyl ethers; polyethylene glycol stearate,
yethylenated derivatives of castor oil ing hydrogenated castor oil and its derivatives,
ycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids or
mers of ethylene oxide and of propylene oxide;
(f) amphoteric surfactants, such as substituted lauryl compounds of betaine; or
(g) a mixture of at least two of the compounds listed in (a)-(f) above.
In one embodiment of the crystallization inhibitor, a crystallization inhibitor pair will be
used. Such pairs e, for example, the combination of a film-forming agent of polymeric
type and of a surface-active agent. Othcr crystallization inhibitor pairs include a hylene
glycol and a nic surfactant. Additional crystallization pairs including other mixtures are
also contemplated. These agents can be selected from the nds mentioned above as
crystallization inhibitor.
In one embodiment of the film-forming agent, the agents are of the polymeric type which
PCT/U82012/054719
include but are not limited to the s grades of nylpyrrolidone, polyvinyl alcohols,
polyethylene glycols and copolymers of vinyl acetate and of vinylpyrrolidone.
In one embodiment of the surface-active agents, the agents include but are not limited to
those made of non-ionic surfactants. In another embodiment of the surface active , the
agent is a polyoxyethylenated ester of sorbitan. In yet another embodiment of the surface-active
agent, the’agents include the various grades of pelysorbate, for example Polysorbate 80 and
polyoxyethylenated derivatives of castor oil including hydrogenated castor oil derivatives.
7 In another embodiment of the invention, the film-forming agent and the surface-active
agent can be incorporated in similar or cal amounts within the limit of the total amounts of
IO crystallization inhibitor mentioned above.
In some embodiments, the crystallization inhibitor can be present in a proportion of about
1 to about 30% (w/v). Typically, the llization inhibitor may be present in‘a tion of
about 1% to about 20% (w/v), about 1% to about 10% (w/v), or about 5% to about 15% (w/V).
able inhibitors are those whose addition to the formulation inhibits the ion of
crystals of the active agents when the formulation is applied. In some embodiments, formulations
may include compounds that function as crystallization tors other than those listed herein.
In these embodiments, the suitability of a crystallization inhibitor may be determined by testing
if it will sufficiently inhibit the formation of crystals so that a sample containing 10% (w/v) of
the isoxazoline active agent in a solvent as described above with 10% (w/v) of the crystallization
inhibitor will result in less than 20, preferably less than 10 crystals when placed on a glass slide
at 20 0 C for 24 hours.
In some embodiments of the invention, an emollient and/or spreading and/or film-
forming agent may be added to the topical compositions of the inventionfEmollients, spreading
agents “and film forming agents are well known in the art. In s embodiments, the
emollients, spreading agents and film forming agents that may be used in the l
compositionsiinclude the components listed in (a) to (g) above, ineluding polymer derivatives
such as polyvinylpyrrolidonc, polyvinyl alcohols and copolymers of vinyl acetate and
vinylpyrrolidone; anionic surfactants; cationic tants; non¥ionic surfactants; eric
surfactants; amine salts, and combinations thereof. In one embodiment, the emollient is used in a
proportion of from about 0.1 to about 10%, or about 0.25 to about 5% (w/v).
Optionally, a fragrance may be added to any of the compositions of the invention.
PCT/U82012/054719
Fragrances which are useful for the invention include but are not limited to:
(i) carboxylic acid esters such as octyl acetate, isoamyl acetate, isopropyl acetate and
isobutyl e;
(ii) fragrant oils such as lavender oil.
The inventive formulations may contain other inert ingredients such as antioxidants,
preservatives, or pH stabilizers. These compounds are well known in the formulation art.
Antioxidants such as vitamin E, alpha tocopherol, ascorbic acid, ascorbyl palmitate, citric acid,
fumaric acid, malic acid, sodium’ascorba’te, sodium metabisulfate, sodium metabisulfite, n-
propyl gallate, BHA (butylatcd hydroxy anisole), BHT (butylatcd hydroxy toluene), BHA and
IO citric acid, monothioglycerol, tert-butyl hydroquinone (TBHQ), and the like, may be added to the
present formulation. The antioxidants are generally added to the formulation in amounts of from
about 0.01 to about 2.0%, based upon total weight of the formulation, with about 0.05 to about
1.0% being ally preferred.
Preservatives, such as the parabens (methylparaben and/or propylparaben), are suitably
used in the formulation in amounts ranging fiom about 0.01 to about 2.0%, with about 0.05 to
about 1.0% being especially preferred. Other vatives include benzalkonium chloride,
benzethonium chloride, benzoic acid, benzyl l, bronopol, butylparaben, cetrimide,
chlorhexidine, ehlorobutanol, chlorocresol, cresol, ethylparaben, imidufea, methylparaben,
, phenoxyethanol, phenylethyl alcohol, phenylmereuric acetate, phenylmereuric borate,
phenylmereuric nitrate, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid,
thimerosal, and the like. Preferred ranges for these compounds e from about 0.01 to about
nds which stabilize the pH of the ation are also contemplated. Again, such
compounds are well known to a practitioner in the art as well as how to use these compounds.
Buffering systems include, for example, systems selected from the group ting of acetic
cetate, malic acid/malate, citric acid/citrate, ic artrate, lactic acid/lactate,
phosphoric acid/phosphate, glycine/glycimate, tris, glutamic acid/glutamates and sodium
carbonate. “
In other embodiments, the l compositions of the invention may be in the form of a
pour-on ation. Pour-on forrriulations are described, for example, in US. Patent No.
6,010,710, which is incorporated herein by reference. Some pour-on formulations are
PCT/U82012/054719
advantageously oily, and generally comprise a t or vehicle and also a solvent (e.g. an
organic solvent) for the active ingredient if the latter is not soluble in the diluent. Other pour-on
formulations may be in hydrophilic carriers, including in alcohol, glycol or glycol ether based
carriers. Pour-on formulations are typically administered to ock animals such as cattle and
sheep. Typically, pour-on formulations are administered to the animal as a stripe to an external
surface of the animal, e.g. a stripe from head to tail of the animal. In one embodiment, the
process comprises applying the solution to ock animals before they arrive in the Feed Lot, it
being le for this application to be the final one before the animals are slaughtered.
Typically, the isoxazolinc(s) active agents are present in the formulation at a
IO tration of about I to about 25% (w/v).’ In some embodiments of the invention, the
isoxazoline active agents are present in the formulation as a concentration from about 1 to about
% (w/v), about 1 to about 10% (w/v), about 5 to about 15% (w/v), or about 5 to 10% (w/v). In
other embodiments, the isoxazoline active agent(s) are present in the compositions at a
concentration of about 1 to about 5% (w/v), about 3-6 % (w/v) or about 0.5% to about 2.0%
(w/v).
The volume of the topical composition applied is not restricted as long as the amount of
substance administered is practical and shown to be safe and effective. lly, the volume
applied depends on the size and weight of the animal as well as the tration of active, the
extent of infestation by parasites and the type of administration. For spot—on compositions, the
volume d is typically of the order of about 0.1 ml to about 10 ml, about 0.1 ml to about 5
ml, or about 0.1 to about 1 ml, or, or. In other embodiments, the volume may be about 4 ml to
about 7 ml. For larger animals, the volume may be higher including, but not limited to, up to 10
ml, up to 20 ml or higher. In one embodiment of the volume, the vo1ume is on the order of about
0.5 nil to about 1 ml or about 0.5 ml to about 2 ml for cats, and on the order of about 0.3 to about
3 ml or 4 ml for dogs, depending on the weight of the animal.
For the pour-on form ofthe composition, the volume applied can be of the order of about
0.3 to about 100 mL. In other embodiments, volume applied of the pour-on formulations may be
about 1 ml to about 100 ml or about 1 ml to about 50 ml. In still other embodiments, the volume
may be about 5 ml to about 50 ml or about 10 ml to about 100 ml.
Dosage forms may contain from about 0.5 mg to about 5 g of a combination of active
agents. More typically, the amount of active is present in an amount of from about 1 mg to about
PCT/U82012/054719
500 mg of an active agent, about 1 mg to about 100 mg or about 1 mg to about 25 mg. In still
other embodiments, the amount of the active agent present in the compositions is about 10 mg
about 50 mg or about 10 mg to about 100 mg. In other embodiments, the amount of active agent
present in the compositions is about 50 mg to about 200 mg, about 100 mg to about 300 mg,
about 100 mg to about 400 mg, about 200 mg to about 500 mg, about 300 mg to about 600 mg,
about 400 mg to about 800 mg, or about 500 mg to about 1000 mg.
The compositions of the invention are made by mixing the riate amount of the
active agents, pharmaceutically acceptable carrier or diluent 'and optionally a crystallization
inhibitor, antioxidant, preservative, film former, etc., to form a composition of the invention. In
IO some embodiments the composition can be obtained by following the method of making these
forms described above by the description of making these forrns'found in general formulation
text known to those in the art, e.g. Remington — The Science and ce macy (21“
Edition) (2005), Goodman & Gilman’s The cological Basis of Therapeutics (ll'h
Edition) (2005) and Ansel ’5 Pharmaceutical Dosage Forms and Drug Delivery .Sj.r.s'tenzs (8th
Edition), edited by Allen et al., Lippincott ms & Wilkins, (2005).
Methods of Treatment
In another aspect of the ion, a method for preventing or ng a parasite
infestation/infection in an animal is provided, comprising administering to the animal aitopical
composition comprising an effective amount of at least one isoxazoline active agent together
with a pharmaceutically acceptable carrier that is suitable for application to the skin of the
animal. The compositions or formulations of the invention have long-lasting efficacy against
ectoparasites (e.g. fleas and ticks) and in certain embodiments may also active against
endoparasites that harm animals.
In one embodiment of the invention, methods for the treatment or prevention of a
parasitic infestation or infection in a ic animal are provided, which comprise
stering a topical composition sing an ive amount of at least one isoxazoline
active agent to the animal. Ectoparasitcs against which the methods and compositions of the
invention are effective include, but are not limited to, fleas, ticks, mites, mosquitoes, flies and
lice. In n embodiments wherein the compositions include one or more additional active
agents that are active against internal parasites—the compositions and methods of the invention
may also effective against rasites including, but not limited to, cestodes, nematodes,
PCT/U82012/054719
hookworms and orms of the digestive tract of animals and humans.
In one embodiment for ent against ectoparasites, the rasite is one or more
insect or arachnid including those of the genera Ctenbcephalides, Rhipicephulus, Dermacentor,
lxodes, Boophilus, Ambylomma, Haemaphysalis, I-Iyalomma, Sarcoptes, Psoroptes, Otodectes,
Chorioptes;Hypoclerma, Damalz'nia, az‘hus, Haematopinus, Solenoptes, Trichodectes, and
Felicola.
In another embodiment for the treatment against ectoparasites, the ectoparasite is from
the genera Ctenocephalides, ephalus, Dermbcentor, bedes and/or Booplzi/us. The
rasites treated include but are not limited to fleas, ticks, mites, mosquitoes, flies, lice,
IO bloWfly and combinations thereof. Specific examples include, but are notlimited to, eat and dog
fleas (Ctenocephaliclesfilis, Ctenocebhalicles sp. and the like), ticks (Rhipiceplzalus sp., Ixodes '
sp., Dermacentor sp., Amblyoma sp. and the like), and mites (Demodex sp., Sarcoptes sp.,
0t0dectes sp. and the like), lice (Trichodectes sp., Cheyletiella sp., Lignonathus sp., and the
like), mosquitoes (Aedes sp., Culex sp., Anopheles sp., and the like) and flies (Hematobia sp.
including Haematobia irritans, Musca sp., Stomoxys sp. including Stomoxys calcitrans,
Dematobia sp., Cochliomyia sp., and the like).
Additional examples of ectoparasites include but are not d to the tick genus
lus, ally those of the species microplus (cattle tick), decoloratus and annulatus;
myiases such as Dermatobia hominis (known as Beme in Brazil) and Cochliomyia vorax
(greenbottle); sheep myiases such as Luci/fa sericata, Lucilia cuprina (known as blowfly strike
in Australia, New Zealand and South Africa). Flies proper, namely those whose adult constitutes
the parasite, such as Haematobia irritans (horn fly) and Stomoxys calcitrans (stable fly); lice
such as Linognathus , etc.; and mites such as Sarcoptes scabiei and Psoroptes ovis. The
above list is not exhaustive and other ectoparasites are Well known in the art tobe harmful to
animals and humans. These include, for ekample ing dipterous larvae.
In some embodiments of the invention“, the cempos‘itioh can also be used to treat against
cndoparasites such as those helminths selected from the group consisting locephala,
smma, Anecamr, s, Capillaria, Cooperia, Dipylidium, Dirbfilaria, ococcus,
Enterobius, Fascia/a, Haemonchus, Oesophagostumzmz, Ostertagia, Toxocara, Strongyloides,
Toxascaris, Trichinella, Trichuris, and Tfichdstrongylus, among—others.
In one embodiment, the invention provides methods for the treatment and prevention of
PCT/U82012/054719
parasitic infections and infestations of animals (either wild or domesticated), including livestock
and companion animals such as cats, dogs, horses, birds including chickens, sheep, goats, pigs,
turkeys and cattle, with the aim of ridding these hosts of parasites ly tered by
such animals.
In a'preferred embodiment, the invention provides methods and compositions for the
treatment or prevention of parasitic infections and infestations in ion animals including,
but not limited to, cats and dogs. The methods and compositions are particularly effective for
preventing or treating parasitic infestations of cats and dogs with fleas and ticks.
In another preferred embodiment, the methods and compositions of the invention are used for the
IO treatment or prevention of parasitic infections and infestations in cattle or sheep. When treating
livestock animals such as cattle or sheep, the methods and compositions are particularly effective
against Rhipicephalus (Boophilus) micfoplus, Haematobia irritans (hem fly), Stomoxys
calcitrans e fly), and sheep myiases such as Luci/fa sericata, Luci/id cuprina (known as
blowfly strike in Australia, New Zealand and South Afi'ica).
The terms “treating” or “treat” or “treatment” are intended to mean the ation or
administration of a composition of the invention to an animal that has a parasitic infestation for
the eradication of the parasite or the reduction of the number of the parasites infesting the animal
undergoing treatment: It is noted that the itions of the invention may be used to prevent
such a parasitic infestation.
The compositions of the invention are administered in parasiticidally effective amounts
which are which are suitable to control the parasite in question to the desired , as described
below. In each aspect of the invention, the nds and compositions of the invention can be
d against a Single pest or combinations thereof.
_ _ The compositions of the invention may be administered continuously, for treatment or
prevention of parasitic infections or ations. In this manner, the cempositions of the
invention deliver an ive amount of the active compounds to the animal in need thereof to
control the target parasites. By “effective amount” is intended a ient amount of a
composition of the invention to eradicate or reduce the number of parasites infesting the animal.
In some ments, an ive amount of the active agent achieves at least 70% efficacy
against the target te. In other embodiments, an effective amount of the active agent
achieves at least 80%, or at least 90% efficacy against the target pests. Preferably, an effective
PCT/U82012/054719
amount of the active agent will achieve at least 95%, at least 98% or 100% efficacy against the
target parasites.
_ Generally,
a dose of from about 0.001 to about 100 mg per kg of body weight given as a
single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but, of course,
there can be instances where higher or lower dosage ranges are indicated, and such are within the
scope of this invention. It is Well within the routine ’skill of the tioner to determine a
particular dosing regimen for a specific host and parasite.
1n some’embodiments fer companion animals, the dose of the oline active agent
administered from the topical compositions of the invention is between about 0.1 to about 30 mg
IO per kg of body weight. More typically the dose of the isoxazoline active agent administered is
about'0.5 to about 20 mg/kg or about 0.5 to about 15 mg/kg body weight. Preferably, the dose of
the isoxazoline active agent administered is about 0.5 to about 10 mg/kg, about 0.5 to about 8
mg/kg or about 0.5 to about 5 mg/kg of body weight.
In certain embodiments for the treatment and prevention of te infestations and
infections in cats, the dose of the isoxazoline active agent administered will be about 0.5 to about
2 mg/kg of body weight, preferably about 1 mg/kg of bodyweight. In other embodiments for the
very long lasting treatment and protection of cats against parasitic infestations or infections a
dose of about 2 "to about 15 mg/kg of bodyweight or preferably about 5 to about 15 mg’kg of
ight will be administered.
In some embodiments for the ent and protection of dogs from parasitic infestations
and ions, a dose of about 2 to about 15 mg/kg of ight of the isoxazoline active agent
will be administered. In other embodiments, a dose of about 2 to about 8 mg/kg or about 2 to
about 5 mg/kg of bodyweight will be administered.
In Other embodiments for the treatment of ock animals such as cattle or sheep, doses
of the isoxazoline active agent administered may be about 1 to about 30 mg/kg of body’weight.
More typically the doses administered will be about 1 to about 20 mg/kg or about 1 to'about' 15
mg/kg. Preferably, a dose of the isoxazoline active agent administered to livestock animals will
be abbut 1 to about 10 mg/kg ofbody weight.
Higher amounts may be provided for very prolonged release in or on the body of the
animal. In another treatment embodiment, the amount of active agents for birds and other
animals which are small in size is greater than about 0.01 mg/kg, and in r embodiment for
PCT/U82012/054719
the treatment of small-sized birds and other animals, the amount of is between about 0.01 and
about 20 mg/kg of weight of animal. More typically the dose of the isoxazoline for small-sized
s and‘bir'ds is about 0.5 to about 15 mg/kg, about 0.5 to about 10 mg/kg of body weight, or
about 0.5 mg/kg to about 5 mg/kg of body weight.
In one embodiment of the method of use in dogs or eats, a composition comprising an
isoxazoline nd has an efficacy against fleas and/or ticks of at least about 90.0% or higher
for about 1 month, or longer. In another embodiment, the compositions of the invention provide
an efficacy against fleas and/or ticks of at least 95.0% or higher for about 30 days, or longer.
In another embodiment, the topical compositions of the invention e an efficacy
IO against fleas and/or ticks in cats and dogs of at least about 80% for two months, or longer. In
another ment, the topical compositions provide efficacy against fleas and/or ticks in cats
and dogs of about 90% for about two months, or longer. In Still another embodiment, the
itions provide an efficacy of about 95% for about 2 months or longer.
In another embodiment, the composition has an efficacy of at least about 80% t
fleas and/or ticks for about 3 months, or longer. In still r ment, the topical
compositions of the invention provide an efficacy of at least about 90% against fleas and/or ticks
for 3 months or longer. In yet another embodiment, the topical compositions of the invention
provide an efficacy of at leaSt about 95% against fleas and/or ticks for 3 months or longer. In still
another embodiment, the topical itions of the invention provide an y against fleas
and/or ticks in cats and/or dogs of at least 80% or at least 90% for about 3 months to about 6
months or longer.
In one embodiment of the invention, the topical spot-on compositions of the invention are
administered to the animal over a localized region’of the’animal, cg. between the two shoulders.
In one embodiment of the invention, the localized region has a surface area of about 10 cm2 or
larger. In r embodiment of the invention, the localized region has a surface area of
between about 5 and about 10 cm2, or smaller.
In another embodiment of the invention, the pour-on topical compositions of the
invention will be administered in a line along the back ofthe animal “approximately between the
shoulders and the hind rs.
The solutions according to the invention may be applied using any means known per se,
e.g. using an applicator gun or a metering flask, pipette, syringes, roll on, rs, capsules, foil
PCT/U82012/054719
packages, vials, twist tip ners, metered-dose aerosols or sprays and other single dose and
multi-dose containers.
' In'an'other aspect of the invention, a kit for the treatment or prevention of a parasitic
infestation in an animal is provided, which comprises at least one isoxazoline active agent
together with a pharmaceutically acceptable r and a dispensing device for topical
application of the composition. The sing device may be a pipette, syringes, roll on,
droppers, capsules, foil packages, vials, twist tip containers, metered-dose aerosols or sprays and
other single’ dose and multi-dose containers, which includes an ive dose of each active
agent in the ceutically acceptable carrier or diluent.
IO An important aspect of the‘invention is to provide a multiple-use container sing a
l ition of the invention, from which accurate single dose aliquots of the long g
topical forniulations may be administered. The ation must remain stable with repetitive
exposure to the e environment, particularly oxygen and water. This embodiment may be
particularly useful with the very long lasting formulations of the invention that require
administration to an animal infrequently, such as once every 3-6 months, or similar. Some
solvents such as ethcrs (including DMI, Transeutol® and the like) give rise to peroxides, which
then yield ketones and aldehydes that may be further degraded to acids. The presence of acids
may contribute to the degradation of acid hydrolysis-susceptible molecules, including
isoxazoline active agents. Thus, formulation stability is particularly ant for the multi-dose
container application, where the formulations can be exposed to oxygen and water during
multiple rounds of opening and closing. Importantly, it was found that the use of certain
antioxidants described herein, including BHT and BHA, efficiently inhibit the degradation of the
active agent in ether solvents. For example, a 12% (w/v) solution of Compound A in DMI
exhibited no significant change in assay over the course of an eleven week accelerated stability
study at 50 °C in clear glass ners. In other embodiments, antioxidants such as vitamin E,
alpha tocopherol, ascorbic acid, ascorbyl palmitate, citric acid, fumaric acid, malic acid, sodium
ascorbatc, sodium metabisulfate, sodium metabisulfitc, n-propyl gallate, BHA (butylatcd
hydroxy anisole), BHT (butylatcd hydroxy toluene), BHA andcitri‘c acid, monothioglycerol and
the like, may be added to the topical compositions to inhibit the formation of oxidative species.
The antioxidants are generally added to the formulation in amounts of from about 0.01 to about
2.0%, based upon total weight of the ation, with about 0.05 to about 1.0% being especially
WO 39948 PCT/U82012/054719
preferred.
EXAMPLES
lhe invention is further described by the following non-limiting es which further
illustrate the invention, and are not intended, nor should they be interpreted to, limit the scope of
the invention.
Formulation Examples
Liquid vehicles suitable for l isoxazoline—containing formulations for control of
parasites Were investigated. As a non-limiting example, the isoxa’zoline nd 3-
chloro-S-(trifluoromethyl)phcnyl]-4,5-dihydro(trifluoromcthyl)isoxazolyl]—N-[2—oxo
IO [(2,2,2-trifluoroethy|)amin’o]ethy|]-l -naphthalanecarboxamide (Cmpd. A), was investigated for
topical ry to s, including cats, dogs and livestock animals such as cattle.
Formulations comprising an isoxazoline compound in combination with one or more additional
active agents, including (S)-methoprene, pyriproxyfen and nitenpyram, were also prepared and
tested.
ations were prepared with a variety of liquid carrier vehicles and evaluated for
effectiveness to control eetoparasites, particularly fleas and ticks in cats and dogs, and ticks,
mites and lice in cattle. Solvent systems comprising either one solvent, including a diester of a
dicarboxylic acid and/or an ether such as dimethyl isosorbide, or a combination of solvents
including a r of a dicarboxylic acid, specifically l sebacate, and at least a second
solvent(s) are encompassed by the invention. In various embodiments, formulations comprising a
single solvent such as DES or DMI or a combination of ts were investigated. Solvents
combined with a diester of a dicarboxylic acid include, but are not limited to: l) a propylene
glycol ester or ether, including PG monocaprylate, PG caprylate, PG monolaurate, PG
ylate/dicaprate, PG caprylie/capric triglycerides (LABRASOLfi) or a combination thereof;
2) an ether (egfdimethyl isosOrbide); 3) a Second ester (triacetin, lauryl lactate); 4) a fatty acid
ester including, but not limited to, isopropyl palmitate, isostearyl lactate, dibutyl adipate, dibutyl
scbacatc, octyl palmitate, polyethyleneglycol stcarate and cctearyl octanoate; 5) a glycol or
polyglycol ether such as ”l‘ranseutol'fi', PEG 400 and the like; 6) an oil such as mineral oil,
diglycerides, triglycerides, jojoba oil, in and castor oil; 7) a long chain aliphatic alcohol
65 ' _
PCT/U82012/054719
such as isostearyl alcohol; and 8) mixed esters sucrose and carboxylic acids, including sucrose
acetate isobutyrate (SAIB) and the like.
In other embodiments, the topical compositions of the invention comprise TranscutoliK,
glycerol formal, triacetin, propylene carbonate, benzyl l or DMI.
' '
Non-limiting forrriulations comprising an isoxazoline nd (Cmpd. A) alone or in
combination with the non-limiting additional active agents (S)-methoprene,’pyriproxyfen and
nitenpyram are provided in below.
Formulation l -_ Add leneglycol monoethyl ether (Transcutol®) (50% of volume required);
Polysorbatc 80 and Ethanol are added; the BHA, BHT, povidonc l7, and Cmpd. A are then
IO added and mixed until dissolved, and the mixture is QS with Transcutol®.
Ingredients Function
Cmpd. A Active 3 7, 6.0 w/v
thoprcnc Active
Polysorbatc 80 Surfactant
Ethanol Spreading agent
Butylated hydroxyanisole Antioxidant
Butylated hydroxy toluene idant
Povidone K- 1 7 Thickener 5.0 w/v
Diethylene glycol monoethyl ether Solvent S
Formulation 2 - Add glycerol formal (GF. 50% of required volume), add Cmpd. A, dissolve; add
DMI; add (s)—methoprene; QS GF.
. , . w/v
w/v
Glycerol formal (GF) Spreading agent QS
Formulatlon 3 - Add diisopropyl adipate (DIPA, 50% of ed volume), add Cmpd. A,
dissolve; add (s)-methoprene; QS DIPA
PCT/U52012/054719
Diisopropyl adipate (DIPA) Spreading agent
Formulation 4 - Add diethyl sebaeate (DES 517% ulred volume); add PG monolauratc; add
Cmpd. A, dissolve; add (S)-methoprene; QS DES.
Formulatlon 5 - Add DES (56% of required volume); add PG monocaprylate; add Cmpd. A,
dissolve; add (S)-methoprene; QS DES.
Propylene glycol monoeaprylate tion enhancer 25.0
(DCl:pryol 90)
Formulat1on 6 - Add DIPA (30% of ed volume); add Ethyl hexyl pelargonate; add Cmpd.
A, dissolve; add (S)—methoprcne; QS DIPA
DIPA Spreading agent
PCT/U52012/054719
Formulation 7 - Add DIPA (50% of required volume); add diisopropyl sebaeate; add ne
fluid; add Cmpd. A, dissolve; add (S)—methoprene; QS DIPA
ooo-ooooooo
Diisopropyl scbacatc 25.0 v/v
ne fluid Spreading agent
DIPA Spreading agent
Formulation 8 - Add Miglyol 840 (50% of required volume); add lauryl lactate; add Cmpd. A,
dissolve; add (S)-methoprene; QS Miglyol 840
———ow
Miglyol 840 Spreading agent/ QS
permeation enhancer
Formulation 9- Add Miglyol 840 (50% of required volume); add triacetin; add Cmpd. A,
ve; add (S)--methoprene; QS Miglyol 840
Miglyol 840 Spreading agent/ QS
permeation enhancer
Formulation 10- Add Migly01840(50%ofrcqu1rcd volume); add Cmpd. A, dissolve; add (S)-
methoprene; QS Miglyol 840
ients Function %
PCT/U52012/054719
l 840 Spreading agent/
permeation enhancer
Formulat1on I I - Add DES (5W of required volume); add Cmpd. A, dissolve; add (S)-
methoprene; QS DES
Spreading agent]
permeation enhancer
Formulation 12 - Add DES (50% of required volume); add Cmpd. A, dissolve; QS DES
DES ing agent/ QS
permeation enhancer
Formulation 13 - Add DES (50% of required volume); add PG monocaprylate; add Cmpd. A,
dissolve; QS DES.
Propylene glycol prylate Permeation enhancer
(Capryol 90)
DES Spreading agent
Formulation l4 - Add DES (30% of required volume); adtfPG dicaprylate/dicaprate ancYPG
monoeaprylate; add Cmpd. A, dissolve; add (S)-methoprene QS DES.
PCT/U52012/054719
(S)-methoprcne 9.0% w/v
Propylene glycol dicaprylate/dieaprate Permeation er 25.0 v/v
(Capryol PGMC)
Propylene glycol monocaprylate (Capryol 90) 25.0 v/v
Formulation 15 - Add DES (50% of required volume); add, with stirring, lauryl lactate; add
Cmpd A, ve; QS DES
Lauryl e 25.0 V/v
Formulation 16- Add DIPA (50% of required volume); add DMI; add Cmpd. A (fissolvc; QS
DIPA
Formulation f7 - Add DES (30% of required volume); add UM]; add Cmpd. A, dissolve; QS
Formulation 18 — Add DES (40% of required volume); add DMI; add Cmpd. A, dissolve; QS
7 7
PCT/U52012/054719
Dimcthyl isosorbide (DMI) QS 100%
Formulat1on f9 — AddDTPA (50% of cd volume); add trlaeetm; add Cmpd. A, dissolve;
QS DIPA
Formulation 20 — AddDES (60% of ed volume); add m1neral 011, medium; add Cmpd. A,
dissolve; QS DES
Formulation 21 — Add DES (60% of required volume), add mineral oil, light, add Cmpd. A,
dissolve; QS DES ' '
Formulation 22 - Add DES (60% of required volume); add, with stirring, Transcutol®; add
Cmpd. A, mix until dissolved; add SAIB; QS with DES
Cmpd. A Active 6.0 w/v
PCT/U52012/054719
Sucrose acetate isobutyrate (SAIB) Controlled release agent
Formulation 23 - Add DES (60% of required volume); add, with ng, Transcutolfl"; add, with
stirring, PEG 400; add Cmpd. A, mix until dissolved; QS with DES
Formulation 24- Add ’I‘ranscutol‘l‘ (60% of required volume); add, with stirring, PEG 400;
add Cmpd. A, mix until dissolved; QS ’I‘ranscutol"
Formulation 25 - Add DES (60% of required volume); add, with stirring, Transcutol'fi; add, with
stirring, PEG 400; add Cmpd. A, mix until dissolved; QS with DES
In . ts Function
ML Cm dA
PEG 400 Controlled release a- ent
DES Spreading agent
Formulat1on 26- Add DES (66% of required volume); add with stirring, PEG 400; add Cmpd.
A, mix until dissolved; QS with DES
mm—__
PEG 400 t and Controlled
release _a _ent
_I-_—
PCT/U82012/054719
ation 27 - Add GF (50% of required volume), add Cmpd. A, dissolve; add nitenpyram,
dissolve; add DMI; QS GF.
Glycerol formal Spreading agent
Formulation 28 - Add BM] (50% of required volume), add Cmpd. A, dissolve; add nitenpyram,
dissolve; add (S)-methoprene and dissolve; QS with DMI.
ation 29 - Add BM] (50% of required volume), add Cmpd. A, dissolve; add nitenpyram,
ve; add pyriproxyfen and dissolve; QS DMI.
Formulation 30 - Add Transcutol® (50% of required volume), add Cmpd. A, dissolve; add
nitenpyram, dissolve; add pyriproxyfen and dissolve; QS Transcutol®.
PCT/U82012/054719
Formulation 31 - Add GF (50% of required volume), add Cmpd. A, dissolve; add nitenpyram,
dissolve; add pyriproxyfen and ve; QS GF.
Formulation 32 - Add tin (50% of required volume), add Cmpd. A, dissolve; add
nitenpyram, dissolve; add pyriproxyfen and dissolve; QS triacetinf
Formulation 33 - Add ene carbonate (50% of required volume), add Cmpd. A, dissolve;
add nitenpyram, dissolvejadd pyriproxyfen and dissolve; QS propylene carbonate.
Cmpd. A was found to be stable in at least DES, DIPA, DMI, triacetin, GF and propylene
carbonate (at 50°C in glass s).
Biological y Examples
Example 1: Efficacy of a’Spot-on Composition Comprising a Combination of Cmpd. A and (S)-
methoprene Against Dermacemor variabilis Ticks and Ctenocephalidesfizlz‘s Fleas in Dogs
Twenty eight beagle dogs were studied to ine the effectiveness of a combination of
Cmpd. A and (S)—methoprene when stered once as a topical solution against induced
infestations ofDermacenior variabilis and Ctenocephalidesfe/is. _
Four Treatment Groups containing seven dogs each were formed. Dogs in Group 1 were
untreated (control). Dogs in Groups 2, 3 and 4 were treated topically with n compositions
comprising 3.7% (w/v) Cmpd. A and 9% (w/v) (S)-methoprene administered to deliver 2.5
mg/kg Cmpd. A and 6 mg/kg (S)-methoprene (Group 2: Transcutol with 10% (w/v) ethanol, 5%
(w’/V)’TWEEN 80 and 5% (W/v) polyvin’ylpyrrolidon’e; Group 3: DM1 and glycerol formal (GF);
and Group 4: DIPA). All dogs were treated once on Day 0.
IO All dogs were infested with imately 100 C. fall's on Days -I, 8, 15, 22, 29, 35, 43
and 57, and for all Groups except 5, on Day 71. All dogs were also ed with approximately
50 D. variabilis on Days-l, 7, 14, 21, 28, 34 and 42. Fleas were counted upon removal on Day ‘-
6. Both ticks and fleas were counted upon removal on Days 2, 9, 16, 23, 30, 36 and 44. Fleas
only were d upon removal for all Treatment Groups on Day 58 and for all Treatment
Groups except 5 on Day 72. Flea efficacy is listed in Table l and tick efficacy is listed in Table 2
below.
Blood samples were collected from all dogs in the study on Days -6, 0 (at 4 h and 12 h),
l, 2, 9, 16, 23, 30, 36, 44, 51, 58, 64, 72, 79 and 86. Plasma samples were analyzed for the
tration of Compound A using an LC/MS/MS analytical method that was GLP validated
for the purpose.
Percent reduction (also ed as efficacy) t fleas was 100% through and
including Day 30 for all treatment groups (see Table 1). Percent reduction against fleas was
above 95% through Day 58 for Group 3.
The percent reduction against ticks was >94% through and including Day 23 (48 hours
infestation, see Table 2). Percent reduction was >92% for Groups 6 and 7 on Day 30.
These study data demonstrate that topical formulations comprising Cmpd. A and (S)-
methoprene in three different carrier vehicles provided 100% percent reduction for fleas through
Day 30 for all treated groups. Tick efficacy“was 100% on Days 9 and 16 and two treatment
groups (6 and 7) were 292% on Day 30.
Table 1: Efficacy of a n Composition Comprising a Combination of Cmpd. A and (S)-
methoprene Ctenocephalidesfelis
Treatment Group % Reduction Fleas
" Day Day Day Day Day Day Day Day Day
2' 9 16 23 30 36 44 58 72
Group2
100.0 100.0 100.0 100.0 100.0 100.0 86.5 33.2 --
% Reduction
Group3
100.0 100.0 100.0 100.0100.0 100.0 99.6 98.5 89.0
% Reduction
100.0 100.0 100.0 100.0100.0 99.8 95.2 89.3 68.9
Table 2: Efficacy of a Spot-on Composition Comprising a Combination of Cmpd. A and (S)-
mcthoprcnc Against Dermacentor ilis Ticks
Treatment Group ‘70 Reduction Ticks
Dav Day Day Day Day Day Day
2‘ 9‘ 16 23' 30 36 44
Group2
% Reduction 89.0 100.0 100.0 94.8 65.0 23.3 20.7
Group3
% Reduction 88.5 100.0 100.0 99.2 94.6 88.3 77.6
Group4
% Reduction 84.3 100.0 100.0 97.2 92.0 52.2 57.0
Example 2: Efficacy of Spot-on Formulations Containing Compound A and (S)-methoprene
Against Ctenocephalidesfelis.
Following the initial studies described in Example 1, additional topical formulations
comprising Compound A in combination with an insect growth regulator, (S)-methoprene, in
carrier vehicles comprising both a spreading solvent and a permeation solvent were d.
Thus, the efficacy of five ent topical formulations comprising Compound A and (S)-
rcnc against the cat flca (Ctenécepha/ides felis) in dogs was dctcrmincd using to a
protocol similar to that of Example 1.
Seven Treatment Groups with four dogs each were evaluated. Dogs in Group 1 were
untreated, and served as a control group. Dogs in Groups 2-6 were d topically with
PCT/U82012/054719
formulations comprising Cmpd. A and (S)-methoprene in different carrier vehicles administered
at 4.0 mg/kg Cmpd. A + (S)—methoprene administered at 6 mg/kg (Group 2: Miglyol 840; Group
3: DIPA / 25% tin; Group—4: DIPA / 25% DMI; Group 5 DIPA / 25% ethyl hexyl
pelargonate; and Group 6: DIPA + 25% diisopropyl sebacate + 3% silicone fluid). Dogs in
Group 7 were treated at a dose level of 7.0 mg7kg“Compound A + thoprene at 6 mg/kg
with ’a formulation comprising DIPA + 25%’diisoprop’yl sebacate + 3% silicone fluid. The
trations of Compound A and (S)-methoprene in formulations of Groups 2-5 were 6.0%
(w/v) and 9.0% (w/v), respectively, and the concentration of Compound A and (S)-methoprene
in formulations of Groups 6 and 7 were 10.5% (w/v) and 9% (w/v), rcspcctivcly.
IO Dogs were ed with approximately 100 C. fizlz‘s fleas on Day -I. Dogs were treated
with the respective topical formulations on Day 0. Fleas were removed'and counted on Day 2.
ationsflwith about 100 fleas were also made on Days 8, 15, 22, 29, 36 and 43. Fleas were
combed and counted 24 d: 3 hours after infestation on Days 9, 16, 23, 30, 37 and 44.
Table 3 below provides the % efficacy for each of the topical formulations. As
demonstrated by the data, each of the formulations was highly ious against the cat flea
through at least 44 days.
Table 3: Efficacy of Spot-on Composition Against Ctenocephalides/élis
Geometric Mean Flea Count/
% Reduction
Treatment Group
Day2 Day9 Day Day Day Day Day
' ' 16 23' 30 37 44
Group2
% Reduction
' " ' ' l00.0 l00.0 l00.0 100.0 100.0 l00.0 98.6
Group3
% Reduction
‘ ” ‘ ’ 100.0 99.6 100.0 100.0 100.0 100.0 100.0
Group4
% Reduction
100.0 100.0 100.0 100.0 100.0 100.0 100.0
GroupS
% Reduction
' " ' ' 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Group6
% Reduction
' ” ' ' 99.6 100.0 100.0 100.0 100.0 100.0 100.0
Group7
PCT/U82012/054719
% Reduction
100.0 100.0 100.0 100.0 100.0 100.0 100.0
e 3: Efficacy of Spot-on Formulations Containing Compound A and (S)-Methoprene
Against Rhipz'cephalus neus. — h
In another study, the efficacy against ticks of onal topical formulations comprising
isoxazoline Compound A in combination with (S)-mcthoprcnc in further carrier vehicles
comprising both a spreading solvent and a tion-enhancing solvent was ined. Thus,
six topical formulations sing Compound A and (S)-methoprene were tested for efficacy
againSt Rhipz'cephalus Sanguineus ticks iIi beagle dogs according to a protocol similar to that Of
Example 1.
Seven Treatment Groups with four dogs each were evaluated. Dogs in Group 1 were
untreated, and served as a control group. Dogs in Groups 2-6 were treated topically with Cmpd.
A in ent carrier vehicles stered at 4.0 mg/kg + (S)-methoprene administered at 6
mg/kg (Group 2: Miglyol 840 / 25% lauryl lactate; Group 3: DIPA / 25% triacetin; Group 4:
DIPA/ 25% DMI; Group 5 DIPA / 25% Capryol 90/ 25% Capryol PGMC; and Group 6: DES /
I5 25% propylene glycol monolaurate). Dogs in Group 7 were treated at a dose level of 7.0 mg/kg
Compound A + (S)-methoprene at 6 mg/kg with a formulation comprising DES / 25% propylene
glycol monolaurate. The concentrations of Compound A and thoprene in the formulations
used with Groups 2—6 were 6.0% (w/v) and 9.0% (w/v), respectively. The concentrations of
Compound A and (S)-methoprene in the formulation used with Group 7 were 10.5% (w/v) and
9% (w/v), respectively.
All dogs were infested with approximately 50 R. sanguineus on Days -1, 7, 14, 21, 28,
, 42, 49, 56 and 63. Further, ent Groups '1, 5, 6 and 7only were infested on Days 70, 77
and 84, and Treatment Groups 1, 6 and 7 only on Day 91. Ticks were counted upon removal on
Days 2, 9, 16, 23, 30, 37, 44,51, 58 and 65. Tick counts were conducted for Treatment Groups 1,
5, 6 and 7 only on Days 72, 79 and 86 and Treatment Groups 1, 6 and 7 only on Day 93.
Tables 4A and 48 below presents the efficacy of the spot-on formulations administered
to Groups 2-7 against R. sanguineus.
PCT/U82012/054719
Table 4A: Efficacy Against Rhipicephalus Sanguineus in Dogs
‘70 ReductiOn Ticks
Treatment Group
Day2 Day9 Day 16 Day 23 Dav 30 Day 37 Day 44
Group2
19110" 96.9 100.0 100.0 100.0 100.0 100.0 98.6
Group3
%Reduction 94.5 100.0 100.0 100.0 94.5 97.9 97.7
Group4
”/0 Reduction 98.2 100.0 100.0 100.0 97.5 94.5 98.6
Groups
% Reduction 98.2 100.0 100.0 98.1 100.0 97.9 100.0
Group6
m 1qqp_1qqp_qu.9_1qq9_qu.9_10_q._0_1099_
Group7
%Reduction 96.9 100.0 100.0 100.0 100.0 100.0 100.0
Table 4B: Efficacy Against Rhipicephalus Sanguineus in Dogs (continued)
% Reduction Ticks
Treatment Group Day Day Day ' ' Day Day Day Day
51 58 65 72 79 86 93
Group2
‘Zqfiejlicflm 10_Q,9 91.3 80.3 ND‘ ND ND ND
Group3
% Reduction (is; 89.9 65.2 ND ND ND ND
Group4
% Reduction 96.4 82.2 77.1 ND ND ND ND
Groups
% ion 9_6__7 94.7 87.6 32.1—86.9—612 ND
Group6
% Reduction 96.7 100.0 100.0 94.7 90.1 56.0 42.1
Group7
% Reduction 98.3 97.7 95.5 94.7 100.0 84.5 75.]
ND = not done
As Tables 4A and 4B show, Groups 3 and 4 maintained at least a 90% reduction in tick
count through Day 51, Groups 2 and 5 through Day 58, and Groups 6 and 7 through Day 79. In
particular, Treatment Groups 6 and 7 demonstrated superior efficacy for an extended period of
time. Thus, formulations sing a combination of an isoxazoline and an insect growth
regulator in a carrier vehicle comprising a combination of a spreading solvent and a perrncation
IO enhancer were determined to provide surprisingly long g efficacy against R. sanguineus.
PCT/U82012/054719
_Example 4: Dose Characterization of n Formulations of Cmpd. A Against Amblyomma
americanum Ticks in Dogs
The efficacy of 'a spot-on ition of the invention comprising an isoxazoline
compound (Cmpd. A) in a carrier vehicle comprising either DES alone or DES + lauryl lactate
(LL), against ticks (Amblyomma amerz’cammz),in dogs was d. The compositions contained
3.0 %, 4.5%, or 6.0% Cmpd. A in either DES alone or DES + lauryl lactate, which red
doses of 4.0 mg/kg, 3.0 mg/kg, and 2 mg/kg, respectively, of Cmpd. A to dogs infested with A.
Americanum tidks.’
Seven Treatment Groups were evaluated. Treatment Group 1 was administered a placebo
IO formulation and served as a control. Treatment Groups 2, 3 and 4 were administered a’ topical
formulation comprising 6.0% (w/v), 4.5% (w/v) and 3.0% (w/v) of Cmpd. A in DES,
respectively, corresponding to doses of 4.0 mg/kg, 3.0 mg/kg and 2.0 mg/kg, respectively.
Treatment Groups 5, 6 and 7 were administered a topical formulation comprising 6.0% (w/V),
4.5% (w/v) and 3.0% (w/v) of Cmpd. A in DES + 9% lauryl lactate, respectively, corresponding
to doses of 4.0% mg/kg, 3.0 mg/kg and 2.0 mg/kg body weight Cmpd. A, respectively.
All dogs were treated once topically on Day 0 by parting the hair and applying the
solution from a syringe ly onto the skin in a single spot on the midline of the neck between
the base of the skull and the er blades.
All dogs were ed with approximately 50 A. amerz‘cammz on Days -1, 7, 14, 21, 28,
35 and 42. Ticks were counted upon removal on Days 2, 9, 16, 23, 30, 37 and 44. The %
reduction of ticks for each Group is ted Table 5 below.
Blood samples were collected from all dogs on Days -5, 0 (at 4 h and 12 h), l, 2, 9, 16,
23, 30, 37 and 44.7Plasma samples were analyzed— for the concentration of Compound A using a
LC/MS/MS method that was GLP validated fer the analysis of the compound.
Treatment Groups 5 and 6 (4.0 mg/kg and 3.0 mg/kg Cmpd. A in DES + LL,
respectively) maintained at least 90% efficacy h five weeks, and Treatment Group 2 (4.0
mg/kg in DES alone) maintained at least 90% efficacy through Week 3.
PCT/U82012/054719
Table 5: Efficacy Against Amblyomma americanum in Dogs
% Reduction Ticks
Treatment Group Day Day Day' Day Day' Day Day
2 9 16 23 30 37 44
Group2
% Reduction 97.4 100.0 100.0 100.0 82.5 97.9 84.2
Group3
% Redu‘ction 90.0 100.0 97.6 82.0 70.0 80.4 56.0
Group4
% ion 95.4 100.0 100.0 79.5 90.3 57.1 38.8
GroupS
‘Zgfied_u_ct_ion 100.0 100.0 100.0 94.3 100.0 89.0 84.8
Group6
‘Zgfied_u_ct_ion 98.4 100.0 100.0 93.1 92.1 89.0 53.6
Group7
"/0 Reduction 98.4 100.0 100.0 80.6 88.9 74.6 42.4
e 5: Dose Characterization and determination of Speed of Kill of a Single Spot-on
Treatment with Formulations of Cmpd. A Against Ctenocephdlidesjélis fleas and Rh‘ipicephalus
sanguineus ticks on Dogs
The efficacy of a ation comprising an isoxazoline compound (Cmpd. A) in a
r comprising 40% DES/DMI against Cténucephalide.s' felis fleas and Rhipicephalus
sanguineus ticks in Dogs was studied. As sed above, DES is a solvent with good spreading
properties and DM1 eXhibits good permeation properties. Three treatment groups containing
three dogs each were evaluated. All dogs were treated once topically on Day 0 by parting the hair
and applying the solution from a syringe directly onto the skin in a single spot on the midline of
the neck n the base of the skull and the shoulder blades.
Treatment Group 1 was a placebo control and received 0.067 mL/kg of body weight.
Treatment Group 2 was—administered a l spot-on formulation comprising 6.0% (w/v)
Cmpd. A in 40% DES/DMI to deliver a dose of4.0 mg/kg body weighthreat’ment Group 3 was
administered a topical spot-on formulation comprising 12% (w/v) Cmpd. A in 40% DESZDMI to
deliver a dose of 4.0 mg/kg body weight.
All dogs were infested with approximately 100 C. felis on Days -I, 7, 14, 21, 28, 35 and
42. Fleas were counted upon l from dogs approximately 24 hours post infestation on
PCT/U82012/054719
Days 1, 8, 15, 22, 29, 36 and 43. The % reduction (efficacy) of each Treatment Group over time
is listed in Tables 6A, 6B and 7, respectively.
Table 6A: Efficacy Against Ctenocéphalide'sfelis in Dogs - Day 0 to Day 22
Treatment Group Day 1 Day 8 Day 15 Day 22
Group2
% Reduction 100.0 100.0 100.0 100.0
Group3
% Reduction 100.0 100.0 100.0 100.0
Table 6B: Efficacy Against Ctenocephalidesfelis in Dogs - Day 28 to Day 43
Treatment Group Day 29 Day 36 Day 43
Group 2
% Reduction 100.0 100.0 99.2
% Reduction 100.0 100.0 100.0
The percent efficacy against ticks 1s presented in Table 7. Both Treatment Groups
demonstrated good efficacy at least through 31 days.
Table 7: Efficacy against Rhipicephalus sanguineus Ticks
Control—
Group 2
% Reduction 100.0 91.5 100.0 85.2
—'ErBfiB?—m—_'—m—"—
% Reduction 100.0 72 6 100 0 51 3
Example 6: y of Spot-on Formulations Comprising Compound A at Different Doses
Against Rhipicephalus sanguineus Ticks in Dogs
A further study was conducted to examine the efficacy of a topical ations sing
Compound A in three different formulations containing DES against ticks in dogs. TWentyifour
beagles were studied to ine the iveness against d infestations’of Rlzipz'cephalus
sanguineus of spot-on formulations comprising Cmpd. A in different carriers administered at 4.0
mg/kg to dogs.
' ' Treatment Group 1 dogs were treated with a placebo solution. Treatment Group 2 was
treated with a formulation comprising 6% (w/v) Cmpd. A in DES; Treatment Group 3 were
d with a composition comprising 6% (w/v) Crripd. A in 40% DES/DMI; and Treatment
Group 4 were treated with a formulation comprising 6% (w/v) Cmpd. A in DES with 30%
Capryol 90. All dogs were treated once topically on Day 0. Topical solutions were applied by
parting the hair and applying the solution from a syringe direefly onto the skin in a single spot on
the midline of the neck between the base of the skull and the shoulder .
' All dogs Were infested
IO with imate‘ly‘ 50 R. sanguiiieuson Days -l_. 7, 14, 2|, 28, 35
and 42. Ticks'were counted upon removal from'dogs on Days 2, 9, 16, 23, 30, 37, and 44. All
ticks were counted upon removal at 48 (i3) hours pest treatment or infestation.
The percent efficaeies of the treated groups compared to the untreated control group were
determined for the 48 hour reatment/infestation counts. Percent efficacy for each ng
time 48 hours after treatment or infestation are listed in Table 8. Treatment Group 3 maintained
3 90% efficacy 48 hours after infestation at every sampling time from Day 9 h Day 44.
ent Group 2 was able to maintain at least 90% efficacy 48 hours after infestation
throughout the six weeks of the study.
Table 8: y Against Rhipicephalus sanguineus in Dogs
Treatment
Group Day2 Day9 Day16 Day 23 Day 30 Day37 Day 44
Group2
%Reduction 93.2 100.0 100.0 100.0 97.8 95.3 97.5
Group3
%Rediiction 72.8 100.0 100.0 100.0 100.0 93.5 82.9
Group4
%Rediiction 97.2 100.0 100.0 100.0 98.4 96.1 78.1
Example 7: Efficacy of Spot-on Formulations Comprising Isoxazoline Compound A in
ent Carrier Vehicles at 1 mg/kg Against Ctenocephalidesfelis Fleas in Cats
The efficacy of several spot-on ations comprising Cmpd. A dosed at 1 mg/kg body
weight in different carrier vehicles against fleas in cats was studied. Five eats each were
alloeated to 6 Treatment Groups. The six cats per study group were subjected to weekly
infestations followed by 24h flea counts for 5 to 8 weeks, according to the following Group
allocations: Group 1 —'untreated control; Group 2 - 1.0% (w/v) Cmpd. A in DMI; Group 3 ‘-
l.0% (w/v) Cmpd. A in diethyl sebacate (DES); Group 4 - 1.0% (w/v) Cmpd. A in 9% lauryl
lactate + DES; Group 5 — 1% (w/v) Cmpd. A in 8% ethyl oleate + DES; and Group 6 - 1% (w/v)
Cmpd. A in a vehicle comprising Transeutol'g' + 10% (w/v) ethanol + 5% polyvinylpyrrolidone +
% TWEEN 80. Cats were infested with approximately 100 C. fclis on Day -1 and treated on
IO Day 0 with the ponding spot-on formulation by application of the formulation directly on
the skin in the midline of the neck, between the base of the skull and the shoulder blades'in a
single spot using a 1 mL syringe. Twelve hours after treatment, fleas were removed and counted.
The cats were immediately ested with approximately100 fleas. Fleas were removed and
counted on Day 1 at approximately 24 hours reatment. Cats were also infested with fleas on
Days 7, 21, 38, 35, 42 and 49. Fleas were d and d approximately 24 hours afier
infestation on Days 8, 22, 29, 36, 43 and 50. The efficacy for each formulation is ted in
Table 9 below.
Table’9i 'Efficacy of Spot-on Formulations Against Ctenocephalides felis Fleas in Cats in
Different Formulations at a Dose of 1 mg/kg
% Reduction
Treatment Group Day0 Day Day Day' Day Day Day Day
{12 hr! 1 8 22 29 36 43 50
Group 2
% Reduction 22.3 28.0 99.3 99.5 98.5 94.2 94.3 87.7
Group3
%Redliction 9.6 72.7 99.7 97.4 95.1 79.3 72.2 44.8
Group4
%Red1icti0n 9.2 36.5 99.7 98.5 98.1 89.3 92.7 79.2
Groups
% Reduction 65.9 77.2 98.4 96.9 95.0 85.5 79.7 64.0
Group6
% Reduction 17.7 75.6 100_._0 99.3 97.5 93.8 93.9 79.6
As Table 9 trates, all of the spot-on formulations comprising Cmpd. A were
highly effective against fleas for at least 29 days. The formulation administered to Group 2
longer lasting efficacy above 90% until at least Day 43 and maintained efficacy above 85% until
Day 50. The ation of Group 5 (8% ethyl oleate in DES) exhibited significant efficacy
after 12 hours. _ ' '
Example ’8': Efficacy of Spot-on Formulations sing Isoxazoline Compound A in ent
Carrier Vehicles at 1 mg/kg t Ctenocepfzalides fie/is Fleas in Cats Protected from
Grooming.
In another study, the efficacy of four spot-on formulations comprising Cmpd. A dosed at
1 mg/kg body weight in different carrier vehicles against fleas in cats Was studiedFive eats each
were allocated to five Treatment Groups: Group 1 - Untreated; Group 2 — 0.833% (w/v) Cmpd.
IO A in dimethylsulfoxide (DMSO); Group 3 — 0.833% (w/v) Cmpd. A in DMI; Group 4 — 0.833%
(w/v) Cmpd. A in Transcutol‘g; and Group 5 — 0.833% (w/v) Cmpd. A in DES. Each cat in the
study was fitted with a protective neck collar on Day -1 prior to treatment to t the animals
from orally ingesting the topically applied formulation while grooming. Cats were infested with
approximately 100 C. felis on Day -1 and treated on Day 0 with the corresponding n
formulation by application of the formulation directly on the skin in the e of the neck,
between the base of the skull and the shoulder blades in a single spot using a 1 mL syringe.
Infestations with approximately 100 C. felis were conducted weekly on Days 7, 14, 21, 28 and
. Fleas were removed and cOunted approximately 24 i 3 hours fellowing treatment on Day 1
and then on Days 8, 15, 22, 29 and 36. The efficacy for each formulation is ted in Table 10
below.
Table 10: Efficacy of Spot-on Formulations Against CIenocep/zalidesfelis Fleas in Cats
% Reduction
Treatment Group Day Day Day Day" Day Day Day
1‘ 2‘ 8‘ 15 22‘ 29 36
Group 2
% Reduction 43.16 60.54 98.48 95.91 97.90 90.10 74.49
Group3
%Reduction 37.90 88.97 99.62 99.32 98.80 92.66 79.54
% quuquop 76:32 533.12 953.95 99.01 96_.19 95.41 86:61
Group 5
%Reduction 54.40 82.77 98.82 99.26 99.82 92.43 88.11
Example 9: Long lasting Efficacy of Spot-on Composition t Ctenocephalidesfelis Fleas
in Cats.
'The efficacy of spot-on compositions comprising Cmpd. A in DMI at different doses
against ephalidesfélis fleas in cats was studied. Four treatment groups were formed with
five cats per ent group: Group 1 — untreated control; Group 2 —' Compound A at 5.0 %
(w/v) in DMI to deliver a dose of 5 {rig/kg; Group 3 — Compound A at a tration of 10.0 %
(w/v) in DMI to deliver a dose of 10 mg/kg; and Group 4 — Compound A at a concentration of
.0 % (w/v) in DMI to deliver a dose of 15 mg/kg. Treatment was administered once on Day 0.
The cats were each infested with approximately 100 C. fleas at each time point evaluated.
.felis
IO Cats in all treatment groups were infested 0n Days -1, 0 (approx. 12 h following
treatment), 7, 28, 49, 70, 91, 1'05, “1 19 and 133. Cats were also infested ~on Days 126 and 140
(Treatment Groups 1 and 2); Days 147, 154, 155, 161, 168 and 175 (Treatment Groups 1, 3 and
4); Days 182, 189 and 197 (Treatment Groups 1 and 4). After each infestation, fleas were
removed and counted imately 48 hours (i3 hours) for most time points.
The results of the study are shown in Tables 11A, 118 and 11C below and in Figure 1.
The study demonstrated surprising long lasting efficacy of the spot-on formulations. The results
indicate that formulations sing Cmpd. A at different concentrations were ious
compared to Group 1 (untreated control) for extended periods of time. For example Group 2
demonstrated 90% efficacy up to Day 121; Group 3 showed 90% efficacy up to Day 163 and
Group 4 exhibited 90% cy up to Day 191. This extremely long lasting tion above
90% from one topical application is unpredictable and remarkable.
Table 1 1A: Efficacy of Against Ctenocephalidesfelis Fleas in Cats
% Reduction Fleas
Treatment Group Day0 Day Day Day Day
Day2 Day9
(12 hr) 30 51 72 93
Group2
% Reduction 61.1 100.0 100.0 100.0 100.0 100.0 100.0
Group3
"/0 Reduction 95.4 100.0 100.0 100.0 100.0 100.0 100.0
Group4
%Re_(_l|iction 85-} 100_.0 100_._0 100_.0 100_.0 100.0 100.0
Table 1 18: Efficacy of Against Ctenocephalidesfelis Fleas in Cats (continued)
% Reduction Fleas
Treatment Group Day' ' Day Day Day Day Day Day
107 121 128 135 142 149 155
Group2
tion 100.0 92.3 89.1 88.3 80.0 ND ND
Group3
%£e_d_u_ction 100.0 100.0 ND 99.8 ND 99.5 50.0
Group4
% Reduction 100.0 100.0 ND 100.0 ND 1000 78.0
Table I IC: Mean Flea Count f% Reduction (continued):
Treatment Group % Reduction Fleas
Day Day Day Day Day Day Day
157 163 170 177 184 191 199
Group2
%£e_d_lflon ND ND ND ND ND ND ND
Group3
°élegfilieflon 98-1 94.5 87.8 7qu ND ND ND
Group4
%Reduction 100.0 100.0 96.2 94.8 95.7 90.6 79.2
Example 10: Efficacy of Spot—on Formulations Against Ixodes s Ticks in Cats
‘ The efficacy of spot-on formulations comprising Cmpd.
A were studied against induced
infestations of [xodes ricimls ticks in cats. Three ent groups with six cats per group were
randomly allocated: Group 1 — Control, untreated; Group 2 —'Cm_pd. A (2.5% w/v_in DMI) at 0.1
ml/kg bedy weight (2.5 mg/kg); and Group 3 — Cmpd. A (5.0% W/v in DMI) at 0.1 ml/kg body
weight (5 mg/kg). Treatment Was administered once on Day 0 and efficacy was assessed based
on 48-hour tick (1. s) counts following weekly experimental challenge from Day 7 on. As
shown in Tables 12A and 12B below, Cmpd. A (2.5% w/v in DMI) at 2.5 rug/kg body weight
administered once topically completely prevented the ation of I. s until Day 56 and
offered > 90% tion until at least Day 77. In fact, the topical spot-on formulation offered
substantial protection against 1. ricinus ticks until the last day of assessment — Day 93. Due to
limitations on tick availability 5 mg/kg was tested only up to Day 44 with 100% efficacy. The
excellent long-lasting efficacy of the fbrmulation of the invention against 1. ricinus ticks in cats
is very surprising and unexpected.
Table 12A: Efficacy Against Ixodes ricinus in Cats
% Reduction Ticks
Treatment Group
Day 2 Day 9 Day 23 Dav 30 Day 37 Day 44
Group 2
‘Zgiegllctlon 23.71 100.00 99.60 100.00 99.58 100.00
Group 3
% Reduction 70.27 100.00 100.00 100.00 100.00 100.00
Table TZB: Efficacy Against Ixodes ricinus m Cats (continued)
% Reduction Ticks
Treatment Group
Day 51 Dav 58 Day 65 Day 72 Day 79 Day 86 Day 93
Group2
% Reduction 100.00 100.00 99.02 99.21 95.54 84.92 76.65
Group3
% Reduction NDl ND ND ND ND ND ND
Example 11: Efficacy of n ation Containing a Combination of Compound A.
pyriproxyfen and yram—Against Ctenocephalidesfelis Fleas in Cats.
The efficacy of three spot-on compositions comprising a combination of Compound A,
pyriproxyfen and nitenpyram against Ctenocephalides felis fleas in cats was studied and
”compared with an untreated control and with a spot-on composition comprising nitenpyram
IO alone. Cats were allocated into five Treatment Groups with 5 cats per group: Group] — cats were
untreated (control); Group 2 — cats were d spot—on solution containing 0.83% (w/v)
Compound A, 2.08% (w/v) nitenpyram, and 4.17% (w/v) pyriproxyfen in Transcutol'fiw to deliver
doses of 1.0 mg/kg Compound A, 2.5 mg/kg yram and 5.0 mg/kg pyriproxyfen; Group 3 —
cats were treated a spot-on solution containing 0.83% (w/v) Compound A, 4.17% (w/v)
nitenpyram, and 4.17% (w/v) pyriproxyfen in Transcutol® to deliver doses of 1.0 mg/kg
nd A, 5.0 mg/kg yram and 5.0 mg/kg pyriproxyfen; Group 4 — cats were d
with “a spot-on composition containing 0.83% (WA/VICOmpound A, 8.33% (w/v) nitenpyram and
4.17% (“w/v) pyriproxyfcn in Transcutol'g' to deliver doses of 1.0 mg/kg Compound A, 10.0
mg/kg nitenpyram and 5.0 mg/kg oxyfen; Group 5 — cats were treated 'with a spot-on
composition containing 2.08% (w/v) nitenpyram alone in Transcutol® to deliver a dose of 5.0
mg/kg body weight.
PCT/U82012/054719
Treatment was administered once on Day 0. The cats were each infested with
approximately 100 C. felis fleas at day -1, on Day 0 approximately 12 hours post treatment and
then on Days 1 (approx. 24 hours post treatment), 2, 7, 14, 21, 28 and 35. After each infestation,
fleas were removed and counted imately 12 hours (i: 3) on Day 0, and then on Days 1, 2,
8, 15, 22, 29 and 36 (24 3:3 hours after infestation).
The results of the study are shown in Table 13 below. The study demonstrated that a n
composition comprising a combination of an isoxazoline compound (Compound A), a
neonieotinoid (niténpyra’m) and an insect growth regulator (pyriproxyfen) exhibits extremely fast
acting and long-lasting efficacy.
IO Table 13: y of Spot-on Formulation Comprising Three Active Agents
Against Ctenocephalidésfelis Fleas in Cats
% Reduction
Treatment Group Day 0 Day 1 Day 2' Day 8 Day 15 Day 22
gllh) 124h! g24h) 124M 124h) 124M
Group 2
% Reduction 99.17 100.00100.00 100.00 100.00 98.76
Group3
ion 9_9_-2L22-£2%JMQ09_0_2251_2171_
Group4
%Rediiction 97.69 100.00100.00 100.00 100.00 98.08
Group 5
%Reduction 99.44 99.79 100.00 100.00 96.76 93.63
Example 12: Efficacy of Spot-on Compositions Comprising Compound A Against 0t0dectes
cynotis (ear mites) in Cats.
The efficacy of two spot—on compositions comprising Compound A at doses of 5 mg/kg
and 10 mg/kg against Otodectes cynotis in cats was evaluated ed to an untreated control.
Eighteen healthy cats were grouped into three study groups consisting of six cats per group. Cats
in the ent groups were infested with tes cynotz's obtained from naturally infested
donor eats prior to acclimation on Day -7. Group 1 was an untreated control group. Cats in
Groups 2 and 3 were treated once on Day 0 with a n composition comprising Compound A
at two different concentrations and doses by application of the formulation directly on the skin in
the midline of the neck n the base of’the skull and the shoulder blades with a 1 mL
disposable syringe. Cats in Group 2 were treated with a n composition containing 5.0%
PCT/U82012/054719
(w/V) Compound A in a carrier containing 40% (v/v) diethyl sebacate (DES) in
dimethylisosorbide (DMI) at a dose of 5 mg/kg body ; and cats in Group 3 were treated
with a spot-on composition containing 10.0% '(w/v)' Compound A in a carrier—containing 40%
(v/v) DES in BM] at a dose of 10 mg/kg body weight. Assessment of the ear mite infestation by
otoscopic ation was med on all Cats on Days -7, 3. 7 and 14. Visible live ear mites
(adult or immature) were counted and debris/cemmen level was estimated for both ear ducts. A
quantitative assessment of ear mites by ear duct flushing, mite collection and live mite count was
performed on Day 14. Relative to the untreated control, Group 2 d the infestation of ear
mites by 99.0% (only one mite found) and Group 3 reduced the ation of ear mites by
IO 100.0%(no live mites found in any cat).
Example 13: Efficacious Plasma Concentration for Topical Compositions.
Plasma concentrations of Compound A from dogs in the studies of Examples 1 and 4
were determined according to the description in Example 1, and the plasma concentration versus
% efficacy against A. americamun and D. variabilis were fit to a Sigmoidal Emax model. The
EC90 (concentration required to achieve 90% y) against A. anum and D. variabilis
ticks were determined to be 92 ng/mL and 70 ng/mL, respectively. Using a similar approach, the
EC90 for R. sanguineus ticks from a separate study was found to be 69 ng/mL. For comparison,
the ECgo values from an oral dosage form against A. antericanum, "D. variabilis “and R.
sanguineus ticks was found to be 158 ng/mL, 110 ng/mL and 101 ng/mL, respectively. Since
Compound A is systemically active, the lower concentration of the compound in the plasma
required to achieve 90% efficacy from the topical compositions of the invention is surprising and
unexpected.
Example 14: Efficacy of Pour-on Formulation Against Haematobia ns (Horn Fly) in
Cattle.“
The y of a n formulation of the invention comprising isoxazoline
Compound A was tested and“ compared with an untreated control. Two healthy, female Angus
crossbread cattle of one year of age weighing between 224 to 330 kg were used in each study
group. Cattle in Group 1 were untreated (control) and cattle in Group 2 were treated with a pour-
on formulation comprising Compound A at a concentration of 10% (w/v) in DES at a dose of 1
ml/10 kg once on Day 0. The ation was applied by measuring the ed amount of the
solution into a marked disposable syringe and applying the material evenly along the mid-line of
PCT/U82012/054719
the back of each animal from the withers to the tail head. Each animal was infested with
approximately 200 horn flies ed into each of the animal rooms on Day 1, approximately 24
hours post treatment. Approximately 200 horn flies were released again on Days 7, 14, 21, 28
and 36. Horn fly counts were performed at 5 hours and 24 hours after each infestation. Tables
14A and 148 below show the efficacy of the pour-on formulation of the invention.
Table 14A: Efficacy of n Formulation t Horn Fly
% Reduction
Treatment Groupl Day 1 Day 2 Day 7 Day 8 Day 14 Day 15
5h 24h 5h 24h 5h 24h
Group 2
% Reduction 81.2 99.6 84.2 99.7 89.5 99.2
Table 1482 Efficacy of Pour-on Formulation Against Horn Fly (Continued)
% Reduction
Treatment Groupl Day 21 Day 22 Day 28 Day 29 Day 35 Day 36
(5 h) (24 h) (5 h) (24 h) (5 h) (24 h)
Group 2
% Reduction 67.6 97.4 1 1.7 90.4 42.6 90.4
As the tables 14A and 148 show, cant efficacy against horn flies was observed
after only 5 hours post infestation. Efficacy of at least 90% was observed 24 hours after
infestation through the end of the study (day 36).
Example 15: Efficacy of Pour—0n Formulation Against Rhipicepha/us (Boophilus) microplus
ticks
The efficacy of two pour-on formulations of the invention comprising Compound A at
doses of 2.5 mg/kg and 10 trig/kg were tested against infestations of Rh‘ipicep'halus iBoophz'lus)
microplus ticks compared with an untreated control. Five healthy head of cattle of 6 to 15
months of age ng between 100 to 200 kg were used in each study group. Cattle in Group 1
were untreated ol). Cattle in Group 2 were treated on Day 0 with a pour-on formulation
comprising Compound A at a concentration of 2.5% (w/v) in DES at a dose of 2.5 mg/kg; and
cattle in Group 3 were treated on Day 0 with a pour-on formulation sing nd A at
a concentration of 10% (w/v) in DES at a dose of 10 mg/kg. Several weeks before treatment,
cattle are infested three times a week with approximately 2500 Rhipz'cephalus (Boophilus)
microplus larvae to establish ongoing ations. Cattle in Groups 2 and 3 were treated with the
2012/054719
respective itions on Day 0 by measuring the required amount of the solution into a
marked disposable e and applying the material evenly along the ne of the back of
each animal from the withers to the tail head.
Each animal was challenged by infestation with approximately 5000 R. microplus larvae
on Days 7 and 21 and every 14 days thereafter. Ticks ng from each animal in the previous
24 hotlrs were collected daily and counted from Day 1 until the end of the study. Since the life
cycle of the ticks from the point of infestation with larvae until engorged ticks fall off is
approximately 21 days (average), the assessment of efficacy for the challenges on Days 7 and 21
and every 14 days thereafter, was done for a range of 7 or 8 days starting approximately 21 days
IO after the Challenge. The assessment of y atthe beginning of the study—was done from day 1
until Day 21.
In addition, the ticks collected were weighed as a group to measure the impact of the
treatment on the weight gain of the ticks compared to the control to assess the vitality and
reproductive capability of the treated ticks. Tables 15A and 153 below shows the total tick count
% efficacy of the two pour-on formulations against R. microplus h 139 days post treatment
compared with an untreated control group. Tables 16A and 16B show the % efficacy of the two
pour-on formulations based on the weight of the ticks collected. Figures 2 and 3 shows plots of
the % efficacy of the two formulations ’based on total tick counts and total weight, respectively.
As evidenced from the tables and the figures, the pour-on formulations of the invention at both
2.5 mg/kg and 10 mg/kg provide excellent efficacy against Rhipicephalz/s (Boophilus) microplus
ticks for an extended period of time. The pour-on compositions exhibited tick count efficacy
above 90% for at least day 139 after administration of the composition. Furthermore, as shown in
Tables 16A and 168, the'two pour-on compositions were extremely effective against ticks based
on the weight of the ticks collected. This data shows that the itions were highly effective
at inhibiting the reproductive capability of the ticks for an extended duration of time. The
extremely long lasting efficacy above 90% for pour-on composition t ha‘picepha/us
i/us) microplus ticks is remarkable compared with pour-on formulations known in the art.
Table 15A: Tick Count Efficacy Against Rhipicephalus (Boophilus) micmplus
Average ‘Vo Efficacy (Tick Count)
Treatment Group Day Day Day Day Day Day Day
1-21 28-34 41-48 55-62 69-76 83-90 97-104
mm)—7—Zl—TS—geav-49—63—77—
Group 2
0/o Efficacy 58.8 75.6 77.0 91.2 88.3 90.7 79.8
Group 3
0/0 cy 78.1 92.0 98.0 97.8 99.3 98.9 92.4
Talfle 15B: Tick Count Eiiicacy Against halus (Boa/71117115) microplus
Average % Efficacy (Tick Count)
Treatment Group Day Day Day Day
111-118 132-139 146-153 7
Challenge Day 91 l 12 126 140
Group 2
% Efficacy 79.0 86.2 30.3 74.0
Group 3
% Efficacy 96.6 92.4 72.4 85.8
Table 16A: Tick Weight Efficacy Against Rhipicephalus (Boophilus) microplus
e % Efficacy (Tick Weight)
Treatment Group Day Day Day Day Day Day Day
1-2'1 28-34 41-48 55-62 69-76 83-90 97-104
Challenge Dav 7 21 35 49 63 77
Group 2
% Efficacy 69.1 81.8 72.9 87.7 84.8 87.4 76.0
Group 3
% Efficacy 85.4 95.2 98.3 96.6 99.2 98.6 90.2
Table 16B: Tick Weight Efficacy Aga1nstR72ipicepha/us (Boophflus) microplus
Average % Efficacy (Tick Weight)
ent Group Day Day Day Day
111-118 132-139 146-153 160-167
Challenge Day 9] n2 T26 140
Group 2
% Efficacy 74.0 83.2 20.6 63.4
Group 3
% Efficacy 96.0 92.4 61.4 76.3
PCT/U82012/054719
Example 16: Efficacy of n ation Against Linognathus vim/1' (sucking lice) in
' The efficacy of two pour-on formulations of the ion comprising isoxazoline
Compound A at doses of 2.5 mg/kg and 10 mg/kg were tested against natural and induced
infestations with Linognaz‘hus vitu‘li (sucking lice) in'cattle compared with an untreated control.
Four healthy head of cattle weighing between 100 to 300 kg Were used in each study group.
Cattle in Group 1 were untreated (control). Cattle in Group 2 were treated on Day 0 with a pour-
on formulation comprising Compound A at a concentration of 2.5% (w/v) in DES at a dose of
2.5 mg/kg; and cattle in Group 3 were treated on Day 0 with a pour-on formulation comprising
IO Compound A at a concentration of 10% (w/v) in DES at a dose of 10 mg/kg. The formulation
was applied by measuring the required amount of the solution into a marked disposable syringe
and applying the material evenly along the mid-line of the back of each animal from the withers
to the tail head.
Live lice s plus nymphs) were counted on days 2, 7, 14, 21, 28, 35, 42, 49 and 56
by counting lice on six selected sites approximately 5 cm x 15 cm on the body surface of the
animal by direct examination. In the absence of lice on the selected sites, a thorough body search
was conducted. The total louse counts per animal were determined by summation of the live
louse s at each site per animal. Tables 17A and 17B below show the efficacy of the two
pour—on formulations against Linognathus vim/i over 56 days. As the tables show, both pour-on
formulations were ious through at least day 56 of the study with 100% y observed
starting day 7. Efficacy on day 2 of the study was greater than 90% in each of the study groups.
The long g efficacy against Linognathus vituli from one topical treatment is unexpected and
surprising.
Table 17A: Efficacy of Pour-on Formulation Against Linognathus vitulz'
1 ‘70 Reduction
Treatment GrouP
Da 2 Da 7 Da 1Dar28
Group 2
% Reddction 92 100 100 100 100
Group 3
% Reduction 98 100 100 100 100
PCT/U82012/054719
Table 178: Efficacy of Pour-on Formulation Against
Linognathus vituli (continued)
070 ion
Treatment Group
Day 35 Day 42 Day 49 Day 56
Group 2
% Reduction 92 100 100 100
Group 3
% Reduction 98 100 100 100
Example [7: Efficacy of Pour-on Formulation Against Sarcoptes scabiez‘ var. bovis (mange
mites) in Cattle.
The efficacy of two pour-on formulations of the invention comprising isoxazoline
Compound A at doses of 2.5‘ mg/kg and 10 mg/kg were tested against natural and induced
infestations with Sarcoptes scabz'ei var. bovis ’mites) in cattle Compared with an untreated
control. Four healthy head of cattle weighing between 100 to 300 kg were used in each study
group. Cattle in Group 1 were untreated (control). Cattle in Group 2 were treated on Day 0 with a
n formulation comprising nd A at a concentration of 2.5% (w/v) in DES at a dose
of 2.5 mg/kg; and cattle in Group 3 were treated on Day 0 with a pour-on formulation
sing Compound A at a tration of 10% (w/v) in DES at a dose of 10 mg/kg. The
ation was; applied by measuring the required amount of the solution into a marked
disposable syringe-and applying the material evenly along the ne of the back of each
animal from the withers to the tail head.
Live (motile) Sarcoptes scabiei var. how's (mange mites) were d on days 7, 14, 20,
27, 34, 41, 48 and 55 in scrapings collected from the edges of active lesions or, if lesions
regressed during the study, from the area where active lesions were at the commencement of the
study. Serapings were made from six sites with an area of at least 3 cm x 3 cm in size on each
animal. Tables" 18A and 188 below show the efficacy of the two pour-on ations against
Sarcoptes scabiei var. bovis over 56 days. As the data shows, both pour-on formulations'were
efficacious through at least day 56 of the study with efficacy of higher than 95% starting on day
7. The efficacy of the 10% (w/v) formulation exhibited an efficaey‘of 100% from day 14‘through
day 55, while the efficacy of the lower concentration pour—on formulation (Group 2) showed
100% starting from day 27 through the end of the study.“The long lasting efficacy of the pour-on
PCT/U82012/054719
formulations of the invention against Sarcopzes scabiei var. how's from one topical ent is
unexpected and surprising.
Table 18A: Efficacy of Pbur-on Formulation Against
Sarcoptes scabiei var. b0vis
07° ion
Treatment Group
Day 7 Daxr 14 Day 20 Day 27
Group 2
% Reduction 96.7 98.2 99.6 100
Group 2
% Reduction 96.8 100 100 100
Table 188: Efficacy of Pour-on Formulation Against
Sarcoptes scabiei var. bovis (continued)
% Reduction
Treatment CW"
Day 34 Day 41 Day 48 Day 55
Group 2
% Reduction 100 100 100 100
Group 2
% Reduction 100 100 100 100
As the non—limiting examples above demonstrate, the compositions of the invention
comprising at least one isoxazoline active agent show superior long lasting efficacy against
rasites in a mammal (e.g. dogs, cats and cattle).
fl: ’1: ’1: it * * * * * *
The tim is r described by the following numbered paragraphs:
1. A topical veterinary composition for treating or preventing a tic infection or infestation
in an animal comprising:
a) at least one isoxazoline active agent of Formula (I):
o—_\I A64 \A4
wherein:
PCT/U82012/054719
A' A5 and A6 are independently selected from the group consisting of CR3
, A2, A3, A4,
and N, provided that at most 3 of Al, A2, A3, A4, A5 and A6 are N;
3‘, B2 and B3 are independently selected from the group consisting of CR2 and N;
W is O or S;
R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or
C4-C7 cycloalkylalkyl, each optionally substituted with one or more sUbstituents independently
selected from R6:
each R2 is independently H, halogen, C1-C6 alkyl, C1-C5 haloalkyl, C1-C6 alkoxy, C1-C6
haloalkoxy, C 1-C6 alkylthio, C1-C6 haloalkylthio, C 1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C 1-
IO C6 alkylsu'lf‘onyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C5 dialkylamino, C7-C4
alkoxycarbonyl, —CN or —NOz;
each R3 is independently H, halogen, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-
CO halocycloalkyl, C l-Co alkoxy, C1-C6 haloalkoxy, C 1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6
alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C 1-C6
alkylamino, C2-C6 dialkylamino, —CN or —N02;
R4 is H, C 1-C6 alkyl, C2-C6 alkenyl, C7-C6 alkynyl, C3-C6 cycloalkyl, C4-C7
alkylcycloalkyl, C4-C7 cycloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 carbonyl;
' R5
is H, OR”), NRHR” or Q"; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6
lkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each ally tuted with one
or more substituents ndently selected from R7; or
R4 and R5 are taken er with the nitrogen to which they are attached to form a ring
containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group
consisting of N. S and 0, said ring optionally substituted with 1 to 4 tuents independently
selected from the group consisting of C1-C2 alkyl, halogen, —CN, —N02 and C1-C2 alkoxy;
each R6 is ndently n, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6
alkylsulfinyl, C l-C6 alkylsulfonyl, —CN or —N02; '
each R7 is independently halogen; C1-C6 alkyl, C3-C6 lkyl, C1-C6 alkoxy, C1-C6
alkylthio, C1-C6 alkylsiilfinyl, C1-C6 alkylsulfonyl, C 1-C6 alkylamino, C2-C8 dialkylamino, C3-C6
cycloalkylamino, C2-C7 alkylcarbonyl, C2-C7 alkoxycarbonyl, C2-C7 alkylaminocarbonyl, C3-C9
dialkylaminocarbonyl, C2-C7 haloalkylearbonyl, C2-C7 halOalkoxycarbonyl, C2-C7
PCT/U82012/054719
haloalkylaminocarbonyl, C3-C9 dihaloalkylaminocarbonyl, hydroxy, —NH2, —CN or —N02; or
each R8 is ndently halogen, C1-C5 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6
haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6
haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, C2-C4 earbdnyl, —CN or —
‘ ’
N02;
each R9 is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-C6
halocycloalkyl, C1-C6 alkoxy, C1-C6 koxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6
alkylsulfinyl, C l-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C 1-C6 haloalkylsulfonyl, C 1-C6
alkylamino, C2-C6 dialkylamino, +CN, —N02, phenyl Or pyridinyl; ‘ '
R10 is H; or C1-C6 alkyl, C2-C6 l, Cg—C6 alkynyl, C3-C6 cycloalkyl, C4-C7
alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted With one of more halogen;
‘ R” ’
is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, Cit-C7
alkylcycloalkyl, C4-C7 eyeloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl;
R12 is H; Q3; or C1-C6 alkyl, C2-C6 l, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7
alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally tuted with one or more
substituents independently selected from R7; or
R11 and R—12 are taken together with the nitrogen to which they are attached to form a ring
containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group
consisting of N, S and 0, said ring optionally substituted with 1 to 4 substituents independently
selected from the group consisting of C1-C2 alkyl, halogen, —CN, —N02 and C1-C2 alkoxy;
Q' is a phenyl ring, a 5- or 6-membered heterocyclic ring, or an 8-, 9- or lO-membered
fused bicyclic ring system ally containing one to‘three heteroatoms selected from up to l
0, up to l S and up to 3 N, each ring or ring syStem optionally substituted with one or more
substituents independently selected from R8; 7
each Q2 is independently a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring
ally tuted with one or more substituents independently selected from R9;
R Q3 is a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted
with one or more tuents independently selected from R9; and
n is 0, l or 2; and
b) a pharmaceutically acceptable carrier that is suitable for application to the skin of an
PCT/U82012/054719
animal; and wherein the carrier does not comprise irol and is not a binary mixture of
propylene glycol and glycerol formal.
2. The’topical veterinary cemposition of paragraph 1, wherein in the isoxazoline active agent of
Formula (I):
W is O;
R4 is H or C1-C6 alkyl;
R5 is -CH2C(O)NHCH2CF3;
cach ofA', A2, A3, A4, A5 and A6 is CH;
IO R| is C1-C6 alkyl each optionally substituted with one or more substituents independently
7 7
selected from R6;
R6 is halogen or C1-C6 alkyl; and
3‘, 32, and B3 are ndently CH, C-halogen, C-Ci-C6 alkyl, o haloalkyl, or C-
C1-C6 alkoxy.
3. The topical veterinary composition of paragraph 1, wherein in the isoxazoline active agent of
Formula (I):
W is O;
R' is cry;
132 is CH;
B1 is chloro;
i33 is CH;
each ofA', A2, A3, A“, A5 and A6 is CH;
R4 is H; and
R5 is -CH2C(O)NHCH2CF3.
4. The topical veterinary ition of paragraph 1, n the pharmaceutically
acceptable carder‘comprises a r ota diearboxylic acid, a glycol ester, a glycol ether, a fatty
acid ester, a polyethylene glycol, or polyethylene glycol ester, an oil, an alcohol, a glycerol ester,
a glycerol ether, propylene glycol, ethylene glycol, a glycol carbonate, dimethyl isOsorbide, N-
methylpyrrolidone, or a mixture thereof.
PCT/U82012/054719
. The topical nary composition of paragraph 4, wherein the diester of a
dicarboxylic acid is a diester of a C6-C16 dicarboxylic acid. '
6. The topical veterinary composition of paragraph 5, n the diester of a C6-Cl6
dicarboxylic acid’is diethyl sebaeate or diisopropyl’adipate’.
7. The topical veterinary composition of paragraph 4, wherein the pharmaceutically
acceptable carrier comprises mixture of a diester of a oxylic acid and a propylene glycol
IO ester, a fatty acid ester, a polyethylene glycol ester, a polyethylene glycol, an oil, a C6-Czoilong-
chain aliphatic alcohol, a C1-C8 alcohol,'glycol ether, or a‘combinatit'm thereof.
8. The topical veterinary composition of paragraph 4, wherein the pharmaceutically
acceptable carrier comprises a mixture of a diester of a oxylic acid and further ses a
mixed ester of sucrose and acetic and isobutyric acid, a low melting wax, a hard fat or a block
eo-polymer of ethylene oxide and ene oxide, or a ation thereof.
9. The l veterinary composition of paragraph 4, wherein the pharmaceutically
acceptable carrier comprises dimethyl isosorbide, glycerol formal, propylene carbonate, triacetin,
diethyleneglyeol monoethyl ether, polyethylene glycol 400 or benzyl alcohol, or a mixture
thereof.
. The topical veterinary composition of any one of aph 1 to 9, wherein the
composition r comprises at leasta second actiVe agent.”
11. The topical veterinary composition of aph 10, wherein the at least second
active agent is an insect growth regulator, a neonicotinoid or an avermectin or milbemycin.
12. The topical veterinary composition of paragraph 11, wherein the isoxazoline active
agent is 4-[5—[3-chloro(trifluoromethyl)phenyl]l4,5-dihydro(trifluoromethyl)—3-isoxazolyl]-
N-[2-oxo[(2,2,2-trifluoroethyl)amino]ethyl]-l-naphthalaneearboxamide and the neonicotinoid
PCT/U82012/054719
is nitenpyram.
13. The topical veterinary composition of paragraph 11, wherein the at least second
active agent is an insect growth regulator.
14. The l veterinary composition of paragraph 13, n the insect growth
regulator is (S)-methoprene, pyriproxyfen, rene. cyromazine, fluazuron, lufenuron, or
novaluron.
IO 15. The topical veterinary composition of paragraph I I, wherein the avermectin or
milbemycin is eprinomectin, ivermectin, selamecfin, milbemectin, milbemycin D, ycin
oxime, or moxidectin
16. The topical veterinary composition of paragraph 10, wherein the at least second
active agent is an anthelmintic active agent selected from thiabendazole, oxibendazole,
mcbcndazolc, fcnbcndazolc, oxfcndazolc, albcndazole, triclabcndazolc, fcbantcl, lcvamisolc,
pyrantel, morantel, praziquantel, closantel, clorsulon, an amino acetonitrile active agent, or an
aryloazolyl cyanoethylamino active agent.
17. The topical veterinary composition of any one of aph 1 to 16, wherein the
ition is a spot-on composition.
18. The topical veterinary composition of any one of paragraph 1 to 16, wherein the
composition is a pour-on composition.
19. A method for the treatment or prevention of a parasitic infestation or infection in an
animal sing stering to the animal an cffcctivc amount of the topical vctcrinary
composition of‘ any of paragraph I to 18.
2012/054719
. The method of paragraph 19, wherein the isoxazoline is 4-[5-[3-ehloro
(trifluoromethyl)phenyl]—4,5-dihydro(trifluoromethyl)isoxazolyl]-N-[2-oxo[(2,2,2-
trifluoroethyl)amino]ethyl]naphthalenecarboxamide.
21. Use of an isoxazoline of formula (I) in paragraph 1 in the preparation of a topical
veterinary composition for the treatment or protection of an animal against parasites.
* * *
Having thus described in detail s embodiments of the present invention, it is to be
understood that the ion defined by the above paragraphs is not to be limited to particular
IO details set forth in the above description as many apparent van'ations thereof are possible without
departing from the spirit or scope of the present invention.
_ _ _ 102
Claims (26)
1. A topical n or pour-on veterinary composition for treating and/or ting a parasitic infection or infestation in a non-human mammal comprising: a) at least one isoxazoline active agent of Formula (I): wherein: A1, A2, A3, A4, A5 and A6 are independently selected from the group consisting of CR3 and N, provided that at most 3 of A1, A2, A3, A4, A5 and A6 are N; B1, B2 and B3 are independently selected from the group ting of CR2 and N; W is O or S; R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 l, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently ed from R6; each R2 is independently H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 ulfinyl, C1-C6 haloalkylsulfinyl, C1- C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, C2-C4 alkoxycarbonyl, —CN or —NO2; each R3 is independently H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 lkyl, C3- C6 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, —CN or —NO2; R4 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C4-C7 cycloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl; R5 is H, OR10, NR11R12 or Q1; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 lkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R7; or R4 and R5 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one onal atom ed from the group consisting of N, S and O, said ring optionally substituted with 1 to 4 substituents independently selected from the group consisting of C1-C2 alkyl, halogen, —CN, —NO2 and C1-C2 alkoxy; each R6 is independently halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, —CN or —NO2; each R7 is independently n; C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 alkylamino, C2-C8 lamino, C3-C6 cycloalkylamino, C2-C7 alkylcarbonyl, C2-C7 alkoxycarbonyl, C2-C7 alkylaminocarbonyl, C3-C9 dialkylaminocarbonyl, C2-C7 haloalkylcarbonyl, C2-C7 haloalkoxycarbonyl, C2-C7 haloalkylaminocarbonyl, C3-C9 dihaloalkylaminocarbonyl, hydroxy, —NH2, —CN or —NO2; or each R8 is independently halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, C2-C4 alkoxycarbonyl, —CN or — NO2; each R9 is independently n, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-C6 cloalkyl, C1-C6 alkoxy, C1-C6 koxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 ulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, —CN, —NO2, phenyl or pyridinyl; R10 is H; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one of more halogen; R11 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C4-C7 cycloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl; R12 is H; Q3; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R7; or R11 and R12 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group ting of N, S and O, said ring optionally tuted with 1 to 4 substituents independently selected from the group consisting of C1-C2 alkyl, n, —CN, —NO2 and C1-C2 alkoxy; Q1 is a phenyl ring, a 5- or 6-membered heterocyclic ring, or an 8-, 9- or 10-membered fused bicyclic ring system optionally containing one to three heteroatoms selected from up to 1 O, up to 1 S and up to 3 N, each ring or ring system ally substituted with one or more substituents independently selected from R8; each Q2 is ndently a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from R9; Q3 is a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from R9; and n is 0, 1 or 2; and b) a ceutically acceptable carrier that is suitable for the application to the skin of a non-human , wherein said r comprises a liquid polyethylene glycol.
2. The topical veterinary composition of claim 1, wherein: W is O; R4 is H or C1-C6 alkyl; R5 is -CH2C(O)NHCH2CF3; each of A1, A2, A3, A4, A5 and A6 is CH; R1 is C1-C6 alkyl each optionally substituted with one or more substituents independently selected from R6; R6 is halogen or C1-C6 alkyl; and B1, B2, and B3 are independently CH, C-halogen, C-C1-C6 alkyl, C-C1-C6 haloalkyl, or CC1-C6 alkoxy.
3. The topical veterinary composition of claim 1 or claim 2, wherein: W is O; R1 is CF3; B2 is CH; B1 is C-Cl; B3 is C-CF3; each of A1, A2, A3, A4, A5 and A6 is CH; R4 is H; and R5 is -CH2C(O)NHCH2CF3.
4. The topical veterinary ition of any one of claims 1 to 3, wherein the pharmaceutically acceptable carrier further comprises an alkyl diester of a dicarboxylic acid.
5. The topical veterinary composition of claim 4, wherein the alkyl diester of a dicarboxylic acid is an alkyl diester of a C6-C16 dicarboxylic acid.
6. The topical veterinary ition of claim 5, wherein the alkyl diester of a C6-C16 dicarboxylic acid is diethyl sebacate, dibutyl sebacate, diisopropyl sebacate, diisopropyl adipate, dibutyl adipate or utyl adipate.
7. The topical veterinary composition of any one of claims 1 to 6, wherein the pharmaceutically acceptable carrier comprises polyethylene glycol 300, polyethylene glycol 400 or polyethylene glycol 600.
8. The topical nary composition of any one of claims 1 to 7, wherein the pharmaceutically acceptable r comprises polyethylene glycol 400.
9. The topical veterinary composition of any of claims 1 to 8, wherein the oline active agent of formula (I) is present in a concentration of about 1 to about 25% (w/v).
10. The topical veterinary composition of any of claims 1 to 9, wherein the isoxazoline active agent of a (I) is present in a concentration of about 1 to about 10% (w/v).
11. The topical veterinary composition of any of claims 1 to 10, wherein the isoxazoline active agent of formula (I) is present in a concentration of about 1 to about 5% (w/v).
12. The topical veterinary composition of any of claims 1 to 8, wherein the isoxazoline active agent of formula (I) is present in a concentration of about 0.5 to about 2.0% (w/v).
13. The topical veterinary ition of any one of claims 1 to 12, further comprising at least a second active agent.
14. The topical veterinary ition of claim 13, wherein the at least second active agent is an insect growth regulator, a neonicotinoid or an ctin or milbemycin.
15. The topical veterinary composition of claim 13 or claim 14, wherein the at least second active agent is an insect growth regulator.
16. The topical veterinary composition of claim 15, wherein the insect growth regulator is thoprene, pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, or novaluron.
17. The topical veterinary ition of claim 14, wherein the avermectin or milbemycin is eprinomectin, ivermectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, or moxidectin.
18. The topical veterinary composition of claim 13, wherein the at least second active agent is an anthelmintic active agent selected from thiabendazole, oxibendazole, mebendazole, fenbendazole, oxfendazole, albendazole, triclabendazole, febantel, levamisole, pyrantel, morantel, uantel, closantel, clorsulon, an amino acetonitrile active agent, or an aryloazol yl cyanoethylamino active agent.
19. The topical veterinary composition of any one of claims 1 to 18, wherein the composition is a spot-on composition.
20. The topical veterinary composition of any one of claims 1 to 18, wherein the composition is a pour-on composition.
21. The l veterinary composition of any one of claims 1 to 18, n the composition is a spot-on composition, and wherein the volume of the composition is between about 0.1 to about 10 ml.
22. The l veterinary composition of claim 21, wherein the volume of the composition is between about 0.1 to about 5 ml.
23. The topical veterinary composition of claim 21 or claim 22, wherein the volume of the composition is between about 0.1 to about 1 ml.
24. The topical veterinary composition of any one of claims 1 to 18, n the composition is a pour-on composition, and wherein the volume of the composition is between about 10 to about 100 ml.
25. The topical veterinary composition of any one of claims 1 to 24, wherein the isoxazoline compound of formula (I) is 4-[5-[3-chloro(trifluoromethyl)phenyl]-4,5-dihydro (trifluoromethyl)isoxazolyl]-N-[2-oxo[(2,2,2-trifluoroethyl)amino]ethyl] naphthalanecarboxamide.
26. A topical spot-on or pour-on nary ition according to claim 1, substantially as hereinbefore described with reference to the examples and excluding, if any, comparative examples. wo
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161533308P | 2011-09-12 | 2011-09-12 | |
US61/533,308 | 2011-09-12 | ||
NZ725115A NZ725115A (en) | 2011-09-12 | 2012-09-12 | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ742345A NZ742345A (en) | 2020-05-29 |
NZ742345B2 true NZ742345B2 (en) | 2020-09-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019203419B2 (en) | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof | |
NZ742345B2 (en) | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof | |
NZ622466B2 (en) | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof | |
NZ710442B2 (en) | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof | |
NZ710442A (en) | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof | |
OA16809A (en) | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof. |